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Colorectal cancer (CRC) is the second most common cause of cancer related death in 
The Netherlands. More than 12,000 new cases were diagnosed in 2008. Almost 50% of the 
patients die of the disease and the majority of the disease-associated deaths can be 
attributed to the presence of distant metastases. The incidence of colorectal cancer in The 
Netherlands has increased in the period between 1989 and 2008 by 1% per year (source: 
www.iknl.nl). In men, 14% of all malignant tumours are colorectal cancers, which makes it 
the third most frequent tumour (after lung cancer and prostate cancer); in women, colorectal 
cancer is the second most frequent tumour (13% of the total number of cancers, preceded 
only by breast cancer) (Source: www.oncoline.nl). In 10% to 15% of colorectal cancers 
there is familial clustering and in almost 5%, CRC is associated with an autosomal dominant 
cancer syndrome (like Lynch syndrome or Familial Adenomatous Polyposis). In these highly 
penetrant hereditary disorders the lifetime risk to develop colorectal cancer varies between 
25% and 100%, if no preventive measures are taken. The remaining 85% to 90% are 
sporadic cases. Until the beginning of the century, all colorectal cancers were thought to 
originate from adenomatous polyps, a process that has been described as a stepwise 
sequence of events by Vogelstein et al1-3. In this model for colorectal cancer development, 
the adenomatous polyp plays a crucial role as the precursor lesion that undergoes genetic 
changes as it develops from an early adenoma, via an intermediate and high grade 













Figure 1. Schematic overview of the adenoma-carcinoma sequence of colorectal cancer development, according to 
Fearon and Vogelstein1. Some of the genes that are involved in the different phases of this multistep process are 
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A decade ago, an alternative route to colorectal cancer development was described5, 6. 
This alternative pathway, called the serrated pathway, describes the development of a 
different precursor lesion (i.e., a sessile serrated polyp or sessile serrated adenoma) to 
cancer. In contrast to the traditional adenoma-carcinoma sequence, BRAF mutations and 
widespread DNA hypermethylation (CpG island hypermethylation phenotype or CIMP) play 
an important role in the serrated pathway7-9. Currently it is estimated that a majority of 
colorectal cancers develop according to the “classic” adenoma-carcinoma pathway (i.e., 
according to the Vogelstein model), but a substantial part of cancers probably originate from 
a sessile serrated adenoma via the serrated pathway10, 11. 
Colorectal cancer treatment and prognosis is largely dependent on the cancer stage at 
the time of diagnosis. Whereas the 5-year survival of patients with a Dukes’ A carcinoma12, 
which is limited to the mucosa, is more than 90%, it decreases to less than 10% in Dukes’ D 
patients who have distant metastases (Source: Surveillance, Epidemiology and End Results 
[SEER] program). Crossing of natural barriers, leading to invasive growth, and angiogenesis 
are crucial in the process of tumour progression and dissemination. At presentation, 25% of 
the patients with colorectal cancer already have distant metastases and this number 
increases up to 40% during the course of the disease. A shift towards detection of earlier 
stages of colorectal cancer can be achieved by population screening for colorectal cancer, 
which will start in The Netherlands in 2013. Especially in Dukes’ B and C patients, who have 
an intermediate prognosis, the prognosis of individual patients is highly variable. Much 
research has been performed to identify markers involved in the malignant process that 
could be of additional value to determine prognosis and might identify patients eligible for 
adjuvant treatment. 
Matrix metalloproteinases: structure and substrate specificity 
Matrix metalloproteinases (MMPs) constitute a group of proteases that are involved in 
tissue remodelling and matrix turnover in many physiopathological conditions. The MMPs 
belong to the metzincin family, consisting of zinc- and calcium-dependent proteinases, that 
share a methionine at the C-terminal of the zinc-ligand which forms a Met-turn and a 
HEXXHXXGXXH zinc-binding motif13. Other members of the metzincin family, which share 
structural and functional features, are the subfamily of a disintegrin and metalloproteinase 
(ADAMs) and the group of a disintegrin and metalloproteinase with thrombospondin motifs 
(the ADAMTS family). The MMPs constitute a family of zinc-dependent endopeptidases, 
first described in 1962 by Gross and Lapière when they identified an enzyme that 
contributes to tail resorption during tadpole metamorphosis14. Since then, 27 MMPs have 
been identified of which 23 are present in humans.  
All of the MMPs share the following features: 1) they are capable of degrading at least 
one of the extracellular matrix components, 2) they contain a zinc ion at the active site and 
are inhibited by chelating agents, 3) they are secreted as latent pro-enzymes (zymogens) 
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that need activation by plasmin, trypsin, thrombin or other proteases (including other 
MMPs), 4) they are inhibited by specific inhibitors, the tissue inhibitors of metalloproteinases 
(TIMPs) and 5) they all share similar amino acid sequences15. The 23 human MMPs share 
a highly conserved structure including a N-terminal pro-peptide domain, a zinc-containing 
catalytic domain and, with the exception of MMP-7, MMP-23 and MMP-26, a C-terminal 
hemopexin-like domain16. According to their structure and major functions, MMPs can be 
subdivided in collagenases (MMP-1, -8, -13 and -18), gelatinases (MMP-2 and -9), 
stromelysins (MMP-3, -10, and -11), matrilysins (MMP-7 and -26), membrane-type MMPs 
(MMP-14, -15, -16, -17, -24 and -25), and a rest group. The global structure of the different 
subgroups of MMPs is shown in figure 217, 18. Although every MMP has its own 
characteristic substrate profile, there is overlap between the different MMPs and most 
MMPs have a rather broad substrate specificity19. Under pathological conditions, like in 
cancer, almost all MMPs are present. Due to compartmentalization, a phenomenon that is 
discussed in the next paragraph, the catalytic activity of certain MMPs may be preferred 
over others20.  
 
 
Figure 2. Domain structure of the major classes of MMPs. Adapted from Cauwe et al. (2007)49, Busti et al. (2010)17 
and Brauer et al. (2006)18. 
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Regulation of matrix metalloproteinases 
Regulation of MMP activity takes place at different levels: regulation of gene expression, 
secretion and activation of latent MMPs, compartmentalization and regulation of enzymatic 
activity by endogenous activators and inhibitors. 
 
1. Regulation of gene expression 
The regulation of MMP gene expression is complex and is different under physiological 
(e.g., embryonic development, childhood development, wound healing, bone turnover) and 
pathological (e.g., cancer, arthritis, cardiovascular disease) circumstances. Transcription 
factors that bind to specific sites in the promoter region of the gene regulate transcriptional 
activity. Most of these transcription factors belong to the AP-1, SP-1, β-catenin/Tcf-4, NFκB 
and PEA3 families21. The levels of these transcription factors are influenced by cytokines 
(like interleukins, interferons, tumour necrosis factor alpha [TNF-α]) and growth factors (like 
transforming growth factor-beta [TGF-β], epidermal growth factor [EGF], vascular 
endothelial growth factor [VEGF] and platelet-derived growth factor [PDGF]) and 
hormones22. The end effect on the transcriptional level can be either stimulatory (e.g., 
growth factors, proto-oncogenes) or inhibitory (e.g., glucocorticoids and TGF-β)15. As the 
MMP-promoters show a high structural similarity, they are often co-regulated by the same 
transcription factors. On the other hand, and somewhat surprisingly, functionally similar 
MMPs (like the gelatinases) often have a distinct composition of the promoter region and 
are therefore regulated by different transcription factors21.  
Single nucleotide polymorphisms (SNPs) located in the promoter region of the genes 
may create or disrupt transcription factor binding sites and thereby influence transcriptional 
activity in either a positive or negative way. By these mechanisms, SNPs may be 
associated with cancer susceptibility and/or correlate with the disease phenotype or 
prognosis of patients who have already been diagnosed with cancer. The most common 
SNPs in the promoter region of the MMP genes and their correlation with either 
susceptibility for gastrointestinal (GI) cancer, or the course of disease of patients who 
already have developed cancer of the GI tract, are discussed in chapter 2.  
 
2. Secretion and activation of latent MMPs  
Except for MMP-11 and the membrane bound MT-MMPs, all MMPs are secreted as 
latent pro-enzymes, also called zymogens. These pro-enzymes are inactive due to the 
presence of a prodomain which binds to the zinc ion in the catalytic domain, thereby 
preventing the substrate from binding to the catalytic site. Proteinases (like trypsin, 
chymase but also MMPs themselves) are able to cleave the prodomain from the latent 
MMPs, creating a shorter and active MMP molecule. In this stepwise activation process, a 
zinc2+ ion is first released from the cysteine complex. It was recently discovered that 
proteolytic removal of the prodomain is not a definite prerequisite for the activation process 
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to take place. Allosteric activation, which takes place when a thiol-binding reagent binds to 
the inactive MMP, resulting in displacement of the propeptide from the active site, is an 
alternative way of activating MMPs23.  
 
3. Compartmentalization 
Specificity of proteolysis is regulated by the affinity of an enzyme for a certain substrate. 
Furthermore, where and how an MMP is released and kept in the pericellular environment, 
also referred to as compartmentalization, is at least as important as the enzyme-substrate 
interaction20. Similar to the membrane-bound MMPs, the nonmembrane-bound MMPs 
released from the cells are kept locally in a high concentration by specific cell-MMP 
interactions, for example the binding of MMP-2 to αvβ3 integrin and MMP-9 to CD4420, 24, 25. 
Thereby, their proteolytic activity can be targeted towards specific substrates in the 
pericellular space.  
 
4. Endogenous regulators of enzymatic activity 
Tissue inhibitors of metalloproteinases (TIMPs) are the natural inhibitors of the MMPs. 
Currently, four TIMPs have been identified (known as TIMP-1 to -4) that reversibly bind to 
MMPs in a 1:1 ratio, forming binary non-covalent complexes which are resistant to heat-
denaturation and proteolytic degradation26. All TIMPs are capable of binding at least five 
different MMPs (but not at the same time) and the substrate spectrum of TIMP-2 even 
includes all MMPs. However, each TIMP has its own substrate preference. TIMPs are also 
able to bind the proforms of MMPs, and this interaction is relatively specific: TIMP-2, TIMP-
3 and TIMP-4 bind to proMMP-2 (but not proMMP-9), whereas TIMP-1 and TIMP-3 bind to 
proMMP-9 (but not proMMP-2)27. The binding of a TIMP to an MMP does not always have 
inhibitory effects, as illustrated by the binding of TIMP-2 in combination with MT1-MMP to 
proMMP-2, leading to the activation of proMMP-228-30. Besides these endogenous MMP-
specific inhibitors, other antiproteases like α2-macroglobulin, which is present in tissue 
fluids and plasma, also inhibit MMPs. Binding of this plasma protein to MMP leads to 
endocytosis, resulting in irreversible clearance of the MMPs from the circulation31. 
Furthermore, RECK (reversion-inducing cysteine-rich protein with Kazal motifs), a 110 kDa 
membrane-anchored glycoprotein with multiple EGF-like repeats and serine protease 
inhibitor-like domains32, is an inhibitor of MMP-2, MMP-9 and MT1-MMP secretion and 
activity32, 33. On the other hand, endogenous activators of MMPs can also increase the 
MMP-production. EMMPRIN (extracellular matrix metalloproteinase inducer) is an MMP-
inducer that is present in normal cells, but can be tumour-cell derived as well and is even 
up-regulated in cancer cells34, 35. This 58,000 kDa heavily glycosylated protein, member of 
the immunoglobulin superfamily, has been shown to stimulate production of MMP-1, -2, -3, 
and -9 by local endothelial cells and fibroblasts36-39.  
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secretion and activation of latent MMPs, compartmentalization and regulation of enzymatic 
activity by endogenous activators and inhibitors. 
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to take place. Allosteric activation, which takes place when a thiol-binding reagent binds to 
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up-regulated in cancer cells34, 35. This 58,000 kDa heavily glycosylated protein, member of 
the immunoglobulin superfamily, has been shown to stimulate production of MMP-1, -2, -3, 
and -9 by local endothelial cells and fibroblasts36-39.  
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Functions of MMPs under physiological and pathological circumstances 
Tissue remodelling is essential in physiological processes like growth and embryonic 
development. The nature and variety of the substrates of MMPs suggests a major role for 
this proteinase family in tissue morphogenesis and this assumption has been confirmed in 
various experimental models40-44. Also in reproductive processes like the menstrual cycle, 
ovulation, and the involution of the uterus, MMPs are overexpressed44, 45. Under 
physiological conditions, various MMPs are involved in the formation of new blood vessels46 
and in adults, their role in bone turnover and development as well as wound healing, in 
which processes take place that resemble those in malignant disease, like migration, ECM 
degradation and invasion, has been well established47.  
The proteolysis of extracellular matrix components is one of the first recognized 
functions of MMPs. Although substrate specificity is broad and most MMPs are capable of 
degrading more than one component of the extracellular matrix (ECM), each MMP has its 
specific substrate profile, which is not limited to ECM components (like collagens, laminin, 
fibronectin, vitronectin, tenascin, elastin, entactin and proteoglycans) but extends to 
cytokines, growth hormones and binding proteins48. In the last decade it has become clear 
that MMP function is much more comprehensive than regulation of cell growth by cleavage 
of cell surface-bound growth factors and receptors, and by release of sequestered growth 
factors from the ECM. This now also includes regulation of apoptosis, influencing cell 
motility by cleavage of adhesion molecules and revealing matrix signals, regulation of 
angiogenesis (in a pro- as well as anti-angiogenic way), interfering with the immune system 
and modulation of the bioactivity of chemokines49, 50. All these processes are relevant in 
different stages of cancer development and progression. The first step in cancer growth and 
metastases is to cross the natural barriers (e.g., the basement membrane), a process in 
which the proteolytic properties of the MMPs are of importance. After the cancer has 
invaded into the deeper layers of the normal tissue, vascular invasion and angiogenesis as 
well as the ability for individual cancer cells to survive in the circulation become important. 
In most cases, the liver is the primary target organ for metastases of colorectal cancer. 
Before cancer cells are able to embed and to multiply in another organ, a so called 
“metastatic niche” needs to be created51. MMPs have been demonstrated to play an 
important role in the formation of this specific environment in the target organ that permits 
the growth and/or invasion of cancer cells at a distant site52. Figure 3 illustrates the different 
cell types that are implicated in the aforementioned processes and shows which MMPs are 
involved at the different stages of tumour growth, invasion and metastasis. 
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Figure 3. Overview of the different processes in tumour development and metastasis, and the MMPs that are involved 
in each of these processes. The right panel shows the cellular source of the MMPs. Most MMPs are produced mainly 
by stromal cells (like inflammatory cells, fibroblasts and endothelial cells) that are present abundantly in the tumour 
microenvironment. Only a small part of MMP production occurs in the tumour cells themselves. Some examples of 
the MMPs and TIMPs that are produced by the various stromal cells and neoplastic cells are shown. Adapted from 
Kessenbrock et al. (2010)54. 
CHARACTERISTICS OF MMPs STUDIED IN THIS THESIS 
 
Matrix metalloproteinase -2 and -9 
MMP-2 (gelatinase A or 72 kDa type-IV collagenase) and MMP-9 (gelatinase B or 92 
kDa type-IV collagenase) are named after two of their major substrates. Both enzymes 
contain fibronectin type II-like repeats within their catalytic domains (Figure 2), which 
increases the affinity for binding to gelatin (denatured collagen) and elastin53. Although 
tumour cells have been reported to secrete MMP-2 and MMP-9, both gelatinases are 
produced mainly by stromal cells. MMP-2 is expressed constitutively by many different cell 
types including macrophages, endothelial cells, mast cells, fibroblasts, hematopoietic 
progenitor cells and dentritic cells31, 54. MMP-9 is produced mainly by inflammatory cells, like 
neutrophilic granulocytes, macrophages, mast cells and lymphocytes, but other cell types 
including dendritic cells and fibroblasts are also sources of MMP-9. In 1980, Liotta et al. 
demonstrated that the degradation of collagen type IV by MMPs leads to invasion of the 
cancer cells into the deeper layers of the bowel wall and subsequent metastasis55. Due to 
their capability to degrade type-IV collagen, which is a major component of the basement 
membrane, the gelatinases have been regarded with particular interest in cancer research.  
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As is the case for MMPs in general, the functional spectrum of MMP-2 and MMP-9 
extends far beyond their collagenolytic activity. Besides collagen type IV and gelatin, other 
ECM components like elastin, laminin and aggrecan, but also non-ECM molecules like 
growth factors (e.g. TGF-β), chemokines and other proMMPs are targets for MMP-2 and/or 
MMP-956-67. An important role in angiogenesis has been established for MMP-9, which 
triggers the angiogenic switch by releasing VEGF68. In an in vivo animal model, MMP-2 has 
been shown to be required for the switch to an angiogenic phenotype69. On the other hand, 
angiogenesis could be inhibited by the MMP-9 mediated formation of angiostatin, which is a 
breakdown product of plasminogen and a potent angiogenesis inhibitor70. MMP-9 is 
essential in the formation of a metastatic niche, in which its ability to break down basement 
membrane barriers and induce the release of VEGF are crucial71. Inflammation is another 
essential aspect of cancer progression72. One of the ways in which MMP-2 and MMP-9 are 
implicated in inflammation is by activation of pro-TNF-α, which is a pro-inflammatory 
cytokine that is produced in large quantities in cancer and has been shown to promote 
cancer cell survival73, 74. Proteolysis of chemokines by MMP-2 or MMP-9 can also lead to 
inactivation of pro-inflammatory cytokines and therefore the role of these MMPs in 
inflammation is not only pro-inflammatory, but they serve as regulators of inflammation75. 
The influx of tumour-infiltrating inflammatory cells, like macrophages, neutrophils and mast 
cells into the tumour microenvironment will lead to a local increase of MMP-9 production, as 
these cells are the major source of MMP-9.  
Matrix metalloproteinase-7 
MMP-7 (also known as matrilysin or putative metalloproteinase [PUMP]-1) is the 
smallest member of the MMP-family, consisting of a predomain, prodomain and catalytic 
domain only, lacking a C-terminal hemopexin domain (figure 2). The substrate specificity of 
MMP-7 resembles that of the stromelysins and includes ECM components (like fibronectin, 
gelatins, collagen type IV, laminin and elastin), proMMPs -1, -2 and -9 and other proteins 
(like transferrin, urokinase plasminogen activator (uPA), e-cadherin and TNF-α precursor), 
although the structure of the catalytic domain is more similar to that of the interstitial 
collagenases76-83. It is the only MMP, apart from membrane-type 1-MMP, that is secreted 
mainly by the tumour epithelial cells themselves. Under physiological circumstances, MMP-
7 is expressed in the wound-edges from injured epithelium of mucosal surfaces in the lung 
and intestine, where it is required for re-epithelization84. Loosening of cell-cell contacts (and 
thereby increased cell migration) through MMP-7 mediated shedding of e-cadherin 
ectodomains is probably the underlying mechanism in this process85, 86. Also in healthy, 
non-injured epithelium MMP-7 is constitutively expressed and regulates apoptosis and the 
defence against bacteria by regulating the production of defensins. In a mouse model, 
MMP-7 activates intestinal pro-α defensins, which fight pathogenic intestinal bacteria like 
Escherichia coli and Salmonella Typhimurium87, 88. The various functions of MMP-7 make it 
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a good candidate to be studied in a cancer environment, and it has indeed been 
demonstrated that MMP-7 is involved at different levels of cancer progression and 
metastasis.  
In colorectal cancer, MMP-7 has been reported to induce angiogenesis by accelerating 
the proliferation of endothelial cells89 and it was found to activate the EGF receptor by the 
release of TGF-α, which is an EGF ligand90. MMP-7 also increased tumour cell survival by 
interfering with at least two pathways. Firstly, it’s binding to insulin-like growth factor binding 
protein (IGFBP)-3 resulted in proteolysis of this protein, leading to increased bio-availability 
of IGF-1 and increased tumour cell survival91. Secondly, MMP-7 increased resistance to 
programmed cell death by shedding membrane-bound Fas ligand and thereby creating an 
apoptosis-resistant phenotype92. 
Matrix metalloproteinase-8 (MMP-8) and neutrophil gelatinase-associated lipocalin (NGAL)  
The members of the subfamily of MMPs referred to as collagenases, to which MMP-8 
belongs, share the ability to cleave the fibrillar collagens type I, II and III. The substrate 
range of MMP-8 extends beyond that and includes a wide range of collagens (collagen type 
VII, X) and non-collagenous ECM components (like laminin, proteoglycans) as well as non-
structural substrates like angiotensin, IGFBP-5, chemokines and serine protease 
inhibitors93. MMP-8 is also named collagenase-2 or neutrophil collagenase, the latter of 
which suggests that MMP-8 is derived from polymorphonuclear neutrophils (or PMNs), 
which have indeed long be assumed to be the only source of MMP-8. It has been shown, 
however, that not only other inflammatory cells, like T-cells and plasma cells but also non-
inflammatory cells, like epithelial cells, colonic mucosal cells and myofibroblasts, express 
MMP-8, albeit mainly in acute or chronic inflammatory conditions93. 
Neutrophil gelatinase-associated lipocalin (NGAL), also known as human neutrophil 
lipocalin (HNL) or lipocalin-2, is a 25 kDa protein that belongs to the lipocalin superfamily. 
This family consists of about 20 small lipoproteins that share a similar 3D-structure and the 
capability to bind to small hydrophobic ligands like hormones, fatty acids, prostaglandins 
and retinoids94. Lipocalin-2 has first been described to be present in the granules of human 
neutrophilic leucocytes95, but was later discovered to be expressed by certain epithelial 
cells, mainly under circumstances of inflammation or malignancy96, 97. It is able to covalently 
bind to matrix metalloproteinase-9 (MMP-9) and inhibit its degradation, thereby sustaining 
MMP-9 proteolytic activity98, 99. Furthermore, lipocalin-2 is implicated in the process of iron 
trafficking and metabolism. By binding to bacterial siderophores (“iron carriers” in Greek 
language), which are small molecules with a high affinity for Fe3+, lipocalin-2 acts as a 
bacteriostatic agent as it blocks the growth of the bacteria100. Mammalian cells produce 
siderophore-like molecules that also bind to lipocalin-2, which might lead to either iron 
deposition in the cell (in case of iron-loaded siderophores) or, in case of binding to a 
siderophore not complexed with iron, to cellular uptake of an iron-free siderophore-lipocalin-
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2 complex which induces a state of iron depletion and presumably stimulates apoptosis101-
103. The exact role of lipocalin-2 in cancer seems to be contradictory and dependent of the 
cellular origin of the tumour, as pro-tumour effects (e.g., inhibition of apoptosis) as well as 
anti-tumour effects (e.g., stimulation of apoptosis, inhibition of adhesion and invasion of 
cancer cells, and the arrest of VEGF synthesis) have been reported in various tumour 
types96, 104.  
Matrix metalloproteinases in colorectal cancer 
In the year 2000, Hanahan and Weinberg defined six hallmarks of cancer which consist 
of six biological capabilities that are of importance during the development of human 
cancer105. These hallmarks are: 1) sustaining proliferative signalling by production of 
autocrine growth signals, 2) escaping growth suppressors, 3) insensitivity to apoptosis, 4) 
enabling replicative immortality by loss of senescence, 5) induction of angiogenesis and 6) 
tissue invasion and metastasis. The different functions of MMPs that have been described 
in this chapter demonstrate that they are implicated in some way in all of these processes 
which suggests that they are probably involved in virtually all different types of cancers. 
Over expression of MMP-1, -2, -3, -7, -9, -10, -11, -12, -14 (MT1-MMP), -21 and -25 (MT6-
MMP) has been described in human colorectal cancer and often the MMP-levels in cancer 
tissue were associated with the clinical outcome of the patients106-152. Also in colorectal 
adenomas, MMP-2, -7 and -9 and their inhibitors TIMP-1 and TIMP-2 have been 
demonstrated to be up-regulated118, 139, 148, 153-156. The exact pattern of up-regulation of 
MMPs in the different stages of colorectal cancer development and progression has only 
been partially uncovered, but insight in this process is crucial for the development of MMP-
inhibiting therapeutical strategies.  
 
Outline of the studies described in this thesis 
The studies described in this thesis were focused on the possible impact of MMP-2, 
MMP-7, MMP-8, MMP-9 and NGAL on colorectal cancer development, metastasis and 
survival of the patients. In order to put the different studies in perspective, chapter 1 first 
gives a short introduction on colorectal cancer, MMPs and their specific functions in a 
cancer microenvironment.  
The adenomatous polyp is the most common precursor lesion of colorectal cancer. A 
number of genetic alterations are needed before an adenomatous polyp evolves to 
colorectal cancer. In each step of this process, specific mutations can be identified as 
described earlier in this chapter and illustrated in figure 1. There is evidence that MMPs are 
involved in the early phase of the neoplastic process. Once a cancer has developed, it has 
the potential to metastasize to distant organs. In colorectal cancer, the liver is most often 
the target organ for distant metastases. Throughout the process from adenoma formation, 
via the development of colorectal cancer and eventually the occurrence of distant 
20 | Chapter 1
metastases, MMPs might be of pivotal importance. We speculated that the role of different 
MMPs might vary throughout this process. Chapter 2 describes the analysis of how MMP-2, 
MMP-8, MMP-9 and NGAL could be involved in the different steps of the adenoma-
carcinoma-metastasis sequence.  
Subsequently a study on the use of MMP-2 and MMP-9 measurements in body fluids, as 
a putative reflection of the malignant process in the intestine, for the prediction of the course 
of disease in colorectal cancer patients is described in chapter 3. Besides the (labour-
intensive) technique of quantitative gelatin zymography, also a bio-activity assay (BIA) and 
an enzyme-linked immunosorbent assay (ELISA) were used to measure the MMP-levels in 
urine and peripheral blood. The levels of MMP-2 and MMP-9 in plasma and urine were 
evaluated for their prognostic impact in patients with colorectal cancer. 
Single-nucleotide polymorphisms (SNPs) are the most common form of genetic variation 
and consist of the replacement of a single base pair in the human genome. This 
replacement can occur in coding and non-coding regions of the genome. These subtle 
genetic variations may influence the level of production of the respective protein and affect 
the susceptibility to develop a certain disease, but may also influence the course of a 
disease. Most of the SNPs of MMPs that have been studied in cancer of the digestive tract 
are located in the promoter region of the gene and might therefore influence gene 
expression. Chapter 4 describes a comprehensive evaluation of the literature on SNPs in 
the MMP genes in gastrointestinal cancer (i.e., esophageal, gastric, hepatocellular and 
colorectal carcinoma).  
MMP-2 and MMP-9 were previously demonstrated to be implicated in a variety of 
cancers. Because of their capability to degrade collagen type IV, a major component of the 
basement membrane, they have been in the centre of interest for a long time. In most 
tumours, high levels of MMP-2 and MMP-9 are associated with an unfortunate outcome of 
the patients. The study we performed on the impact of MMP-2 and MMP-9 protein levels 
and their corresponding genotypes in 215 colorectal cancer patients is described in chapter 
5. Particularly the correlation of the genotypes and the phenotypical expression of the 
gelatinases in homogenates of colorectal carcinoma tissue with survival were evaluated in 
this study.  
Changes in normal mucosa distant from a tumour have been previously associated with 
disease outcome. From 198 of the 215 patients described in chapter 3, normal colon tissue 
at 5-10 centimetres distance from the malignancy was available in our biorepository. This 
permitted a look into the MMP-2 and MMP-9 levels in normal colorectal tissue of patients 
suffering from colorectal cancer in relation to their 5-year survival. The results of this study 
are described in chapter 6. 
The results of a study on MMP-7 expression and activity in 174 colorectal carcinomas 
and 52 colorectal adenomas are reported in chapter 7. Two single nucleotide 
polymorphisms of the MMP-7 gene, located in its promoter region and known to modify 
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gene transcription activity in vitro (MMP-7 -153 C/T and -181 G/T SNP) were studied in the 
174 colorectal cancer patients, with special attention to their correlation with tissue levels of 
MMP-7 and survival. Furthermore, this chapter focuses on MMP-7 expression and activity 
during the different stages of colorectal cancer development and the correlation between 
the tumour levels of (active) MMP-7 and outcome of the colorectal cancer patients.  
Finally the different studies described are summarized and discussed in chapter 8 of 
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Background and aim of the study: Matrix metalloproteinases (MMPs) have been implicated 
in colorectal cancer progression and prognosis. However, the role of MMPs in early cancer 
development and in the process of dissemination of the disease has been studied less 
extensively. In the present study, we investigated the expression and activity of MMP-2, -8 and 
-9 and neutrophil gelatinase-associated lipocalin (NGAL) in tissue from various stages of 
colorectal cancer progression. 
  
Methods: The expression of NGAL, MMP-8, -2 and -9 was measured by ELISA in a series of 
normal colorectal mucosa, adenomatous polyps, adenocarcinomas, liver metastasis and 
normal liver (n= 20 of each group), and the activity of MMP-9 was measured by Bio–Immuno-
Activity Assay (BIA) and quantitative gelatin-zymography of tissue homogenates. The degree 
of inflammation was assessed by myeloperoxidase (MPO) activity. 
Results: There was a consistent and significant step-wise increase in the MMP-8 level 
associated with the progression from normal mucosa to adenoma (2-fold) and from adenoma 
to carcinoma (8-fold), with similar high levels in the liver metastases as in the primary 
carcinomas. We found a similar, though less pronounced, increase (up to 3-fold) in MMP-9 in 
this malignancy sequence, with a good correlation between the ELISA and zymography results 
(r = 0.60). NGAL also showed an increase in the normal mucosa - adenoma (4-fold) - 
carcinoma (6-fold) - liver metastasis (3-fold) sequence. The MMP-2 level only showed an 
increase (up to 1.5-fold) in the carcinomas. Interestingly, the primary colorectal carcinomas 
contained a significantly (P < 0.05) higher percentage of both MMP-2 and MMP-9 in the active 
enzyme form than adenomas and liver metastases (respectively 55 ± 6 vs 29 ± 3 and 30 ± 3, 
and 21 ± 1 vs 14 ± 2 and 10 ± 3). Normal liver tissues had low MMP levels. 
Conclusion: In conclusion, the development of colorectal cancer, as illustrated by the normal 
mucosa - adenoma - carcinoma - liver metastasis sequence, is accompanied by a concurrent 
increase in the NGAL and MMP levels, particularly MMP-8 and MMP-9, providing evidence 
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INTRODUCTION 
Colorectal cancer is the third most frequent cancer worldwide, with more than 1,2 million 
new cases each year and 608.000 deaths in 2008 (source: World Health Organization, 
www.WHO.int). Up to 15% of these cancers are clustered within families, while the other 85% 
are classified as sporadic colorectal cancer. In both familial and sporadic cases, the majority of 
these cancers develop from a precursor lesion, the adenomatous polyp, in which sequential 
changes eventually lead to the development of cancer1, 2.  
Matrix metalloproteinases (MMPs) are metal-dependent proteolytic enzymes that play an 
important role in various biological processes as they determine the rate of remodelling of the 
extracellular matrix and are implicated in the regulation of angiogenesis, migration, invasion 
and cancer-cell growth and cell death3, 4. Approximately 25 members of the MMP family have 
so far been identified, which have been numbered in the order of their discovery and 
subdivided based on the characteristics of their substrate specificity in collagenases, 
gelatinases, stromelysins, matrilysins and membrane-type MMPs5. Altogether, the members of 
the MMP family are able to degrade virtually all components of the extracellular matrix, such 
as collagens, laminin, fibronectin, vitronectin, entactin and proteoglycans5. Most MMPs are up-
regulated in malignancy and, in most cases, are thought to contribute to cancer progression 
and dissemination. However, this is not always the case, as illustrated by the protective effects 
of overexpression of some MMPs (e.g., MMP-8 or neutrophil collagenase) that has been 
described for several tumours6-8. 
Lipocalins, together with the fatty-acid-binding proteins (FABPs) and avidins, belong to the 
calycins9. These lipocalins are involved in the regulation of cell homeostasis, modulation of the 
immune response, and clearance of endogenous and exogenous compounds9. Neutrophil 
gelatinase-associated lipocalin (NGAL) is a 25 kD protein of human neutrophils, that is in part 
covalently complexed with MMP-9 (gelatinase B, 92 kDa type IV collagenase). It is located in 
specific granules apart from gelatinase granules in human neutrophils10. 
In colorectal carcinomas, increased levels of active MMP-2 (gelatinase A, 72 kDa type IV 
collagenase) and MMP-9 have been reported compared to normal mucosa11-13. In addition, a 
role in early carcinogenesis has been suggested for MMP-9, but not for MMP-214-16.  
The aim of the present study was to investigate the presence and activity of MMP-2, MMP-
8, MMP-9 and NGAL throughout the sequence from normal tissue, via adenomas and 
colorectal cancer, to liver metastases from colorectal origin. We used several techniques, 
including bio-immuno-activity assay (BIA), ELISA and quantitative zymography, to quantify the 
total and active amount of the proteinases. 
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ABSTRACT 
Background and aim of the study: Matrix metalloproteinases (MMPs) have been implicated 
in colorectal cancer progression and prognosis. However, the role of MMPs in early cancer 
development and in the process of dissemination of the disease has been studied less 
extensively. In the present study, we investigated the expression and activity of MMP-2, -8 and 
-9 and neutrophil gelatinase-associated lipocalin (NGAL) in tissue from various stages of 
colorectal cancer progression. 
  
Methods: The expression of NGAL, MMP-8, -2 and -9 was measured by ELISA in a series of 
normal colorectal mucosa, adenomatous polyps, adenocarcinomas, liver metastasis and 
normal liver (n= 20 of each group), and the activity of MMP-9 was measured by Bio–Immuno-
Activity Assay (BIA) and quantitative gelatin-zymography of tissue homogenates. The degree 
of inflammation was assessed by myeloperoxidase (MPO) activity. 
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(r = 0.60). NGAL also showed an increase in the normal mucosa - adenoma (4-fold) - 
carcinoma (6-fold) - liver metastasis (3-fold) sequence. The MMP-2 level only showed an 
increase (up to 1.5-fold) in the carcinomas. Interestingly, the primary colorectal carcinomas 
contained a significantly (P < 0.05) higher percentage of both MMP-2 and MMP-9 in the active 
enzyme form than adenomas and liver metastases (respectively 55 ± 6 vs 29 ± 3 and 30 ± 3, 
and 21 ± 1 vs 14 ± 2 and 10 ± 3). Normal liver tissues had low MMP levels. 
Conclusion: In conclusion, the development of colorectal cancer, as illustrated by the normal 
mucosa - adenoma - carcinoma - liver metastasis sequence, is accompanied by a concurrent 
increase in the NGAL and MMP levels, particularly MMP-8 and MMP-9, providing evidence 
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PATIENTS, MATERIALS AND METHODS
Patients and Tissues 
Adenomas (n=20) were freshly obtained by endoscopic snare polypectomy at the 
Department of Gastroenterology and Hepatology of the Leiden University Medical Center 
(LUMC). Fresh tissue samples of the adenomas were frozen and stored at -70°C until 
extraction. Part was routinely formalin fixed and embedded in paraffin for histological 
evaluation. Fourteen adenomas were found to be tubulovillous, five were tubular and one 
was villous. The degree of epithelial cell dysplasia was low grade in 14 adenomas and high 
grade in 6 adenomas. 
In addition, fresh tissue was obtained from 20 patients who underwent resection for 
primary colorectal carcinoma at the Department of Surgery of the Leiden University Medical 
Center as previously described17. Representative samples of the carcinoma and 
macroscopically normal mucosa, taken 5-10 cm from the tumour, were frozen and stored at 
-70°C until extraction and parallel samples were routinely fixed and embedded in paraffin. 
Using the Dukes’ classification as modified by Astler and Coller18, the carcinomas were 
classified in stage B1 (n=4), B2 (n=8), C1 (n=2), C2 (n=3) and D (n=3). Differentiation grade 
was poor in 2, moderate in 13 and well in 5 carcinomas. Four out of the 20 carcinomas were 
of the mucinous type. 
Finally, fresh tissue was collected from 20 patients who underwent partial liver resection 
because of colorectal liver metastasis as previously described19. Representative samples of 
the carcinomas and of macroscopically normal liver tissue were frozen and stored at -70°C, 
other parts were routinely formalin fixed and embedded in paraffin. In all cases, the 
diagnosis metastasis of an adenocarcinoma from colorectal origin was confirmed by 
histopathological examination.  
 
Tissue extraction and protein concentration 
Tissue specimens were homogenized in 0.1 M Tris-HCl, 0.1% (v/v) Tween 80 buffer (pH 
7.5), as extensively described previously17, 20, 21. Briefly, the samples were homogenized in 
1 ml buffer per 60 mg wet tissue at 0°C. The homogenates were centrifuged at 8000 g for 
2.5 min at 4°C and the supernatant was stored at -70°C until analysis. The protein 
concentration of the supernatant was determined by the method of Lowry22. 
MMP-2 and MMP-9 gelatin zymography 
Presence of active and latent forms of matrix metalloproteinases was analyzed by 
zymography on 10% SDS-polyacrylamide gels containing 2% gelatin and overnight 
incubation at 37°C, as described previously (12, 24). Sample volumes were adjusted to 
obtain a uniform protein content of 10 µg per sample. The gels were stained with 
Coomassie brilliant blue R-250, dried between sheets of cellophane, and the degree of 
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gelatin digestion was quantified using a LKB Ultroscan XL enhanced laser densitometer 
(633 nm). Two amounts (12 and 24 µg protein of an internal standard preparation, i.e. an 
homogenate of a colonic carcinoma containing both MMP-2 and MMP-9, were included on 
each gel for correction of intergel variation and as reference for the expression in arbitrary 
units (AU). This zymographic analysis was highly linear over an at least 20-fold range (i.e. 
2-40 µg protein per sample). 
 
NGAL, MMP-2, MMP-8 and MMP-9 ELISAs 
The total amount of NGAL, MMP-2, MMP-8 and MMP-9 was determined, in appropriate 
dilutions of the homogenates, by established sandwich-ELISAs, as described previously23-
25. Results were expressed in ng MMP per mg protein. 
 
MMP-2 and MMP-9 Bio-Immuno-Activity Assay (BIA) 
Total MMP-2 and MMP-9 was also measured using a colorimetric assay26. Briefly, 
antibodies to MMP-2 and MMP-9, as in the ELISAs, were used as catching antibody for the 
respective MMPs in the homogenates, during overnight incubation. These MMPs were then 
activated by incubation with 0.5 mM p-aminophenyl-mercuric acetate at 37°C and their 
activity measured with modified pro-urokinase (Ukcol) and S-2444 (0.6 mM), as 
chromogenic substrate, in assay buffer at 37°C. Reactions were performed in 96-well flat-
bottomed microtitre plates, and a Titertek Multiskan photometer was used to follow the 
absorbance change at 405 nm. Results were calculated from a standard curve and 
expressed as units MMP per mg protein.  
 
Myeloperoxidase activity 
Myeloperoxidase (MPO) in tissue homogenates was assessed according to the 
procedure described by Kruidenier et al27. In short, 50 μl tissue homogenate was incubated 
in buffer with 0.026% ortho-dianisidine dihydrochloride and 0.02% hydrogen peroxide. The 
reaction kinetics were followed in colorimetrically at 450 nm in microtitre plates. MPO was 
expressed in Arbitrary Units (AU) per mg protein.  
 
Statistical analysis 
Group means are given as mean ± standard error of the mean (SEM). Differences 
between dependent samples from groups were tested for significance using paired 
Student's t-test with separate variance estimate if the standard deviations were significantly 
different according to the F-test. For testing the significance of a difference in means for 
independent samples the independent-samples Student’s t-test was used. Differences were 
considered significant when P < 0.05 (SPSS for Windows Release 7.0, 1995, SPSS Inc., 
Chicago, U.S.A.). 
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Inflammation, as assessed by the myeloperoxidase activity, was significantly higher (P ≤ 
0.001) in adenomas (4.72 ± 0.35) compared to normal mucosa (1.99 ± 0.28), colorectal 
cancer (2.14 ± 0.30), liver metastases (1.92 ± 0.37) and normal liver tissue (0.51 ± 0.12). 
No relevant difference was observed between carcinomas and metastases. 
 
MMP-8 
There was a consistent and significant step-wise increase in the level of MMP-8 in the 
normal mucosa-adenoma (2-fold)-carcinoma (8-fold) sequence, with a similar level in the 
liver metastases compared to the primary carcinomas (Figure 1). Even after correction for 
inflammation by the MPO content, the increase of MMP-8 in carcinoma and liver metastasis 




















Figure 1. MMP-8 and NGAL, as measured by ELISA, in the colorectal cancer sequence. * P ≤ 0.05 vs. normal 




































































Figure 2. Levels of MMP-8, NGAL (left axis), and MMP-9 (right axis), as determined by ELISA, in colorectal 
neoplasia, corrected for MPO activity. Values are expressed in ng NGAL or MMP/MPO. * P ≤ 0.05 vs. normal 
mucosa; ** P ≤ 0.01 vs. normal mucosa; # P ≤ 0.05 vs. adenoma; ## P ≤ 0.01 vs. adenoma. 
 
 
Neutrophil granulocyte-associated lipocalin (NGAL) 
Adenomas (4-fold) and carcinomas (6-fold) showed a marked increase in NGAL content 
compared to normal mucosa and resembled the trend of MMP-9 (Figure 1). Liver 
metastases were found to contain more NGAL than normal liver. After correction for 
inflammation the primary colorectal carcinomas still contained 4 times - and liver 
metastases 2 times - the amount of NGAL present in normal colonic mucosa (Figure 2).  
MMP-9 
The MMP-9 ELISA showed a comparable, though less pronounced, increase (up to 3-
fold) in the sequence normal mucosa-adenoma-carcinoma (Figure 3). The MMP-9 content 
in liver metastases was lower than in the primary tumours and comparable to that in 
adenomas. After correction for inflammation, the colorectal carcinomas still contained 
consistently higher amounts of MMP-9 (Figure 2). Quantitative zymography showed 
significantly higher amounts of pro-, active- and total MMP-9 in carcinomas compared to the 
other tissues. The percentage of active MMP-9 in the carcinomas (21 ± 1%) was 
considerably higher compared to adenomas and liver metastases (14 ± 2% and 10 ± 3%, 


























































P-9 in ng / M
PO




Inflammation, as assessed by the myeloperoxidase activity, was significantly higher (P ≤ 
0.001) in adenomas (4.72 ± 0.35) compared to normal mucosa (1.99 ± 0.28), colorectal 
cancer (2.14 ± 0.30), liver metastases (1.92 ± 0.37) and normal liver tissue (0.51 ± 0.12). 
No relevant difference was observed between carcinomas and metastases. 
 
MMP-8 
There was a consistent and significant step-wise increase in the level of MMP-8 in the 
normal mucosa-adenoma (2-fold)-carcinoma (8-fold) sequence, with a similar level in the 
liver metastases compared to the primary carcinomas (Figure 1). Even after correction for 
inflammation by the MPO content, the increase of MMP-8 in carcinoma and liver metastasis 




















Figure 1. MMP-8 and NGAL, as measured by ELISA, in the colorectal cancer sequence. * P ≤ 0.05 vs. normal 
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Figure 3. MMP-9 in the colorectal cancer sequence. Left axis: quantitative gelatin zymography (Z), results expressed 
in activity units (AU) and ELISA, results expressed in ng per mg protein. Right axis: BIA, results expressed in U/mg 
protein. * P ≤ 0.05 vs. normal mucosa; • P ≤ 0.05 vs. other tissues; •• P ≤ 0.01 vs. other tissues; † P ≤ 0.05 vs. normal 




BIA results were comparable to ELISA and quantitative zymography data (Figure 3). The 
highest MMP-9 content was found in the primary colorectal carcinomas. Liver metastases 
showed a lower MMP-9 content, comparable to adenomas. The overall correlation between 
ELISA, quantitative zymography and BIA was good, ranging from 0.60 (P < 0.001) between 
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MMP-2 
The MMP-2 levels showed only an increase (up to 1.5-fold) in the carcinomas compared 
to normal mucosa (Figure 4). The MMP-2 level in liver metastases showed a comparable 
increase to the carcinomas when assessed by zymography, but not by the other 
techniques. The percentage of active enzyme in carcinomas (55 ± 6%) was significantly 
higher than in adenomas (29 ± 3%) and liver metastases (30 ± 3%). Normal liver tissue 
homogenates were found to contain lower levels of MMP-2 than any of the other tissues, 
although this difference was significant only in the ELISA results. The correlation between 
ELISA and gelatin zymography for MMP-2 was good (r = 0.57; P < 0.001), between BIA and 
ELISA the correlation was moderate (r = 0.32, P < 0.005), and relatively weak between the 
BIA and quantitative gelatin zymography (r = 0.24, P < 0.05).  
 






















Figure 4. MMP-2 in the colorectal cancer sequence. Left axis: quantitative gelatin zymography (Z), results expressed 
in activity units (AU). Right axis: ELISA and BIA, results expressed in ng per mg protein (ELISA) and x10-1 U/mg 
protein (BIA). * P ≤ 0.05 vs. normal mucosa (total enzyme); ** P ≤ 0.01 vs. normal mucosa (active enzyme); ## P ≤ 
0.01 vs. adenoma (active enzyme); †† P ≤ 0.01 vs. normal liver (active enzyme); ••• P ≤ 0.001 vs. other tissues. The 
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Figure 3. MMP-9 in the colorectal cancer sequence. Left axis: quantitative gelatin zymography (Z), results expressed 
in activity units (AU) and ELISA, results expressed in ng per mg protein. Right axis: BIA, results expressed in U/mg 
protein. * P ≤ 0.05 vs. normal mucosa; • P ≤ 0.05 vs. other tissues; •• P ≤ 0.01 vs. other tissues; † P ≤ 0.05 vs. normal 
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MMP-2 
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protein (BIA). * P ≤ 0.05 vs. normal mucosa (total enzyme); ** P ≤ 0.01 vs. normal mucosa (active enzyme); ## P ≤ 
0.01 vs. adenoma (active enzyme); †† P ≤ 0.01 vs. normal liver (active enzyme); ••• P ≤ 0.001 vs. other tissues. The 
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DISCUSSION 
 
Several in vitro and in vivo studies, reviewed by Mook et al.28, have shown the relevance 
of MMP-2 and MMP-9 in colorectal cancer progression and metastasis. Both gelatinases 
are in principle secreted as inactive pro-enzymes. Activation of these pro-MMPs takes place 
through interaction with other MMPs and/or other proteases28. Quantitative zymography has 
been shown previously to be an extremely reliable and sensitive technique for the detection 
of these gelatinases and to distinguish between the proenzyme and active form29, 30. Using 
this technique, we found that pro-, active- and total MMP-2 and -9 levels are higher in 
carcinomas compared to normal colonic mucosa. These findings are in agreement with 
several other reports12, 16, 31-35. 
In the present study, we have also looked into the expression of MMPs in the early and 
later stages of colorectal carcinogenesis. We found that tissue levels of MMP-2, -8, and -9 
and NGAL are increased in carcinomas and liver metastases of colorectal carcinomas, even 
after correction for inflammation, and that MMP-8, MMP-9 and NGAL are increased in 
colorectal adenomas as well.  
Several studies already suggested a role for MMP-9 in early carcinogenesis, whereas 
MMP-2 seems to be of importance later in the adenoma-carcinoma sequence, once a 
carcinoma has developed. An up-regulation of MMP-9 in colorectal adenomas compared to 
the normal mucosa was found in two other zymography studies14, 16. Up-regulation of the 
latent or active form of MMP-2 has never been observed in precancerous lesions. A trend 
towards a step-wise increase of MMP-9 in the colorectal adenoma-carcinoma sequence 
was also demonstrated in immunohistochemical studies of adenoma and carcinoma 
tissue15, 36 and these results were confirmed by performing real time RT-PCR on the same 
tissue specimens15. MMP-9 expression in adenomas appears to be correlated with severity 
of dysplasia, but not with histological subtype14, 16, 37, 38. In accordance with the 
abovementioned studies, we found a significant increase of total and active MMP-9 in 
colorectal carcinoma versus normal tissue measured either by ELISA, BIA or zymography. 
A trend towards increased expression of MMP-9 was observed in adenomas compared to 
normal mucosa, but this did not reach statistical significance. MMP-2 was only moderately 
up-regulated in colorectal cancer but not adenomatous tissue.  
The formation of adenomas was further studied in APC-Min mice39 after knocking out 
either the MMP-2 or the MMP-9 gene. Ablation of the MMPs did not influence adenoma 
size; however, adenoma number was reduced by 40% and proliferation was reduced by 
50% in the MMP-9-/- mice compared to their MMP-9+/+ littermates40. Knockout of MMP-2 did 
not reduce adenoma number or the number of proliferating cells. These findings support the 
hypothesis that there is a role for MMP-9, but not for MMP-2, early in the adenoma-
carcinoma sequence. 
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MMP-8 (neutrophil collagenase, collagenase-2) is a 75 kDa neutrophil-derived matrix 
metalloproteinase that degrades type I, II en III collagen and a wide range of non-
collagenous substrates like serine protease inhibitors and chemokines41. Several studies in 
breast cancer, lung cancer and melanoma have shown that increased expression of MMP-8 
can play a protective role in the progression of metastasis of cancer, probably through 
regulation of the inflammatory process induced by carcinogens and the modulation of 
tumour cell adhesion and invasion42, 43. These findings illustrate that the influence of MMP-8 
on cancer varies between cancer types and throughout the cancer process41, which makes 
it unsuitable as a target for anticancer drugs. Little is known about its role in colorectal 
cancer. Our results show that MMP-8 is significantly increased in adenomas, carcinomas 
and liver metastases compared to normal mucosa. The consequence of MMP-8 
overexpression in the colorectal cancer sequence, i.e., protection or contribution to 
carcinogenesis, needs to be further explored. 
NGAL [or neutrophil gelatinase-associated lipocalin, also called lipocalin-2 or human 
neutrophil lipocalin (HNL)] is a 25 kDa glycosylated protein that forms homo-dimers in 
neutrophil granules and heterodimers with MMP-9. It prevents inactivation of MMP-9 by 
binding to the gelatinase and thereby preventing its degradation, is a carrier of small 
lipophilic ligands, e.g. N-formyl peptides, and is involved in migration processes10. NGAL 
was significantly enhanced in adenomas and carcinomas compared to normal mucosa. In 
liver metastases, NGAL levels were lower than in the carcinomas.  
Neutrophil granulocytes are a major source of NGAL, MMP-8 and MMP-9 secretion. 
After correction for inflammation, the levels of both MMPs and NGAL were not significantly 
different in normal colon tissue and adenomas, suggesting that the increased expression in 
adenomas can mainly be attributed to an increased neutrophil influx. In carcinomas and 
liver metastases,  however, the increase in MMP-8, MMP-9 and NGAL levels persisted 
even after correction for inflammation. These findings demonstrate that an influx of 
neutrophils into the tumour microenvironment is only partially responsible for the increase in 
MMP-8 and MMP-9 in the tumour and indicate that there is a true increase in the production 
of these proteins within the malignant tissues. In a series of gastric cancer patients, MMP-9 
and NGAL-staining was present in a substantial part of epithelial cells44. Also in colorectal 
cancer specimens, intensive epithelial NGAL staining was seen in the transitional mucosa 
between normal and malignant tissue, whereas occasionally MMP-9 positivity was observed 
in endothelial cells and incidentally in muscle cells, macrophages and fibroblasts44. Several 
studies suggest that NGAL protects MMP-9 from auto-degradation by the formation of a 
NGAL-MMP-9 complex and thereby increases MMP-9 activity44-46. With and without 
correction for inflammation, we found that NGAL showed -not surprisingly- the same pattern 
in tissue values as MMP-9.  
Pyke et al.47 demonstrated the presence of mRNA of MMP-2 in fibroblasts/fibroblast-like 
cells and of MMP-9 mRNA in macrophages in cancer cell surrounding stromal tissue, but 
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not in the cancer cells themselves. In an experimental mouse model, using the short hairpin 
RNA interference technology (shRNA), Gerg et al.48 were able to demonstrate that MMP-2 
and -9 are also expressed by colorectal cancer cells themselves. Furthermore, distinct roles 
were identified for the two gelatinases in the development of colorectal cancer metastases; 
MMP-9 is important in the process of extravasation and invasion, whereas MMP-2 
influences the outgrowth of metastases but not their formation.  
The liver is the main site of metastasis formation in colorectal cancer. The presence of 
MMP-2 and MMP-9 in colorectal liver metastasis has already been demonstrated by 
immunohistochemistry, in situ hybridization and zymography49-54. In almost all cases, 
expression of MMP-2 and MMP-9 in metastases was higher than in normal liver tissue. We 
found that the MMP-9 and NGAL content of liver metastases from colorectal origin are lower 
than in the primary tumour, whereas MMP-2 and MMP-8 were expressed at an equal level. 
The percentage of active MMP-2 and MMP-9 was found to be lower in liver metastases 
than in the primary colorectal carcinoma and equalled the activity percentage found in 
adenomas. We speculate that the higher percentage of active enzyme reflects an increased 
proteolytic activity in the primary colorectal cancer, contributing to their invasive capacity. 
Few studies have compared the MMP-2 and -9 expression in liver metastases and in the 
primary tumour. In partial concordance with our results, Gentner et al.55 found lower mRNA 
expression of all measured MMPs (including MMP-2, -8 and -9) in liver metastases 
compared to the primary colorectal cancers derived from the same patients. These findings 
were not confirmed by Asano et al.56 who also used RT-PCR to quantify the mRNA 
expression of several MMPs in liver metastases; and although MMP-1, -10 and -11 
expression was found to be decreased in the liver metastases compared with primary 
colorectal cancers, no difference in the expression of MMP-2, MMP-8 and MMP-9 was 
found. A dot blot hybridization study also showed no difference between mRNA levels of 
MMP-2 and MMP-9 in colorectal cancer or liver metastases57. Gelatinase-activity was 
increased in colorectal cancer in comparison to normal colorectal tissue, but the activity was 
lower in hepatic metastases58. It is therefore possible that up-regulation of these MMP-
proteins occurs at a posttranscriptional level. 
In conclusion, our results show that the development of colorectal cancer, as illustrated 
by the normal mucosa – adenoma – carcinoma – liver metastasis sequence, is 
accompanied by a concurrent increase in the MMP levels which might contribute to the 
invasive process. Our findings suggest different roles for MMP-2, -8 and -9 throughout this 
process, which may have implications for the use of anti-MMP therapies in different stages 
of colorectal cancer.  
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Background and aim of the study: There is considerable evidence for the involvement of 
matrix metalloproteinases (MMPs) in colorectal cancer progression and MMP-2 and MMP-9 
have consistently been shown to be increased in colorectal cancer tissue. Less is known 
about the relation between circulating and urinary levels of these MMPs and the outcome of 
colorectal cancer. The aim of the present study was to investigate whether levels of the 
gelatinases MMP-2 and MMP-9 in tissue, plasma and/or urine were related to the clinical 
outcome in patients with colorectal cancer.  
Methods: MMP-2 and MMP-9 levels in cancer tissue and normal mucosa, and in pre- and 
postoperatively obtained plasma and urine of 49 colorectal cancer patients were analysed 
with gelatin-zymography, BIA and ELISA.  
Results: Significantly higher levels of MMP-2 and MMP-9 were detected in carcinoma 
tissue compared to tumour-free adjacent mucosa. Plasma and tumour levels of MMP-9 
were found to be higher in patients with recurrent disease or irresectable disease at 
presentation, compared to patients without evidence of disease after resection. High MMP-2 
levels in urine, when measured by zymography, were associated with higher risk of 
recurrent disease or distant metastases.  
Conclusion: This is the first study to demonstrate that patients with colorectal cancer not 
only have measurable levels of MMP-2 and MMP-9 in their plasma, but also in their urine. 
Furthermore, high zymographic levels of MMP-2 in the urine, as well as high levels of MMP-
9 in plasma, were found to be associated with poor surgical and clinical outcome of these 
colorectal cancer patients. 
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INTRODUCTION
 
Matrix metalloproteinases (MMPs) comprise a family of zinc-dependant proteolytic 
enzymes that are involved in many physiological and pathological processes. One of their 
major functions is the remodelling of extracellular matrix (ECM), which takes places under 
normal circumstances in embryogenesis, bone remodelling and wound healing1. MMP-2 
and MMP-9, also referred to as the gelatinases, are characterized by their ability to degrade 
denatured collagen and type-IV collagen, present in the basal membranes, which was one 
of the first recognized functions of these MMPs. Nowadays, we know that their functional 
repertoire extends far beyond the degradation of ECM components and involves regulation 
of cell proliferation and differentiation, apoptosis, angiogenesis and immune surveillance2. 
The first reports about the implication of MMP-2 and MMP-9 in cancer dissemination 
appeared in the late eighties3-7. Since then, their involvement in colorectal cancer 
progression, invasion and metastasis has been well established8. Gelatinases have also 
been shown to have an impact on the prognosis of colorectal cancer patients. Most of the 
publications on this subject concern MMP-levels in carcinoma tissue, where high MMP-2 
levels are almost invariably identified as an unfavourable prognostic factor9-14. The results 
for MMP-9 are less uniform, possibly due to the anti-angiogenic effects of high levels of 
MMP-9, but the cell type overexpressing MMP-9 seems to be important for the outcome of 
cancer patients as well11, 15-23.  
The correlation between levels of MMP-2 and MMP-9 in the peripheral blood and the 
presence of cancer or the outcome of cancer patients has been investigated in various 
types of cancer, including colorectal carcinoma24-30. Results have not been unequivocal, 
which may possibly be explained by differences in detection techniques (zymography, 
ELISA or BIA), the type of material evaluated (serum or plasma) and the collection methods 
used31, 32. In the last couple of years, more information has also become available about 
urinary levels of MMPs in various kinds of tumours. It has even been suggested that the use 
of urine as a source of biomarkers has several advantages over blood, since it seems to 
contain less interfering proteins, is relatively clean and easier to collect than a blood 
sample33. Furthermore, MMPs were reported to be hardly present in the urine of healthy 
people, so the presence of MMPs in human urine might provide strong evidence for the 
presence of a pathological condition. Up to now, no data are available about urinary MMPs 
in colorectal cancer. In the present study, we investigated whether MMP-2 and MMP-9 
levels in tumour and normal tissue, citrate-plasma and urine are related to the clinical 
outcome of patients with colorectal cancer. The samples were analysed by gelatin-
zymography, enzyme-linked immunosorbent assay (ELISA) and a bioactivity assay (BIA).  
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MATERIALS AND METHODS 
 
Patients and study design 
Forty-nine patients, who were scheduled to undergo a surgical resection of colorectal 
cancer at the Leiden University Medical Center, were included in the study. Urine and 
citrate plasma samples were collected before resection (0 days-1.5 months), and if possible 
approximately 3 weeks (1 week- 2 months) and 4.5 months (2.5-12 months) after the 
resection. None of the patients had received radiotherapy or chemotherapy prior to surgery. 
The urine and citrate plasma samples were collected before 9:00 a.m. under fasting 
conditions. To correct for dilution effects, standardization by urinary creatinine concentration 
was obtained by dividing the MMP-concentration by the creatinine level of the 
corresponding urine sample. Data collection could be completed at all three time points in 
16 patients. From 17 patients only preoperative urine and plasma samples could be 
collected, from 4 patients preoperative and 3 weeks after resection, and from 12 patients 
preoperative and 4.5 months after resection urine and plasma were obtained. From the 
resection specimens, representative samples of the carcinoma and macroscopically normal 
mucosa (5-10 cm from the tumour) were frozen and stored at -70 C. From 5 patients, only 
preoperative biopsy material of tumour and normal tissue was available, from 3 patients no 
tissue samples were available and from 1 patient we only obtained biopsies from the 
carcinoma. Major clinical and pathological data were registered. All patients entered the 
study at the date the first urine and plasma samples were collected, prior to surgery. The 
follow-up period was at least 3.7 years and ended in the event of death or at the last follow-
up date (follow-up range 0-92 months). The carcinomas were staged using the Dukes’ 
classification modified by Astler and Coller34. Patients who had irresectable disease at 
presentation or who developed recurrent disease and/or distant metastases during follow-
up (“tumour-positive” patients) were compared to patients with no evidence of disease after 
resection (NED) with respect to their tissue, plasma and urinary MMP-2 and MMP-9 levels. 
In some of the analyses patients with a Dukes D colorectal cancer undergoing a “palliative 
or no resection”, i.e., with inoperable disease were compared to patients who had 
undergone a resection with curative intent and were still alive at the end of the study period 
(“curative resection, alive”-group) and to patients who had a resection with curative intent 
and died during follow-up (“curative resection, dead”-group). Only one of the patients that 
were still alive and the end of follow-up had a recurrence during the follow-up period, none 
had distant metastases. Of the patients that died after surgery with curative intent, 8 
patients had died because of a recurrence or distant metastases, 6 patients died from 
complications shortly after surgery or unrelated illness (e.g. breast cancer, lung cancer) and 
in 5 patients the cause of death was unknown. 
The study was performed according to the instructions and guidelines of the LUMC 
Medical Ethics Committee and in accordance with the Helsinki declaration. 
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Tissue extraction and protein concentration
Extracts were prepared from 10-100 mg wet tissue samples as previously described35-37. 
The samples were homogenised in 1 ml 0.1 M Tris-HCl, 0.1% Tween-80 buffer (pH 7.5) per 
60 mg wet tissue at 0C. The homogenates were centrifuged twice at 8000 g for 2.5 
minutes at 4C. The supernatants were stored at -20C until analysis. Protein concentration 
of the supernatant was determined by the method described by Lowry et al38.  
Gelatin-zymography 
The presence of active and latent forms of the matrix metalloproteinases MMP-2 and 
MMP-9 was analysed by gelatin-zymography as described previously39-41. Briefly, gels 
containing 10% polyacrylamide and 0.2 % gelatine were loaded with 10 l sample and 5 l 
sample buffer (20% SDS, 8% saccharose, 0.5 M Tris-HCl (pH 6.8) and 0.05% bromophenol 
blue) and electrophorised during 2-2.5 hour, to separate the MMP isoforms on molecular 
weight and activate the proenzymes. The gels were subsequently incubated overnight at 
37C, stained and analysed for gelatine digestion by laser densitometry. An internal 
standard of 5 µg / 10µl and 10 µg / 10µl of one tumour homogenate with MMP-2 and MMP-
9 in active and pro-form was present at each gel for correction of intergel variations. Results 
were expressed in arbitrary units (AU). 
Enzyme-linked immunosorbent assay (ELISA) 
The total amount of MMP-2 and MMP-9 was determined, after a 1:10 dilution of the 
urine and homogenates and a 1:33 dilution of the plasma, by sandwich ELISAs as 
previously described40, 42. Results were expressed in ng MMP per mg protein. 
 
Bio-Immuno-Activity assay (BIA) 
Latent and active MMP-2 and MMP-9 were measured according to the Bio-Immuno-
Activity assay technique previously described43. Briefly the same antibodies to MMP-2 or 
MMP-9 that were used in the ELISA were used as catching antibody for the respective 
MMPs in the samples during overnight incubation at 4 C. The MMP-2 or -9 was then 
activated by incubation with 0.5 mM p-aminophenyl-mercuric acetate at 37°C and the 
activity measured with modified pro-urokinase (Ukcol) and S-2444 (0.6 mM), as 
chromogenic substrate, in assay buffer at 37°C. Reactions were performed in 96-well flat-
bottomed microtitre plates, and a Titertek Multiskan photometer was used to follow the 
absorbance change at 405 nm. Results were expressed as units MMP-2 or MMP-9 per mg 
protein. In urine, the BIA for MMP-2 was not successful as there were no measurable levels 
of MMP-2 in this assay. 
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MATERIALS AND METHODS 
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Forty-nine patients, who were scheduled to undergo a surgical resection of colorectal 
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presentation or who developed recurrent disease and/or distant metastases during follow-
up (“tumour-positive” patients) were compared to patients with no evidence of disease after 
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undergone a resection with curative intent and were still alive at the end of the study period 
(“curative resection, alive”-group) and to patients who had a resection with curative intent 
and died during follow-up (“curative resection, dead”-group). Only one of the patients that 
were still alive and the end of follow-up had a recurrence during the follow-up period, none 
had distant metastases. Of the patients that died after surgery with curative intent, 8 
patients had died because of a recurrence or distant metastases, 6 patients died from 
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in 5 patients the cause of death was unknown. 
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Statistical analyses 
Group means are given as mean  standard error of the mean (SEM). Differences 
between 3 groups were first tested for significance with the Kruskal-Wallis test before the 
exact significance between the groups was tested with the Mann-Whitney U-test (unpaired 
test) or with the Wilcoxon Signed-Rank test (paired test) by SPSS 16.0 statistical package. 
Differences were considered significant when P  0.05. 
RESULTS
Patient characteristics 
The characteristics of the 49 patients are shown in table 1. The mean age ( SEM) of 
the patients was 65.5 ( 1.8) years (range 31-85). During follow-up, 27 patients died and 20 
patients had a metastasis or recurrence. All patients (n=8) who had a palliative resection or 
no surgery at all had Dukes D carcinoma at presentation and died during the follow-up 
period. Forty-seven patients had a single primary colorectal cancer; one patient had 
developed a cancer in the sigmoid colon after curative surgery for a rectal cancer six years 
earlier and one patient had two synchronous tumours in the ascending colon and rectum. In 
one patient with a Dukes B2 carcinoma, the pathology specimen contained pathologic 
lymph nodes suggestive of prostate cancer. This diagnosis was confirmed postoperatively 
but was not known before surgery. 
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MMP levels in carcinomas 
MMP-2 and MMP-9 were significantly higher in carcinoma tissue compared to tumour-
free adjacent colon mucosa (Figure 1). Particularly the pro-MMP-9 and active MMP-2, 
measured by zymography, were found to be dramatically higher (8-fold and 14-fold, 
respectively) in the carcinomas. These results were confirmed by the ELISA and BIA for 
both MMPs (MMP-2 ELISA: tumour 17.7 ± 2.1 vs. normal mucosa 5.4 ± 0.4 ng/mg protein; 
MMP-2 BIA [latent enzyme]: tumour 93.0 ± 11.6 vs. normal mucosa 77.9 ± 15.7 U/mg 
protein. MMP-9 ELISA: tumour 31.7 ± 5.4 vs. normal mucosa 7.1 ± 0.7 ng/mg protein; 

















Figure 1. MMP-2 and MMP-9 levels in normal mucosa and carcinomas of 45 patients with colorectal cancer. Left axis: 
MMP-2 zymography, right axis: MMP-9 zymography; results are expressed in AU/10 µg protein. P ≤ 0.001 pro-, 
active and total MMP-2 and pro-, total MMP-9 in tumour vs. normal mucosa; P ≤ 0.05 active MMP-9 in tumour vs. 
normal mucosa. 
 
The effect of tumour resection on MMP levels in plasma and urine 
The plasma-levels of MMP-9, predominantly pro-enzyme as measured by gelatin-
zymography, increased significantly 3 weeks after the resection and decreased to the 
preoperative level 4.5 months after resection (Figure 2). A similar pattern for MMP-9 in 
urine, that is, an increase 3 weeks after resection and a decrease 4.5 months after 
resection, was observed but these changes did not reach statistical significance (MMP-9 in 
urine preoperatively 310 ± 190, 3 weeks postoperatively 447 ± 432 and 4.5 months after 
resection 34.8 ± 29.1 AU/10µl urine, respectively). Plasma and urine MMP-2 levels did not 
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Statistical analyses 
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but was not known before surgery. 
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MMP levels in carcinomas 
MMP-2 and MMP-9 were significantly higher in carcinoma tissue compared to tumour-
free adjacent colon mucosa (Figure 1). Particularly the pro-MMP-9 and active MMP-2, 
measured by zymography, were found to be dramatically higher (8-fold and 14-fold, 
respectively) in the carcinomas. These results were confirmed by the ELISA and BIA for 
both MMPs (MMP-2 ELISA: tumour 17.7 ± 2.1 vs. normal mucosa 5.4 ± 0.4 ng/mg protein; 
MMP-2 BIA [latent enzyme]: tumour 93.0 ± 11.6 vs. normal mucosa 77.9 ± 15.7 U/mg 
protein. MMP-9 ELISA: tumour 31.7 ± 5.4 vs. normal mucosa 7.1 ± 0.7 ng/mg protein; 

















Figure 1. MMP-2 and MMP-9 levels in normal mucosa and carcinomas of 45 patients with colorectal cancer. Left axis: 
MMP-2 zymography, right axis: MMP-9 zymography; results are expressed in AU/10 µg protein. P ≤ 0.001 pro-, 
active and total MMP-2 and pro-, total MMP-9 in tumour vs. normal mucosa; P ≤ 0.05 active MMP-9 in tumour vs. 
normal mucosa. 
 
The effect of tumour resection on MMP levels in plasma and urine 
The plasma-levels of MMP-9, predominantly pro-enzyme as measured by gelatin-
zymography, increased significantly 3 weeks after the resection and decreased to the 
preoperative level 4.5 months after resection (Figure 2). A similar pattern for MMP-9 in 
urine, that is, an increase 3 weeks after resection and a decrease 4.5 months after 
resection, was observed but these changes did not reach statistical significance (MMP-9 in 
urine preoperatively 310 ± 190, 3 weeks postoperatively 447 ± 432 and 4.5 months after 
resection 34.8 ± 29.1 AU/10µl urine, respectively). Plasma and urine MMP-2 levels did not 
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Figure 2. MMP-2 and MMP-9 levels in plasma collected preoperatively, 3 weeks or 4.5 months after resection 
expressed in relative values, where reference value =1 at t=preoperative. * P < 0.05 vs. preoperative and t=4.5 
months after resection. 
 
 
Relation between MMP levels and tumour recurrence and/or metastasis 
Tumour MMP-9 levels were considerably higher in the patients with tumour recurrence/ 
metastasis than in the patients without evidence of disease after resection (NED), as shown 
in figure 3. Tumour MMP-2 levels only showed a trend towards higher MMP-2 levels in 
tumour positive patients compared to the patients with NED. Also in the plasma samples 
obtained before resection, pro/latent-MMP-9 was modestly (1.2-1.3 fold) higher in tumour 
positive patients compared to patients with NED (P ≤ 0.05) (Figure 4). The plasma MMP-2 
levels, however, were not significantly different in the patients with and without recurrent 
disease or distant metastasis (Figure 4).  
In the analysis of the urine samples we excluded the patient with lymph node positive 
prostate cancer as these urinary MMP-values are probably for the greater part attributable 
to his prostate cancer. The urinary MMP-2 and MMP-9 levels of this patient were 38 and 63 
times higher than the average MMP-levels of the patients with NED. In urine collected 
before colorectal cancer resection, zymography results show a significantly higher level of 
pro-, active and total MMP-2 in tumour positive patients as opposed to the NED patients (P
≤ 0.01 for pro- en total MMP-2, P ≤ 0.05 for active MMP-2; figure 5). These results could not 
be confirmed, however, by the MMP-2 ELISA (tumour positive 8.3 ± 2.4 vs. NED 17.2 ± 3.5 



















































Figure 3. MMP-2 and MMP-9 levels in carcinomas of patients with no evidence of disease after resection (n=28) vs. 
tumour positive patients (n=18). Left axis: MMP-9 zymography and MMP-9 BIA, results are expressed in AU/10 µg 
protein (zymography) and U/mg protein (BIA). Right axis: MMP-2 zymography, MMP-2 and MMP-9 ELISA, MMP-2 
BIA, results are expressed in AU/10 µg protein (zymography), in ng/mg protein (ELISA) and in U/mg protein (BIA). * P
















Figure 4. MMP-2 and MMP-9 levels in plasma collected preoperatively in patients with no evidence of disease after 
resection (NED) and patients with recurrent disease or distant metastases (tumour positive). Results of zymography, 
expressed in AU/10µl plasma. Left axis: MMP-2 zymography. Right axis: MMP-9 zymography. P ≤ 0.05 NED vs. 
































































































































































Figure 2. MMP-2 and MMP-9 levels in plasma collected preoperatively, 3 weeks or 4.5 months after resection 
expressed in relative values, where reference value =1 at t=preoperative. * P < 0.05 vs. preoperative and t=4.5 
months after resection. 
 
 
Relation between MMP levels and tumour recurrence and/or metastasis 
Tumour MMP-9 levels were considerably higher in the patients with tumour recurrence/ 
metastasis than in the patients without evidence of disease after resection (NED), as shown 
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tumour positive patients compared to the patients with NED. Also in the plasma samples 
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levels, however, were not significantly different in the patients with and without recurrent 
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prostate cancer as these urinary MMP-values are probably for the greater part attributable 
to his prostate cancer. The urinary MMP-2 and MMP-9 levels of this patient were 38 and 63 
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Figure 3. MMP-2 and MMP-9 levels in carcinomas of patients with no evidence of disease after resection (n=28) vs. 
tumour positive patients (n=18). Left axis: MMP-9 zymography and MMP-9 BIA, results are expressed in AU/10 µg 
protein (zymography) and U/mg protein (BIA). Right axis: MMP-2 zymography, MMP-2 and MMP-9 ELISA, MMP-2 
BIA, results are expressed in AU/10 µg protein (zymography), in ng/mg protein (ELISA) and in U/mg protein (BIA). * P
















Figure 4. MMP-2 and MMP-9 levels in plasma collected preoperatively in patients with no evidence of disease after 
resection (NED) and patients with recurrent disease or distant metastases (tumour positive). Results of zymography, 
expressed in AU/10µl plasma. Left axis: MMP-2 zymography. Right axis: MMP-9 zymography. P ≤ 0.05 NED vs. 































































































































































Figure 5. Pro, active and total MMP-2 and MMP-9 levels in urine collected preoperatively in patients with no evidence 
of disease after resection (NED) and patients with recurrent disease or distant metastases (tumour positive). Results 
of zymography, expressed in AU/10µl urine. Left axis: MMP-2 zymography. Right axis: MMP-9 zymography. * P ≤ 
0.05 NED vs. tumour positive for active MMP-2; P ≤ 0.01 NED vs. tumour positive for pro- and total MMP-2 
 
 
Zymography results for MMP-9 levels in the urine showed a similar trend towards higher 
urinary MMP-9 levels in tumour positive patients, that failed to reach significance due to 
large variations in the results obtained (Figure 5). The BIA and ELISA did not show any 
correlation between urinary MMP-9 levels and presence or absence of malignancy (ELISA: 
tumour positive 34.0 ± 27.8 vs. NED 33.4 ± 20.1 ng/ml urine and BIA: tumour positive 209 ± 
162 vs. NED 249 ± 151 ng/ml urine). In addition, one of the patients with a Dukes D 
carcinoma had incurable disease due to liver metastases and local invasion into the urine 
bladder. The urinary MMP-levels were more than 10- to 100- fold higher than in the rest of 
the patients, most probably due to the presence of tumour tissue in the bladder. Excluding 
this patient from the analysis did not affect the trend of the results, however.  
MMP levels in relation to surgery and outcome 
Carcinoma tissue from the patients that were alive after a curative resection had the 
lowest MMP-9 levels compared to the patients with irresectable disease and the patients 
who had undergone a curative-intent resection but died during follow-up. Results of the 
zymography are shown in figure 6 and these were corroborated by the ELISA and BIA 
results (data not shown). For MMP-2, the same trend was observed but this did not reach 


















































Figure 6. The MMP-2 and MMP-9 levels in cancer tissue, comparison between patients who had had a curative 
resection and were alive at the end of follow-up (n=22), patients who had had a curative resection and died (n=19) 
and patients who had no or a palliative resection (n=8), measured by zymography. The results are expressed as AU/ 
10 µg protein. * P ≤ 0.05 pro-, active and total MMP-9 vs. curative resection, alive. 
 
 
In the plasma specimens obtained before resection, the MMP-9 levels were significantly 
higher in the Dukes D patients compared to patients who had undergone a resection with 
curative intent (Table 2). In the patients who had undergone surgery with curative intent and 
had died during follow-up, the plasma MMP-9 levels were found to be somewhat lower than 
those in patients who were still alive. These results were independent of the method of 
detection. Plasma MMP-2 levels were not related to clinical outcome at all. 
The level and variation of both MMP-2 and MMP-9 in the urine of patients with 
irresectable disease was very large, even with exclusion of the patient with prostate cancer, 
but much higher than in the other patient groups. Urinary pro- and total MMP-2 levels, 
measured by zymography, of patients who underwent a curative resection but died during 
follow-up were found to be higher than in patients who underwent a resection with curative 
intent and were alive at the end of follow-up (Table 3). The ELISA results of the urine 
samples did not support these zymography findings and even showed higher MMP-2 values 
in the urine of patients who had undergone a curative resection and were still alive at the 
end of the study period (12.5 ± 1.9 ng/ml urine) compared to patients with irresectable 
disease (5.0 ± 3.3 ng/ml urine, P < 0.05). Patients who died after a resection with curative 
intent were found to have the highest urinary MMP-2 levels when measured by ELISA (18.2 
± 5.3 ng/ml urine). Urinary levels of MMP-9 appeared to be lower in the patients who 
underwent surgery with curative intent and were still alive as compared to those that had 
died during follow-up, but due to the large variation these differences did not reach 






































Figure 5. Pro, active and total MMP-2 and MMP-9 levels in urine collected preoperatively in patients with no evidence 
of disease after resection (NED) and patients with recurrent disease or distant metastases (tumour positive). Results 
of zymography, expressed in AU/10µl urine. Left axis: MMP-2 zymography. Right axis: MMP-9 zymography. * P ≤ 
0.05 NED vs. tumour positive for active MMP-2; P ≤ 0.01 NED vs. tumour positive for pro- and total MMP-2 
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resection and were alive at the end of follow-up (n=22), patients who had had a curative resection and died (n=19) 
and patients who had no or a palliative resection (n=8), measured by zymography. The results are expressed as AU/ 
10 µg protein. * P ≤ 0.05 pro-, active and total MMP-9 vs. curative resection, alive. 
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Table 2. MMP-2 and MMP-9 in plasma 






Palliative or no 
resection
(n=8)
MMP-2 Total (Z) 1202 (± 206) 1044 (± 160) 846 (±209) 
MMP-2 ELISA 254 (± 27.7) 341 (± 44.7) 311 (± 41.3) 
MMP-2 BIA latent 960 (± 57.4) 863 (± 59.2) 880 (± 278) 
MMP-9 Total (Z) 279 (± 146)b 111 (± 16.1)a 455 (± 158)a,b 
MMP-9 ELISA 48.2 (± 16.3)b 25.8 (± 2.2)a 55.4 (± 5.7)a,b 
MMP-9 BIA latent 373 (± 70.4)c 340 (± 35.4)a 533 (± 62.0)a,c 
Mean (± SEM) levels of total MMP-2 and MMP-9 levels in plasma collected preoperatively in patients who underwent 
a resection with curative intent and were alive at the end of follow-up (“curative resection, alive”, n=22), patients who 
underwent a resection with curative intent but died during follow-up (“curative resection, dead”, n=19) and patients 
with incurable disease at presentation who did not undergo surgery with curative intent (“palliative or no resection”, 
n=8). (Z) =Zymography results, data expressed in arbitrary units (AU) per 10 µl plasma. ELISA results are expressed 
in ng MMP per ml plasma. BIA results are expressed in U/ml plasma. a P ≤ 0.05 palliative or no resection vs. curative 
resection, dead. b P ≤ 0.005 palliative or no resection vs. curative resection, alive. c P ≤ 0.05 palliative or no resection 
vs. curative resection, alive. 
Table 3. MMP-2 and MMP-9 in urine 






Palliative or no 
resection
(n=8)
MMP-2 Pro   0.6 (± 0.3)a   3.6 (± 1.3)a 15.4 (± 13.1) 
MMP-2 Active 0.1 (± 0.1) 2.7 (± 2.5) 6.0 (± 5.0) 
MMP-2 Total   0.7 (± 0.3)a  6.3 (± 3.4)a 21.4 (± 18.1) 
MMP-9 Pro 3.4 (± 1.6) 92.8 (± 79.3) 866 (± 841) 
MMP-9 Active 2.2 (± 1.3) 19.4 (± 11.3) 162 (± 157) 
MMP-9 Total 5.6 (± 2.9) 112 (± 88.3) 1027 (± 998) 
Mean (± SEM) levels of MMP-2 and MMP-9 levels in urine collected preoperatively in patients who underwent a 
resection with curative intent and were alive at the end of follow-up (“curative resection, alive”, n=21), patients who 
underwent a resection with curative intent but died during follow-up (“curative resection, dead”, n=19) and patients 
with incurable disease at presentation who did not undergo surgery with curative intent (“palliative or no resection”, 
n=8). The patient with prostate cancer is excluded from this analysis. Zymography results (after correction for 
creatinine levels) are expressed in arbitrary units (AU) per 10 µl urine. a P ≤ 0.05 curative resection, dead vs. curative 
resection, alive. 
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for MMP-9 in the urine (ELISA: 4.6 ± 1.1, 27.1 ± 21.7, and 76.3 ± 69.4 ng/ml urine and BIA: 
28.5 ± 9.8, 228 ± 183, and 458 ± 405 ng/ml urine in patients with “curative resection, alive”, 
“curative resection, dead” and “palliative or no resection”, respectively). 
DISCUSSION 
In the present study we found that patients with colorectal cancer not only have 
increased MMP-2 and MMP-9 levels in the carcinomas but also to have readily detectable 
levels of MMP-2 and MMP-9 in their urine and plasma. High carcinoma MMP levels were 
found to be indicative for a worse surgical and clinical outcome. Zymographic MMP-2 levels 
in the urine also correlated strongly with clinical and surgical outcome, whereas high plasma 
MMP-9 values showed a more moderate but significant association with clinical outcome. 
Whereas both gelatinases were increased in cancer tissue compared to normal mucosa, 
MMP-9 was found to be a stronger predictor of outcome than MMP-2 in this cohort of 49 
patients. High levels of MMP-9 in cancer tissue were associated with the presence of 
malignancy at the end of the follow-up period and the highest MMP-9 levels were found in 
patients who had irresectable disease at presentation. MMP-2 levels in cancer tissue 
showed a trend towards higher levels in patients who had a tumour recurrence and/or 
distant metastases, but these differences were not significant.  
Plasma levels of MMP-9 in these colorectal cancer patients were raised three weeks 
after surgery and decreased to preoperative levels in the following months, whereas MMP-2 
plasma levels did not fluctuate in the perioperative period. These results confirm the 
findings of De Hingh et al. and probably reflect the response to major surgery and the 
process of wound healing44. The active form of MMP-9 could only be detected in plasma 
from 5 out of 49 patients, whereas the active form of MMP-2 was detected in none of the 
patients. These results are in accordance with others and suggest that the active forms of 
the gelatinases are only present in very limited amounts in the peripheral blood45-47. Plasma 
levels of pro-MMP-2 and pro-MMP-9 were detectable in almost all patients with colorectal 
cancer. When the patients were subdivided in patients with no evidence of disease after 
surgery and patients with irresectable disease at presentation or recurrent disease, plasma 
MMP-9 levels were modestly but significantly higher in the patients with a recurrence or 
distant metastases compared to the patients with NED. Plasma MMP-2 levels did not 
correlate with surgical outcome. Similar results were obtained when the patients were 
divided into three groups in relation to their clinical outcome, that is, resection and survival. 
Again, patients with the worst prognosis (who had incurable disease at presentation) had 
increased plasma MMP-9 levels compared to patients with the best clinical outcome (i.e. 
surgery with curative intent and still alive at the end of the follow-up period). Interestingly, 
several studies have shown that serum and/or plasma MMP-2 levels are lower in patients 
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Table 2. MMP-2 and MMP-9 in plasma 
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a resection with curative intent and were alive at the end of follow-up (“curative resection, alive”, n=22), patients who 
underwent a resection with curative intent but died during follow-up (“curative resection, dead”, n=19) and patients 
with incurable disease at presentation who did not undergo surgery with curative intent (“palliative or no resection”, 
n=8). (Z) =Zymography results, data expressed in arbitrary units (AU) per 10 µl plasma. ELISA results are expressed 
in ng MMP per ml plasma. BIA results are expressed in U/ml plasma. a P ≤ 0.05 palliative or no resection vs. curative 
resection, dead. b P ≤ 0.005 palliative or no resection vs. curative resection, alive. c P ≤ 0.05 palliative or no resection 
vs. curative resection, alive. 
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“curative resection, dead” and “palliative or no resection”, respectively). 
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increased MMP-2 and MMP-9 levels in the carcinomas but also to have readily detectable 
levels of MMP-2 and MMP-9 in their urine and plasma. High carcinoma MMP levels were 
found to be indicative for a worse surgical and clinical outcome. Zymographic MMP-2 levels 
in the urine also correlated strongly with clinical and surgical outcome, whereas high plasma 
MMP-9 values showed a more moderate but significant association with clinical outcome. 
Whereas both gelatinases were increased in cancer tissue compared to normal mucosa, 
MMP-9 was found to be a stronger predictor of outcome than MMP-2 in this cohort of 49 
patients. High levels of MMP-9 in cancer tissue were associated with the presence of 
malignancy at the end of the follow-up period and the highest MMP-9 levels were found in 
patients who had irresectable disease at presentation. MMP-2 levels in cancer tissue 
showed a trend towards higher levels in patients who had a tumour recurrence and/or 
distant metastases, but these differences were not significant.  
Plasma levels of MMP-9 in these colorectal cancer patients were raised three weeks 
after surgery and decreased to preoperative levels in the following months, whereas MMP-2 
plasma levels did not fluctuate in the perioperative period. These results confirm the 
findings of De Hingh et al. and probably reflect the response to major surgery and the 
process of wound healing44. The active form of MMP-9 could only be detected in plasma 
from 5 out of 49 patients, whereas the active form of MMP-2 was detected in none of the 
patients. These results are in accordance with others and suggest that the active forms of 
the gelatinases are only present in very limited amounts in the peripheral blood45-47. Plasma 
levels of pro-MMP-2 and pro-MMP-9 were detectable in almost all patients with colorectal 
cancer. When the patients were subdivided in patients with no evidence of disease after 
surgery and patients with irresectable disease at presentation or recurrent disease, plasma 
MMP-9 levels were modestly but significantly higher in the patients with a recurrence or 
distant metastases compared to the patients with NED. Plasma MMP-2 levels did not 
correlate with surgical outcome. Similar results were obtained when the patients were 
divided into three groups in relation to their clinical outcome, that is, resection and survival. 
Again, patients with the worst prognosis (who had incurable disease at presentation) had 
increased plasma MMP-9 levels compared to patients with the best clinical outcome (i.e. 
surgery with curative intent and still alive at the end of the follow-up period). Interestingly, 
several studies have shown that serum and/or plasma MMP-2 levels are lower in patients 
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with colorectal cancer compared to healthy controls46, 48. Furthermore, these studies report 
an inverse relationship between circulating MMP-2 levels and prognostic parameters. For 
example, lower MMP-2 levels in the peripheral blood were associated with more advanced 
tumour stage, lymph node involvement and higher CEA levels. We could not confirm these 
results in our study. MMP-9 levels in the peripheral blood have been reported to be 
increased in colorectal cancer24-29, 49. There have been varying reports on the correlation 
between circulating MMP-9 levels and the outcome of colorectal cancer patients. In some 
studies the correlation between MMP-9 levels and prognostic parameters was absent, while 
others reported a correlation between higher MMP-9 levels in the peripheral blood and 
Dukes stage, T-stadium and size of the tumour.  
With the development of personalized medicine, the need for biomarkers which are 
predictive of the outcome of the disease increases. Furthermore, the treatment options for 
recurrent and even metastatic colorectal cancer have increased over the last decades50 and 
because early detection of limited liver metastases creates the possibility of surgical 
metastasectomy and increases long-term disease-free survival, there is an increasing 
demand for biomarkers that can predict the presence of recurrent disease at an early stage. 
Waas and co-workers have followed-up patients who underwent curative resection for 
colorectal cancer for two years and monitored plasma MMP-2 and MMP-9 levels in order to 
predict a recurrence51. They did not find a correlation but noticed an increase in proMMP-9 
that was non-significant due to large variations between the patients. The collection of 
blood, handling of the samples and the choice whether to use serum of plasma is pivotal for 
the interpretation of the results, especially for MMP-9. The level of circulating MMP-9 is 
significantly higher in serum than in plasma due to non-specific high background MMP-9 
signal in serum and also the choice of anticoagulant in the tube is important, as citrate 
inhibits the release of gelatinases by blood cells and is therefore suggested to be more 
suitable than heparin or EDTA for measuring circulating MMPs31, 52-57. Although a time-
dependant variation in the MMP-9 levels in heparin plasma has been reported54, the 
dynamics of the MMP-levels in the different analytes show a similar pattern over time58. 
MMP-2 levels are not affected at all by the use of serum or plasma and type of 
anticoagulant.  
Not surprisingly, most of the research concerning MMPs in urine has been performed in 
patients with cancer of the urinary tract, e.g. bladder cancer, prostate cancer and renal cell 
cancer59-70. However, elevated levels of MMPs are also found in the urine of patients with 
non-urogenital tumours like breast cancer and brain tumours71-75 and even in preneoplastic 
lesions of the breast, urinary MMP-9 and ADAM12 were increased and suggested to 
potentially serve as tools to predict breast cancer risk76. The increase in gelatinase levels in 
the urine is not restricted to (pre-)malignancy and occurs also in benign diseases, like 
endometriosis and coronary artery disease77, 78. 
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Our present study is the first to provide evidence for the presence of measurable 
amounts of MMP-2 and MMP-9 in the urine of colorectal cancer patients. Furthermore, we 
even observed a correlation with outcome, i.e., the zymography results suggest that high 
MMP-2 levels in the urine predict an unfavourable outcome, illustrated by a higher chance 
of recurrent disease and/or distant metastases. These results were not confirmed by the 
ELISA measurements, which yield the lowest levels of urinary MMP-2 in patients with 
irresectable disease. The reason for the inconsistency between the ELISA and zymography 
results is as yet unclear but might be due to the difference in detection techniques, as the 
zymography detects active and pro-enzyme based on their enzymatic activity, while the 
ELISA detects the total amount of MMP, whether bound to an inhibitor complex or not. 
Urea, which is present in large quantities in urine, is known to interfere with the antigen-
antibody binding from the immunoaffinity chromatography protocols and might therefore 
have influenced the ELISA results of the urine. In addition other cross-reactive urinary 
components may have interfered within the ELISA assay. Although we corrected for urinary 
creatinine levels, we did not perform dialysis or apply urease treatment to the urine, which 
might make the ELISA determinations more reliable. MMP-9 levels in urine do not correlate 
with the surgical or clinical outcome in our cohort of colorectal cancer patients. An 
association between urinary levels of MMP-2 and MMP-9 and outcome has been reported 
in bladder cancer, where both gelatinase levels in urine correlate with cancer stage and 
prognosis62, 66-68, 79. 
Analysis of the results of individual patients revealed two patients that had 10- to 100-
fold higher MMP-2 and/or MMP-9 levels in urine than the rest of the patients. One of these 
patients had a synchronous (but previously undiagnosed) prostate cancer, a malignancy 
previously shown to be accompanied by increased gelatinase levels in urine63, 80. The other 
patient with extremely elevated urinary MMP-2 and MMP-9 values was found to have local 
invasion of his sigmoid cancer into the bladder. In bladder cancer, MMP-2 and MMP-9 in 
the urine are elevated in a substantial portion of the patients, probably due to a direct 
release of MMP-2 and -9 from the tumour in the bladder wall into the urine66, 68, 79, 81-85. The 
same mechanism seems to be responsible for the high levels of urinary MMPs in this CRC 
patient.  
A major drawback to the use of circulating MMPs as a marker of recurrent disease is the 
aspecificity of MMPs for a particular illness. Plasma MMP levels are elevated not only in a 
number of malignant disorders, but also benign conditions and even in patients with irritable 
bowel syndrome plasma MMP-2 levels were reported to be elevated compared to patients 
with colorectal adenomas and healthy controls24. The same problem occurs with the use of 
gelatinase levels in urine as a marker of recurrent disease. Although MMP-2 and MMP-9 
are hardly detectable in the urine of healthy controls, they can be found in patients with 
endometriosis, juvenile (hamartomatous) polyps, kidney disease and a number of other 
benign and malignant diseases78, 81, 86, 87. Still, in patients without comorbidity MMP-2 and 
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example, lower MMP-2 levels in the peripheral blood were associated with more advanced 
tumour stage, lymph node involvement and higher CEA levels. We could not confirm these 
results in our study. MMP-9 levels in the peripheral blood have been reported to be 
increased in colorectal cancer24-29, 49. There have been varying reports on the correlation 
between circulating MMP-9 levels and the outcome of colorectal cancer patients. In some 
studies the correlation between MMP-9 levels and prognostic parameters was absent, while 
others reported a correlation between higher MMP-9 levels in the peripheral blood and 
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because early detection of limited liver metastases creates the possibility of surgical 
metastasectomy and increases long-term disease-free survival, there is an increasing 
demand for biomarkers that can predict the presence of recurrent disease at an early stage. 
Waas and co-workers have followed-up patients who underwent curative resection for 
colorectal cancer for two years and monitored plasma MMP-2 and MMP-9 levels in order to 
predict a recurrence51. They did not find a correlation but noticed an increase in proMMP-9 
that was non-significant due to large variations between the patients. The collection of 
blood, handling of the samples and the choice whether to use serum of plasma is pivotal for 
the interpretation of the results, especially for MMP-9. The level of circulating MMP-9 is 
significantly higher in serum than in plasma due to non-specific high background MMP-9 
signal in serum and also the choice of anticoagulant in the tube is important, as citrate 
inhibits the release of gelatinases by blood cells and is therefore suggested to be more 
suitable than heparin or EDTA for measuring circulating MMPs31, 52-57. Although a time-
dependant variation in the MMP-9 levels in heparin plasma has been reported54, the 
dynamics of the MMP-levels in the different analytes show a similar pattern over time58. 
MMP-2 levels are not affected at all by the use of serum or plasma and type of 
anticoagulant.  
Not surprisingly, most of the research concerning MMPs in urine has been performed in 
patients with cancer of the urinary tract, e.g. bladder cancer, prostate cancer and renal cell 
cancer59-70. However, elevated levels of MMPs are also found in the urine of patients with 
non-urogenital tumours like breast cancer and brain tumours71-75 and even in preneoplastic 
lesions of the breast, urinary MMP-9 and ADAM12 were increased and suggested to 
potentially serve as tools to predict breast cancer risk76. The increase in gelatinase levels in 
the urine is not restricted to (pre-)malignancy and occurs also in benign diseases, like 
endometriosis and coronary artery disease77, 78. 
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ELISA detects the total amount of MMP, whether bound to an inhibitor complex or not. 
Urea, which is present in large quantities in urine, is known to interfere with the antigen-
antibody binding from the immunoaffinity chromatography protocols and might therefore 
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components may have interfered within the ELISA assay. Although we corrected for urinary 
creatinine levels, we did not perform dialysis or apply urease treatment to the urine, which 
might make the ELISA determinations more reliable. MMP-9 levels in urine do not correlate 
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patient with extremely elevated urinary MMP-2 and MMP-9 values was found to have local 
invasion of his sigmoid cancer into the bladder. In bladder cancer, MMP-2 and MMP-9 in 
the urine are elevated in a substantial portion of the patients, probably due to a direct 
release of MMP-2 and -9 from the tumour in the bladder wall into the urine66, 68, 79, 81-85. The 
same mechanism seems to be responsible for the high levels of urinary MMPs in this CRC 
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aspecificity of MMPs for a particular illness. Plasma MMP levels are elevated not only in a 
number of malignant disorders, but also benign conditions and even in patients with irritable 
bowel syndrome plasma MMP-2 levels were reported to be elevated compared to patients 
with colorectal adenomas and healthy controls24. The same problem occurs with the use of 
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MMP-9 in urine and/or plasma might to some extent serve as a biomarker in the follow-up of 
(colorectal) cancer patients.  
In conclusion, patients with colorectal cancer have detectable levels of MMP-2 and 
MMP-9 in their urine and plasma. Zymography results show that high MMP-2 levels in the 
urine correlate strongly with clinical and surgical outcome, whereas high plasma MMP-9 
values show a more moderate but significant association with clinical outcome. High risk 
groups of colorectal cancer patients could thus be identified based on MMP measurements, 
which could have implications for potential (neo-)adjuvant therapy. Furthermore, these 
results suggest that circulating and urinary gelatinases might serve as biomarkers in the 
follow-up of colorectal cancer patients, although future investigations will be needed to 
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Matrix metalloproteinases (MMPs) are implicated in cancer development and 
progression and are associated with prognosis. Single-nucleotide polymorphisms (SNPs) of 
MMPs, most frequently located in the promoter region of the genes, have been shown to 
influence cancer susceptibility and/or progression. SNPs of MMP-1, -2, -3, -7, -8, -9, -12, -
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INTRODUCTION 
  
The matrix metalloproteinases (MMPs) belong to a metzincin superfamily of zinc-
containing proteinases. Other members of this superfamily are the ADAM (a disintegrin and 
metalloproteinase) family and the ADAMTS (a disintegrin and metalloproteinase with 
thrombospondin motifs) family, which have also been reported to be implicated in cancer 
progression1,2. MMP as well as ADAM/ADAMTS family members are inhibited by tissue 
inhibitors of metalloproteinases (TIMP)s. RECK (reversion-inducing, cysteinerich protein 
with Kazal motifs) is a membrane-anchored inhibitor of MMPs and ADAMs3. Even though 
ADAM, ADAMTS, and RECK are closely related to the MMPs and TIMPs, their single-
nucleotide polymorphisms (SNPs) in gastrointestinal cancer have not been studied and are 
therefore not included in this review. 
MMPs have proven to be of relevance for cancer development and prognosis in various 
organ systems. The 23 members of this family of endopeptidases all share a catalytic 
domain, a pro-peptide and a hemopexin-like C-terminal domain. According to their structure 
and major function or substrates, the MMPs are subdivided in the following subgroups: 
collagenases (MMP-1, -8 and -13), stromelysins (MMP-3, -10 and -11), matrilysins (MMP-7 
and -26), gelatinases (MMP-2 and -9), membrane-type MTMMPs (MMP-14, -15, -16, -17, -
24 and -25), and others4-6. The most firmly established function of MMPs is the 
degradation/remodeling of extracellular matrix. By cleavage of receptors and their ligands 
they also influence various growth and signaling pathways in normal and pathological 
conditions6. In cancer, MMPs are involved in angiogenesis by regulating the bio-availability 
of vascular endothelial growth factor (VEGF) (e.g. MMP-9) and the cleavage of matrix-
bound VEGF (MMPs -3, -7, -9 and -16)7. On the other hand, cleavage of plasminogen by 
MMP-2, -9 and -12 leads to the production of angiostatin, an inhibitor of angiogenesis8,9. 
Furthermore, MMPs have been suggested to interfere in the balance between growth 
signals and growth-inhibiting signals e.g. by modulating the transforming growth factor-β 
(TGF-β) pathway and activation of the epidermal growth factor (EGF) receptor, to regulate 
the induction of apoptosis by cleavage of Fas ligand (by MMP-7), to play a role in the 
creation of a metastatic niche (MMP-3, -9 and -10), and to control inflammation (MMP-2, -3, 
-7, -8, -9, -12) and invasive processes (MMP-1, -2, -3, -7, -13 and -14), see Figure 16,10. It 
has become increasingly clear that MMPs are not always detrimental since they also show 
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Figure 1. Schematic overview of the various types of matrix metalloproteinase-producing cells that are involved in the 
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MMPs are secreted as inactive pro-enzymes that need activation to exert their 
proteolytic properties. Their actions can be counteracted by specific inhibitors, i.e. the 
TIMPs.  
Single-Nucleotide Polymorphism is the most common type of genetic variation. The 
estimated number of SNPs in the human genome is 10 million, but only a small part of 
these polymorphisms are functionally relevant. Most of the functional SNPs are located in 
the promoter region of the gene and are therefore expected to influence gene expression 
(Table 1)12-30. In this paper, we review the association of SNPs in the MMP and TIMP genes 
with the risk, the phenotype, and prognosis of gastrointestinal tumors.  
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Electronic literature searches using PubMed, Embase and Web of Science were used to 
identify published papers concerning SNPs of MMPs, TIMPs, ADAMs, ADAMTS and RECK 
in gastrointestinal cancer up to September 2010. Search terms used included the MeSH 
heading “digestive system neoplasm” as well as all different types of gastrointestinal tumors 
mentioned separately, in combination with the MeSH heading “matrix metalloproteinases”, 
as well as all individual MMPs mentioned separately, combined with the MeSH heading 
“polymorphism, genetic” or synonyms of the term SNP. Papers were included when written 
in English or in any other language, provided that an English abstract was available. Full 
papers, as well as letters and abstracts, were included in this review. Publications 




To generate the forest plot, IBM SPSS statistics 17.0 was used. 
 
ESOPHAGEAL CANCER  
The incidence of esophageal cancer shows great geographical variation. This tumor is 
more common in Southern Africa and Eastern Asia than in Europe and Northern America 
(source: GLOBOCAN; http://globocan.iarc.fr). In the Asian population almost all cases of 
esophageal cancer are squamous cell cancers, whereas in the Western world 
adenocarcinoma occurs more often and its incidence has risen over recent decades. 
Because the pathophysiology and risk factors of squamous cell cancer and 
adenocarcinoma are different, we will discuss these two tumor types separately. An 
overview of the studies included in this paragraph is shown in table 231. 
 
ESOPHAGEAL ADENOCARCINOMA 
Only two papers describe the relationship between polymorphisms of MMPs and 
esophageal adenocarcinoma (EA). One of these studies focused on the protective effect of 
Helicobacter pylori (H. pylori) infection in patients with different genotypes of MMP-1 (-1607 
1G/2G), MMP-2 (-1306 C/T), MMP-3 (-1171 6A/5A) and MMP-12 (-82 A/G)32. In individuals 
with an MMP-2 -1306 CC (wildtype) genotype, H. pylori infection (at any time during life) 
strongly protects against EA (adjusted odds ratio (OR) 0.29, 95% confidence interval (CI) 
0.1-0.7). In persons with a CT or TT genotype, the esophageal cancer risk was not 
influenced by H. pylori infection. To a lesser extent, the protective effect of H. pylori infection 
on the development of EA  was also  seen in carriers  of the MMP-3  wildtype (6A/6A) and 
MMP -12 wild -type  (-82  AA).   However, no  association  between  any  of  the   studied 
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MMP polymorphisms and overall risk of EA was found.The second paper, published by the 
same group, investigated the polymorphisms of MMP-1 (-1607 1G/2G), MMP-3 (6A/5A), 
and MMP-12 (-82 A/G) in relation to the risk and overall survival of EA33. In a cohort of 313 
cancer patients and 455 controls, they found an increased cancer risk in 2G-allele carriers 
of the MMP-1 -1607 1G/2G polymorphism [2G/2G vs 1G/1G: adjusted OR 1.83 (95% CI: 
1.2-2.8), P = 0.005]. 5A-allele carriers of the MMP-3 polymorphism also had an increased 
risk of developing EA in the same patient population (5A/5A vs 6A/6A, OR 1.61, 95% CI: 
1.0-2.5, P = 0.03). The various genotypes of the MMP-12 -82 A/G polymorphism were not 
associated with an EA risk. There was no difference in survival of the patients in relation to 
any of the above mentioned polymorphisms. 
 
ESOPHAGEAL SQUAMOUS CELL CARCINOMA 
Matrix metalloproteinase-2 is overexpressed in esophageal squamous cell cancer 
(ESCC)34-37. There are two known functionally important SNPs in the promoter region of the 
MMP-2 gene, MMP-2 -1306 C/T and MMP-2 -735 C/T. The C to T transition at the -1306 
position disrupts a Sp-1 transcription factor binding site and thereby reduces promoter 
activity22 (Table 1). The allele frequency of the minor (T) allele is significantly lower in the 
Asian population (13.6%) than in the European population (23.3%)38. Increased risk of 
developing ESCC in individuals with -1306 CC genotype (compared to CT+TT genotype) 
has been reported in two large cohorts of Chinese patients (Figure 2)15,39. In Mongolian 
patients, the association between the different genotypes and incidence of ESCC did not 
reach statistical significance40. A recent meta-analysis showed that the -1306 CC genotype, 
which is the genotype with the highest transcriptional activity22, is associated with an 
increased overall cancer risk and this association was maintained in the subgroup analysis 
of ESCC patients38. These findings suggest an important role for the MMP-2 -1306 C/T 
polymorphism in cancer development, which led us to the idea of plotting the results for this 
MMP-2 polymorphism derived from all the publications included in this review. Figure 2 
illustrates that in gastrointestinal cancers the association between MMP-2 -1306 C/T 
polymorphism and cancer risk is not unidirectional. 
The reports on the association of the MMP-2 -735 C/T polymorphism are more 
dispersed. T allele carriers of this polymorphism show a lower transcriptional activity15, 
which could explain the trend towards increased cancer risk in CC carriers compared to 
CT+TT carriers, which was reported in a Chinese population (OR 1.30, 95% CI: 1.04-1.63, 
P =0.056)15. However, these results were not confirmed in another large Chinese cohort39 
and a Mongolian study even found the opposite: higher ESCC cancer risk in TT carriers 
compared to CC, OR = 4.82, 95% CI: 1.59-14.6040.  
No association between the different promoter polymorphisms of MMP-1 (-1607 C/T), 
MMP- 9 (-1562 C/T), MMP-12 (-82 A/G), MMP-13 (-77 A/G) or between a polymorphism in 
the  catalytic  domain of  MMP-9 (R279Q) or R668Q and the  occurrence of ESCC has been 




















Figure 2. Forest plot of gastrointestinal cancer risk associated with the MMP-2 -1306 C/T polymorphism. Results are 
expressed as Odds ratios ± 95% confidence interval (CI) for CC vs CT+TT. The size of the diamonds indicates the 
size of the study cohort. 
 
found13,39,41-43. A polymorphism of MMP-3, located in the promoter region at position -1171 
(5A/6A) was not associated with the overall risk of developing ESCC. However, the cancer 
risk was lower in smokers with a 6A/6A genotype (cancer risk 5A/6A vs 6A/6A: OR = 2.12, 
95% CI: 1.16-3.90) and the risk of lymph node metastases was lower in 6A allele carriers 
(risk of lymph node metastases 5A/6A vs 6A/6A: OR = 2.24, 95% CI: 1.07-4.69)44. An 
increase in ESCC was also observed in AG and GG carriers of the MMP-7 -181 A/G 
polymorphism (AG+GG vs AA: OR = 1.83, 95% CI: 1.12-2.99)45. MMP-7 is one of the 
smallest MMPs and has the capability of degrading a variety of extracellular matrix 
components, including elastin, type IV collagen, fibronectin, vitronectin, aggrecan and 
proteoglycans46. In various cancer types, including esophageal cancer, MMP-7 is over-
expressed and associated with worse prognosis47-49. The G-allele of -181A/G is associated 
with higher basal transcriptional activity in vitro17, which could explain the contribution of 
MMP-7 over-expression to prognosis.  
In summary, the association between genotype and esophageal cancer susceptibility is 
most prominent for the MMP-2 -1306 C/T polymorphism with an increased risk of squamous 
cell cancer and an H. pylori protection against adenocarcinoma in the CC genotype carriers. 
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MMP polymorphisms and overall risk of EA was found.The second paper, published by the 
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which could explain the trend towards increased cancer risk in CC carriers compared to 
CT+TT carriers, which was reported in a Chinese population (OR 1.30, 95% CI: 1.04-1.63, 
P =0.056)15. However, these results were not confirmed in another large Chinese cohort39 
and a Mongolian study even found the opposite: higher ESCC cancer risk in TT carriers 
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found13,39,41-43. A polymorphism of MMP-3, located in the promoter region at position -1171 
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(risk of lymph node metastases 5A/6A vs 6A/6A: OR = 2.24, 95% CI: 1.07-4.69)44. An 
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smallest MMPs and has the capability of degrading a variety of extracellular matrix 
components, including elastin, type IV collagen, fibronectin, vitronectin, aggrecan and 
proteoglycans46. In various cancer types, including esophageal cancer, MMP-7 is over-
expressed and associated with worse prognosis47-49. The G-allele of -181A/G is associated 
with higher basal transcriptional activity in vitro17, which could explain the contribution of 
MMP-7 over-expression to prognosis.  
In summary, the association between genotype and esophageal cancer susceptibility is 
most prominent for the MMP-2 -1306 C/T polymorphism with an increased risk of squamous 
cell cancer and an H. pylori protection against adenocarcinoma in the CC genotype carriers. 
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In an Asian population, ESCC risk is increased in G-allele carriers of the MMP-7 -181 A/G 
polymorphism. No clear association was found between any of the investigated SNPs and 
disease progression or prognosis. 
 
GASTRIC CANCER  
Gastric cancer is the second largest cause of global cancer related mortality. The World 
Health Organization reported 803.000 deaths worldwide in 2004. There is a male 
preponderance and known risk factors are H. pylori infection and tobacco smoking50. Most 
of the data concerning polymorphisms of MMPs in gastric cancer concern the Asian 
population, reflecting the much higher incidence of gastric tumors in the Eastern world 
compared to Western Europe and the United States. Table 3 gives an overview of the 
studies discussed in this paragraph. 
The gelatinases MMP-2 and MMP-9 are upregulated in gastric cancer and increased 
MMP-2 and MMP-9 protein levels in tumor tissue of gastric cancer patients are associated 
with poor prognosis51,52. Two papers reported a significant increase in gastric cancer risk in 
-1306 CC carriers of the MMP-2 SNP53,54, while four other studies did not find such a 
correlation (Figure 2)14,39,55,56. In a recent meta-analysis, the MMP-2 -1306 CC genotype 
was associated with a significant increase in gastric cancer susceptibility38, but this meta-
analysis did not include two studies that reported no difference in cancer risk between the 
different genotypes14,56. Survival was not influenced by the -1306 C/T polymorphism in any 
of these studies. However, Wu et al detected an increase in lymphatic and venous invasion 
in individuals with a CC genotype55. A second functional polymorphism of MMP-2 is a C to T 
transition at position -735 in the promoter region of the gene. This substitution influences a 
Sp1 transcription factor binding site, resulting in lower promoter activity in T allele carriers15, 
similar to the C to T transition at position -1306. There is a trend towards increased cancer 
risk in MMP-2 -735 CC individuals, and this correlation is particularly significant in smokers. 
The C to T substitution at position -1562 of the promoter region of MMP-9 results in the loss 
of binding to this region of a repressor nuclear protein, resulting in an increase in 
transcriptional activity in macrophages20. T-allele carriers of this polymorphism had deeper 
submucosal infiltration, more frequent lymphatic invasion and more advanced stage cancer 
compared to non-T allele carriers57. Nevertheless, none of the four publications describing 
the MMP-9 -1562 C/T polymorphism in gastric cancer found an association between the 
various genotypes and cancer risk14,53,57,58. In addition, Kubben et al did not find an 
association between the MMP-9 polymorphisms and tumor-related survival14. Two non-
synonymous SNPs located in an exon of MMP-9, R279Q and P574R, were both associated 
with the risk of lymph node metastases in gastric cancer (higher risk in the RR and PP 
genotype, respectively), but did not show a relationship with gastric cancer risk59. 
MMP-7 over-expression has been demonstrated in various forms of cancer. In gastric 
cancer, MMP-7 expression  has  been  linked to  cancer  progression  and  survival60-62. The 
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Sp1 transcription factor binding site, resulting in lower promoter activity in T allele carriers15, 
similar to the C to T transition at position -1306. There is a trend towards increased cancer 
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The C to T substitution at position -1562 of the promoter region of MMP-9 results in the loss 
of binding to this region of a repressor nuclear protein, resulting in an increase in 
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submucosal infiltration, more frequent lymphatic invasion and more advanced stage cancer 
compared to non-T allele carriers57. Nevertheless, none of the four publications describing 
the MMP-9 -1562 C/T polymorphism in gastric cancer found an association between the 
various genotypes and cancer risk14,53,57,58. In addition, Kubben et al did not find an 
association between the MMP-9 polymorphisms and tumor-related survival14. Two non-
synonymous SNPs located in an exon of MMP-9, R279Q and P574R, were both associated 
with the risk of lymph node metastases in gastric cancer (higher risk in the RR and PP 
genotype, respectively), but did not show a relationship with gastric cancer risk59. 
MMP-7 over-expression has been demonstrated in various forms of cancer. In gastric 
cancer, MMP-7 expression  has  been  linked to  cancer  progression  and  survival60-62. The 
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genotype distribution of the -181 A/G polymorphism of MMP-7 is significantly different in 
various parts of the world; the frequency of the minor G-allele being 8.8% in the Asian 
population and 42.0% in the European population38. An increased risk of gastric cancer in 
G-allele carriers of the MMP-7 -181A/G polymorphism, who have a higher transcriptional 
activity, was reported in three studies45,63,64. These findings are in line with the observations 
in esophageal squamous cell cancers, as described above. Patients with the GG and AG 
genotype had a more advanced cancer stage. Interestingly, these findings are in contrast 
with two other papers, where either no correlation between the MMP-7 polymorphisms and 
gastric cancer risk was found56 or there was even an inverse correlation, i.e. a higher 
percentage of MMP-7 -181 AA genotype in the gastric cancer group compared to the 
control group14. The discrepancy between these findings might be explained by a difference 
in ethnicity: in the first three papers all patients had an Asian background, whereas the latter 
two papers concern Caucasian patients. 
The SNPs of MMP-1 (-1607 1G/2G), MMP-3 (-1171 5A/6A), MMP-7 (-153 C/T), MMP-8 
(17 C/G) and MMP-8 (-799 C/T) are reported not to be associated with gastric cancer risk or 
prognosis14,42,44,65. Smokers with the AG genotype of the MMP-13 -77A/G polymorphism 
were reported to have a decreased risk of developing gastric cancer39,41. A trend towards 
increased cancer risk was observed in individuals with the AG genotype of the MMP-12 -82 
A/G polymorphism39,41.  
One of the mechanisms that regulates MMP activity, in addition to promoter 
polymorphisms, is the interaction with TIMPs. The contribution of gene polymorphisms of 
TIMP-1 and TIMP-2 has only been studied sporadically in gastric cancer. The 372 C/T 
polymorphism of TIMP-1 did not correlate with cancer risk or cancer-related survival14. The 
G to C substitution at position -418 in the promoter region of the TIMP-2 gene has been 
suggested to disrupt a Sp-1 binding site, presumably leading to decreased TIMP-2 
transcription30. Yang et al studied this TIMP-2 polymorphism in a group of 206 gastric 
cancer patients and 206 controls. The gastric cancer risk was elevated in C-allele carriers 
(CC + GC vs GG, adjusted OR = 1.51, 95% CI: 1.00-2.26, P = 0.049)66. Two other papers 
that described the contribution of this polymorphism on gastric cancer occurrence, did not 
find an association between the different genotypes and cancer risk14,55. In a cohort of 240 
Taiwanese gastric cancer patients, Wu et al55 found increased lymph node metastases, 
increased serosal invasion and increased venous invasion in patients with the TIMP-2 GG 
genotype. Despite these results, neither in the Taiwanese study, nor in a Dutch study, was 
an association with survival reported14,55. The function of the 303C/T polymorphism of 
TIMP-2, located in exon 3 of the gene, is unclear. Both Kubben et al14 and Alakus et al56 
found no correlation between genotype and gastric cancer risk. The finding in the study of 
Alakus et al that patients with the TIMP-2 303CC genotype more often have lymphatic and 
distant metastases seems to contradict with the findings of Kubben et al, who showed a 
significantly better tumor-related survival in patients with the CC genotype. This discrepancy 
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could possibly be due to the low number of patients with a CT or TT genotype in both 
studies.  
To conclude, an increased gastric cancer susceptibility seems to be present in Asian 
(but not in Caucasian) G-allele carriers of the MMP-7 -181 A/G polymorphism, an 
association also seen with ESCC. While some studies reported an association between 
genotype and clinicopathological parameters or prognosis, these results were not confirmed 
by others and are thus not consistent, except for the finding that MMP-7-181 AG or GG 
genotype patients in the Asian population seem to have a more advanced tumor stage than 
patients with the AA genotype63,64. 
 
SMALL INTESTINAL CANCER 
Tumors of the duodenum, jejunum and ileum are rare and there are in fact no data on 
the effect of functional polymorphisms of matrix metalloproteinases in these tumors. Only 
one paper describes MMP-2, -7, -9, -11 and -13 protein levels in 25 patients with a carcinoid 
tumor localized in the ileum. Except for MMP-2, none of the MMP protein levels were 
associated with survival67. Surprisingly, low MMP-2 expression in the primary carcinoid 
tumor is correlated with an unfavorable outcome of the disease. This finding, which 
contrasts with observations made in many other gastrointestinal tumors, might indicate that 
these neuro-endocrine tumors have a different proteolytic phenotype compared to the other 
tumors which are adenocarcinomas or (in case of proximal or mid-esophageal cancers) 
squamous cell carcinomas. 
 
PANCREATIC CANCER 
Over-expression of MMP-1, MMP-2, MMP-7 and MMP-9 protein in pancreatic cancer is 
associated with more advanced tumor stage and poor prognosis68-74, whereas high 
glandular TIMP-2 expression is associated with better survival in pancreatic ductal 
adenocarcinoma75. However, until now, there are no reports on the functional 
polymorphisms of MMPs and TIMPs in malignant tumors of the pancreas.  
  
CHOLANGIOCARCINOMA  
Bile duct tumors are rare in the general population. Patients with primary sclerosing 
cholangitis (PSC) have an increased risk of developing cholangiocarcinoma. Wiencke et al76 
investigated the association of MMP-1 and MMP-3 promoter polymorphisms in 165 PSC 
patients. Fifteen of these patients developed cholangiocarcinoma; all of these were 1G-
allele carriers of the MMP-1 -1607 1G/2G polymorphism, compared to 72% of the whole 
PSC population. This finding is somewhat surprising since the 2G allele of this SNP is 
associated with a higher level of transcription and in most cancers, as for example 
esophageal adenocarcinomas, associated with increased cancer risk or worse prognosis. 
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Taiwanese gastric cancer patients, Wu et al55 found increased lymph node metastases, 
increased serosal invasion and increased venous invasion in patients with the TIMP-2 GG 
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TIMP-2, located in exon 3 of the gene, is unclear. Both Kubben et al14 and Alakus et al56 
found no correlation between genotype and gastric cancer risk. The finding in the study of 
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distant metastases seems to contradict with the findings of Kubben et al, who showed a 
significantly better tumor-related survival in patients with the CC genotype. This discrepancy 
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could possibly be due to the low number of patients with a CT or TT genotype in both 
studies.  
To conclude, an increased gastric cancer susceptibility seems to be present in Asian 
(but not in Caucasian) G-allele carriers of the MMP-7 -181 A/G polymorphism, an 
association also seen with ESCC. While some studies reported an association between 
genotype and clinicopathological parameters or prognosis, these results were not confirmed 
by others and are thus not consistent, except for the finding that MMP-7-181 AG or GG 
genotype patients in the Asian population seem to have a more advanced tumor stage than 
patients with the AA genotype63,64. 
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Tumors of the duodenum, jejunum and ileum are rare and there are in fact no data on 
the effect of functional polymorphisms of matrix metalloproteinases in these tumors. Only 
one paper describes MMP-2, -7, -9, -11 and -13 protein levels in 25 patients with a carcinoid 
tumor localized in the ileum. Except for MMP-2, none of the MMP protein levels were 
associated with survival67. Surprisingly, low MMP-2 expression in the primary carcinoid 
tumor is correlated with an unfavorable outcome of the disease. This finding, which 
contrasts with observations made in many other gastrointestinal tumors, might indicate that 
these neuro-endocrine tumors have a different proteolytic phenotype compared to the other 
tumors which are adenocarcinomas or (in case of proximal or mid-esophageal cancers) 
squamous cell carcinomas. 
 
PANCREATIC CANCER 
Over-expression of MMP-1, MMP-2, MMP-7 and MMP-9 protein in pancreatic cancer is 
associated with more advanced tumor stage and poor prognosis68-74, whereas high 
glandular TIMP-2 expression is associated with better survival in pancreatic ductal 
adenocarcinoma75. However, until now, there are no reports on the functional 
polymorphisms of MMPs and TIMPs in malignant tumors of the pancreas.  
  
CHOLANGIOCARCINOMA  
Bile duct tumors are rare in the general population. Patients with primary sclerosing 
cholangitis (PSC) have an increased risk of developing cholangiocarcinoma. Wiencke et al76 
investigated the association of MMP-1 and MMP-3 promoter polymorphisms in 165 PSC 
patients. Fifteen of these patients developed cholangiocarcinoma; all of these were 1G-
allele carriers of the MMP-1 -1607 1G/2G polymorphism, compared to 72% of the whole 
PSC population. This finding is somewhat surprising since the 2G allele of this SNP is 
associated with a higher level of transcription and in most cancers, as for example 
esophageal adenocarcinomas, associated with increased cancer risk or worse prognosis. 
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The number of PSC patients in this study was too small to draw definite conclusions about 
the role of this promoter-SNP in PSC-associated cholangiocarcinoma. 
 
HEPATOCELLULAR CARCINOMA  
Hepatocellular carcinoma (HCC) is the fifth most common cancer in men and the eighth 
in women worldwide77. The geographic distribution of this most common form of primary 
liver cancer follows the distribution of hepatitis B and C infection, as most of the patients 
have a background of liver cirrhosis or hepatitis B-infection. Several studies have looked 
into the effect of single nucleotide polymorphisms of MMPs on the incidence of HCC and its 
relation to survival of the patients (Table 4).  None of the MMP gene polymorphisms that 
have been studied in HCC patients is correlated with cancer risk. In one paper, the number 
of 2G/2G homozygotes of the MMP-1 -1607 1G/2G polymorphism was slightly increased in 
HCC patients with a background of chronic hepatitis C virus (HCV)-related liver disease 
compared to patients with HCV-related chronic liver disease without HCC78. However, when 
the same patient group was compared with healthy controls, this relationship was no longer 
present79. In hepatitis B virus (HBV) patients with or without HCC, the genotype distribution 
of the MMP-1 -1607 polymorphism was similar80. No association was found between the 
MMP-2 -1306 C/T polymorphism and the risk of hepatocellular carcinoma80, although 
patients with the CC genotype did experience an increase in HCC recurrence after liver 
transplantation compared to patients with the CT genotype (CT vs CC, OR = 0.42, 95% CI: 
0.18-0.99, P < 0.05; there were no TT patients in the cohort). When compared with healthy 
controls, HCV-infected patients with HCC were more often 5A-allele carriers of the -1171 
5A/6A polymorphism79. However, when compared to HCV infected patients without HCC, 
no difference in genotype distribution was found78, which might suggest that the 5A-allele 
interferes with the development of the underlying disease instead of with the development 
of HCC. 5A allele carriers did have larger tumor diameters at the time of diagnosis and a 
poorer prognosis78,79. The SNPs MMP-2 -735 C/T, MMP-7 -181 A/G, MMP-8 -799C/T, 
MMP-9 -1562 C/T, MMP-12 -82 A/G, MMP-13 -77 A/G and MMP-21 C572T were found not 
to be associated with an increased risk of developing HCC78-82. One paper which describes 
the impact of the TIMP-2 -418 G/C polymorphism in a group of 92 HCC patients and 70 
patients with chronic liver disease without signs of HCC found no association with HCC 
occurrence or prognosis83.  
In conclusion, polymorphisms of MMPs are not associated with HCC susceptibility. 
MMP-genotype may possibly influence the course of the disease in HCC patients, as HCV-
infected HCC patients carrying the 5A allele of the MMP-3 -1171 5A/6A polymorphism 
appear to have worse survival rates78,79. In addition, it has been reported that HCC 
recurrence after liver transplantation is increased in MMP-2 -1306 CC genotype carriers 
when compared to CT patients82. 
  
84 | Chapter 4






























COLORECTAL CANCER  
Worldwide, colorectal cancer (CRC) is the fourth most common cancer in men and the 
third most common cancer in women84. Continents with a high incidence of colorectal 
cancer include Europe and North America. The lowest incidence is found in Asia, Africa and 
South America. In Eastern Europe and Japan CRC incidence has increased over recent 
years, probably due to a “Westernization” of lifestyle84. The effect of MMP polymorphisms 
on lung, breast and colorectal cancer has been reviewed previously by Decock et al85. The 
studies that are included in the present review are shown in table 5. 
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The number of PSC patients in this study was too small to draw definite conclusions about 
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MMP-2 -1306 C/T polymorphism and the risk of hepatocellular carcinoma80, although 
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0.18-0.99, P < 0.05; there were no TT patients in the cohort). When compared with healthy 
controls, HCV-infected patients with HCC were more often 5A-allele carriers of the -1171 
5A/6A polymorphism79. However, when compared to HCV infected patients without HCC, 
no difference in genotype distribution was found78, which might suggest that the 5A-allele 
interferes with the development of the underlying disease instead of with the development 
of HCC. 5A allele carriers did have larger tumor diameters at the time of diagnosis and a 
poorer prognosis78,79. The SNPs MMP-2 -735 C/T, MMP-7 -181 A/G, MMP-8 -799C/T, 
MMP-9 -1562 C/T, MMP-12 -82 A/G, MMP-13 -77 A/G and MMP-21 C572T were found not 
to be associated with an increased risk of developing HCC78-82. One paper which describes 
the impact of the TIMP-2 -418 G/C polymorphism in a group of 92 HCC patients and 70 
patients with chronic liver disease without signs of HCC found no association with HCC 
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In conclusion, polymorphisms of MMPs are not associated with HCC susceptibility. 
MMP-genotype may possibly influence the course of the disease in HCC patients, as HCV-
infected HCC patients carrying the 5A allele of the MMP-3 -1171 5A/6A polymorphism 
appear to have worse survival rates78,79. In addition, it has been reported that HCC 
recurrence after liver transplantation is increased in MMP-2 -1306 CC genotype carriers 
when compared to CT patients82. 
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COLORECTAL CANCER  
Worldwide, colorectal cancer (CRC) is the fourth most common cancer in men and the 
third most common cancer in women84. Continents with a high incidence of colorectal 
cancer include Europe and North America. The lowest incidence is found in Asia, Africa and 
South America. In Eastern Europe and Japan CRC incidence has increased over recent 
years, probably due to a “Westernization” of lifestyle84. The effect of MMP polymorphisms 
on lung, breast and colorectal cancer has been reviewed previously by Decock et al85. The 
studies that are included in the present review are shown in table 5. 
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MMP-1, an interstitial collagenase, degrades fibrillar collagens type I, II, III, V, IX, and X, 
that form the most abundant class of extracellular matrix proteins in the interstitium86. The 
MMP-1 gene is located on chromosome 11q22. Insertion of an extra guanine (G) at the -
1607 promoter position creates an Ets-1 transcription factor binding site (5’-GGA-3’) leading 
to a significant increase in transcription activity in normal fibroblasts18. Both alleles are 
common in the general population; the allele frequency of the 2G allele is 64% in the Asian 
population and 52% in the European population87. In the Caucasian population, the 
frequency of the homozygote -1607 2G/2G polymorphism is about 30%. Several papers 
reported an increased colorectal cancer susceptibility in either 2G/2G homozygotes or 2G-
allele carriers of the MMP-1 -1607 polymorphism88-93. However, a number of other studies 
found no association between cancer risk and MMP-1 genotype94-98. With exception of the 
studies of Fang et al and Hettiaratchi et al, all studies included a relatively small number of 
patients, which could explain the differences in results. Hettiaratchi et al included the largest 
cohort (503 Australian CRC patients, 471 controls) of all studies so far96. Besides the lack of 
association between the genotype and CRC susceptibility, in this cohort the 5-year survival 
was increased in 2G/2G homozygotes. All other studies, which have either looked at 
survival or correlation with clinicopathological parameters, showed that the 2G/2G genotype 
is either associated with worse survival99, with unfavourable clinicopathological parameters, 
like increased risk of metastases at time of diagnosis92, a higher number of affected lymph 
nodes89, or with earlier distant metastases88. Patient selection could possibly account for 
this discrepancy, since Hettiaratchi et al only included patients who did not have 
synchronous metastases at the time of diagnosis, and the influence of MMP-1 on the 
cancer process may change during different stages of cancer progression. De Lima et al 
reported a higher risk of lymph node metastases in patients carrying a 1G-allele, although 
this association was not significant with a P value of 0.0995. In all the other abovementioned 
papers, no association of MMP-1 gene polymorphisms and clinicopathological parameters 
was found. In two meta-analyses, 2G-allele carriers showed a significantly increased risk of 
developing colorectal cancer when compared with homozygous 1G allele carriers87,100. 
However, the large cohort of Hettiaratchi et al96 was not included in these meta-analyses 
and inclusion of this study might lead to loss of significance. 
Lièvre et al101 studied the influence of genetic polymorphisms in the MMP-1 (-1607 
1G/2G) gene in 295 patients with large adenomas and 302 patients with small adenomas, 
the premalignant condition to colorectal cancer, and in 568 polyp-free controls. No 
difference was found in the genotype distribution between patients with large adenomas 
and patients with small adenomas or healthy controls.  
In a population of 126 CRC patients and 126 healthy controls, Xu et al102 found an 
increase in CRC susceptibility in patients with the CC genotype of the MMP-2 -1306 C/T 
polymorphism. These findings were not supported by Hettiaratchi et al 96, Elander et al90 
and Ohtani et al103, who found no influence of the MMP-2 genotype on the colorectal cancer 
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In a population of 126 CRC patients and 126 healthy controls, Xu et al102 found an 
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risk (Figure 2). Difference in ethnicity (Australian vs European vs Japanese) or sample size 
might be the underlying cause of this discrepancy. Two metaanalyses, both including the 
study of Xu et al, showed no association between the MMP-2 -1306 C/T polymorphism and 
colorectal cancer susceptibility87,100. Xu et al104 also reported that patients with the CC 
genotype had more frequent serosa/adventitia involvement, while none of the other studies 
described any correlation with clinicopathological parameters or survival, except for the 
study of Langers et al, where the TT genotype was shown to be an indicator of poor 10-year 
survival89-93,96,97,99,103,105. In the Xu et al104 cohort of 126 CRC patients and 126 control 
patients, two other polymorphisms of MMP-2 (-790 T/G, -955 A/C) were not associated with 
cancer susceptibility or infiltration depth, while GG genotype carriers of the MMP-2 -1575 
G/A polymorphism had an increased risk of developing CRC and more frequent serosa or 
adventitia invasion compared to the other genotypes, similar to that with the -1306 CC 
genotype102. The similarity in these observations is probably because the MMP-2 -1575 
G/A, -1306 C/T, -790 G/T and -735 C/T polymorphisms have been found to be in almost 
complete pair-wise linkage (dis)equilibrium28. 
The most frequently studied MMP-9 polymorphism is the C to T substitution at position -
1562 of the promoter region, which increases transcriptional activity. In a population of 185 
Korean colorectal cancer patients and 304 controls, individuals with the CC genotype had 
an increased risk for developing CRC (OR = 1.7, 95% CI: 1.04-2.66, P = 0.033)89. None of 
the other studies found similar results90,103-107. A meta-analysis that included the studies of 
Elander et al90, Xu et al104,107, Woo et al89 and Xing et al106 showed no significant 
association of the -1562 C/T MMP-9 polymorphism and colorectal cancer100. The same 
conclusion was reached in a second meta-analysis87 . Xing et al106 reported a decrease of 
lymph node metastases in 137 Chinese CRC patients with the CC genotype of the MMP-9 -
1562 SNP, whereas the other studies did not find an association with lymph node 
metastases, survival, infiltration depth or any other clinicopathological variable. The 
mechanism of action of MMP-9 in cancer is intriguing and not as straightforward as some of 
the other MMPs. In colorectal cancer, both very high and very low levels of MMP-9 in tumor 
tissue seem to be associated with poor prognosis compared to intermediate MMP-levels105. 
Similarly, in ovarian cancer, the presence of MMP-9 within the ovarian cells is associated 
with better survival, whereas higher stromal expression is a marker of worse prognosis108. 
The -90(CA)14-27 polymorphism, in which the number of CA repeats influences expression of 
MMP-9, is not associated with cancer risk or the risk of lymph node metastases89. Thus, no 
consistent relation emerges between MMP-9 genotypes and CRC expression. In a single 
study of 185 Taiwanese colorectal cancer patients, no association of the MMP-12 -82A/G 
polymorphism and colorectal cancer risk of development or lymph node metastases was 
found89. 
Insertion of an extra Adenosine (A) at position -1171 of the MMP-3 promoter generates 
a 6A allele with lower promoter activity compared to the 5A allele19. This polymorphism has 
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been studied quite extensively in colorectal cancer, and in all but one paper, no contribution 
to cancer risk, clinicopathological parameters or survival was demonstrated89-93,96,97,99,103. 
Only Hinoda et al found a two-fold increase in CRC risk in the 6A/6A homozygotes (OR = 
2.11, 95% CI: 1.16-3.82, P = 0.013) in the previously mentioned study of a Japanese cohort 
of 101 CRC patients and 127 controls. In 302 patients with small adenomas and 568 polyp-
free controls, the 6A/6A genotype of the -1171 MMP-3 polymorphism was associated with a 
significant risk of small adenomas (OR = 1.50, 95%CI: 0.99-2.28, P = 0.008) and this 
association was even stronger in individuals with the combined genotype MMP-3 -1171 
6A/6A + MMP-1 -1607 2G/2G (OR =1.88, 95%CI: 1.08-3.28, P = 0.001)101. When the MMP-
3 genotype of 295 patients of that study with large adenomas was compared to either the 
patients with small adenomas or the polyp-free controls, no difference in genotype 
distribution was found. These findings suggest that this MMP-3 5A/6A polymorphism (and 
the -1607 1G/2G polymorphism) might be of importance early in the process of adenoma 
formation. The 6A/6A genotype of the MMP-3 -1171 5A/6A polymorphism has a lower 
transcriptional activity and higher plasma levels of MMP-3 were measured in 5A/5A 
homozygote patients with acute coronary syndrome compared to 6A/6A homozygotes109. 
Apparently, the association between this polymorphism and increased susceptibility for 
developing early colorectal adenomas does not provide an insight into the functional activity 
of the protein. 
No clear association between MMP-7 -181 A/G polymorphism and colorectal cancer 
incidence, lymph node metastases or survival was found in most of the 
publications89,94,95,103,110. The only exception is by Ghilardi et al111 who showed that the GG 
genotype increases the colorectal cancer risk. Furthermore, in the 58 patients with 
colorectal cancer included in this study, the CC genotype predisposed for lymph node 
metastases and distant metastases at the time of diagnosis111. Ghilardi et al111 also studied 
the C/T polymorphism at position -153 of the MMP-7 promoter and found an increase in 
colorectal cancer risk in T allele carriers, but no association with any of the 
clinicopathological variables. In a study of 174 colorectal cancer patients, Langers et al110 
reported that patients with the CC genotype had a better 10-year survival than the patients 
with the CT or TT genotype (CC vs CT+TT: Log Rank 14.0, P = 0.0009). The study of 
Ghilardi et al111 included 58 patients, a relatively small number for studying the influence of 
gene polymorphisms on cancer susceptibility and prognosis. This may explain the 
discordant results between the different studies and illustrates the need for larger sample 
sizes. Peng et al tried to solve this problem by performing meta-analyses of case control 
studies investigating the role of gene polymorphisms of MMP-1, -2, -3, -7 and -9 on cancer 
susceptibility in lung, head and neck, esophageal, gastric, colorectal, hepatocellular, breast, 
renal, bladder, cervical, ovarian, endometrial, prostate and skin cancer38,87. In these meta-
analyses, a consistent positive association with colorectal cancer risk was observed for the 
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MMP-1 -1607 1G/2G polymorphism, but not for MMP-2 -735C/T, MMP-2 -1306 C/T, MMP-7 
-181A/G and MMP-9 -1562 C/T.  
In summary, although data are still emerging, there appears to be evidence for 
associations between the MMP-1 -1607 1G/2G, MMP-2 -1306 C/T, MMP-7 -181 A/G and 
MMP-9 -1562 C/T polymorphisms and CRC susceptibility. In affected individuals, an 
association of the MMP polymorphism with the course of the disease or prognostic 






The three major regulatory mechanisms that eventually determine the function of MMPs 
are transcription, activation of latent MMPs and inhibition by specific inhibitors. Along with 
local activation and inhibition, regulation of transcription seems to be of major importance 
for the function of MMPs112. Most of the promoter polymorphisms that are described in this 
review have been shown to influence promoter activity and to increase or decrease 
transcription in vitro, as shown in table 1. Some SNPs are associated with gastrointestinal 
cancer susceptibility and in some cases, a correlation with clinicopathological parameters 
and outcome of the disease was observed. Surprisingly, only a few studies have actually 
looked at the correlation between the promoter polymorphism of MMPs and the 
corresponding tumor protein levels. Two studies reported no association between the 
different genotypes and MMP protein expression in the tumor56,105. It would be interesting to 
correlate the values in normal tissues from these patients with their genotypes to further 
elucidate their contribution to the phenotypic expression of the MMPs in cancer patients. 
Besides the regulation of expression by transcription, the presence of MMPs in the (tumor) 
microenvironment depends on the inactivation/clearing, which is regulated by the inhibitors. 
High clearance could lead to low protein levels despite high levels of expression. 
Furthermore, a specific genotype can have different (and even opposite) effects in different 
cell types. Wang et al showed that the -799T/-381G/+17G haplotype of MMP-8 increased 
promoter activity in cells resembling chorion cytotrophoblasts, but the same haplotype 
decreased promoter activity in a leukocyte cell line and had no effect on promoter activity in 
a macrophage cell line23. Cell-specific functional effects of SNPs have been described for 
several cancer-associated proteins113,114. This phenomenon makes the translation of the 
effect of a promoter polymorphism on gene transcription to the in vivo situation even more 
complex, especially as many different stromal cell types as well as tumor cells are involved 
in the production of MMPs (Figure 1). A correlation between a particular polymorphism and 
cancer susceptibility does not necessarily demonstrate the implication of the corresponding 
gene in the process of cancer development or progression. It could also be the result of a 
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linkage (dis)equilibrium between the examined (potentially functionally neutral) SNP and 
another (potentially functionally important) SNP85.  
Although for some MMP-polymorphisms the results between different studies are 
unanimous, there is often a discrepancy between the results of different studies on the 
same polymorphism. However, some trends can be observed. An increased incidence of 
esophageal cancer in CC carriers of the MMP-2 -1306 C/T polymorphism was reported in 2 
studies15,39 and this association was corroborated in a meta-analysis38. In the Asian 
population, G-allele carriers of the MMP-7 -181 A/G polymorphism have an increased risk of 
developing both esophageal cancer and gastric cancer45,63,64. In hepatocellular cancer, no 
association was found between any of the MMP SNPs and cancer risk, although 5A-allele 
carriers of the MMP-3 5A/6A polymorphism might have a worse prognosis. Although some 
studies concerning CRC report a correlation between cancer incidence and the MMP-1 
1G/2G, MMP-2 -1306 C/T, MMP-7 -181A/G and MMP-9 -1562 C/T polymorphism, the only 
association that was found to be significant in a meta-analysis was a higher cancer risk in 
2G allele carriers of the MMP-1 1G/2G polymorphism87. Sometimes, as for the MMP-7 -181 
A/G polymorphism in gastric cancer, the variability in results between the different studies is 
likely to be explained by ethnic differences between the study groups. Different genotype 
distributions of MMP-2 and MMP-9 SNPs have been reported in Caucasians and African-
Americans, which seem to be associated with differences in prevalence of cancer and 
cardiovascular disease115. The diverse results in the publications described in this review 
emphasize the need for studies on larger numbers of patients before definite associations 
between genetic polymorphism and susceptibility to cancer or with the course of the 
disease in affected individuals can be established. There is a need for large cohorts of 
patients who are genotyped, and information about disease progression, lymph node 
metastases, distant metastases and prognosis needs gathered. In the meantime meta-
analyses rather than single studies are the best indicators of the practical value of single 
SNPs. The recent meta-analysis of Zhou et al116 including almost 3000 breast carcinoma 
patients, suggested MMP-2 -1306 C/T as a potential indicator, whereas the SNPs of MMP-
1, MMP-3 and MMP-9 were not indicative.  
Genome-wide association studies (GWAS) may further highlight the genes that are 
important in identifying people at high risk for the development of cancer or patients who are 
likely to have an unfavorable outcome of their disease. To date, fourteen loci identified by 
GWAS analysis have been shown to influence the risk of developing colorectal cancer117. 
None of them is located in any of the MMP genes. However, in an extensive mutation 
analysis of the human genome in which 13.023 genes were involved, Sjöblom et al118 
identified MMP-2, ADAM29 and three ADAMTS family members among the 69 CAN genes 
that are often mutated in colorectal cancer.  
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MMP-1 -1607 1G/2G polymorphism, but not for MMP-2 -735C/T, MMP-2 -1306 C/T, MMP-7 
-181A/G and MMP-9 -1562 C/T.  
In summary, although data are still emerging, there appears to be evidence for 
associations between the MMP-1 -1607 1G/2G, MMP-2 -1306 C/T, MMP-7 -181 A/G and 
MMP-9 -1562 C/T polymorphisms and CRC susceptibility. In affected individuals, an 
association of the MMP polymorphism with the course of the disease or prognostic 






The three major regulatory mechanisms that eventually determine the function of MMPs 
are transcription, activation of latent MMPs and inhibition by specific inhibitors. Along with 
local activation and inhibition, regulation of transcription seems to be of major importance 
for the function of MMPs112. Most of the promoter polymorphisms that are described in this 
review have been shown to influence promoter activity and to increase or decrease 
transcription in vitro, as shown in table 1. Some SNPs are associated with gastrointestinal 
cancer susceptibility and in some cases, a correlation with clinicopathological parameters 
and outcome of the disease was observed. Surprisingly, only a few studies have actually 
looked at the correlation between the promoter polymorphism of MMPs and the 
corresponding tumor protein levels. Two studies reported no association between the 
different genotypes and MMP protein expression in the tumor56,105. It would be interesting to 
correlate the values in normal tissues from these patients with their genotypes to further 
elucidate their contribution to the phenotypic expression of the MMPs in cancer patients. 
Besides the regulation of expression by transcription, the presence of MMPs in the (tumor) 
microenvironment depends on the inactivation/clearing, which is regulated by the inhibitors. 
High clearance could lead to low protein levels despite high levels of expression. 
Furthermore, a specific genotype can have different (and even opposite) effects in different 
cell types. Wang et al showed that the -799T/-381G/+17G haplotype of MMP-8 increased 
promoter activity in cells resembling chorion cytotrophoblasts, but the same haplotype 
decreased promoter activity in a leukocyte cell line and had no effect on promoter activity in 
a macrophage cell line23. Cell-specific functional effects of SNPs have been described for 
several cancer-associated proteins113,114. This phenomenon makes the translation of the 
effect of a promoter polymorphism on gene transcription to the in vivo situation even more 
complex, especially as many different stromal cell types as well as tumor cells are involved 
in the production of MMPs (Figure 1). A correlation between a particular polymorphism and 
cancer susceptibility does not necessarily demonstrate the implication of the corresponding 
gene in the process of cancer development or progression. It could also be the result of a 
92 | Chapter 4
linkage (dis)equilibrium between the examined (potentially functionally neutral) SNP and 
another (potentially functionally important) SNP85.  
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esophageal cancer in CC carriers of the MMP-2 -1306 C/T polymorphism was reported in 2 
studies15,39 and this association was corroborated in a meta-analysis38. In the Asian 
population, G-allele carriers of the MMP-7 -181 A/G polymorphism have an increased risk of 
developing both esophageal cancer and gastric cancer45,63,64. In hepatocellular cancer, no 
association was found between any of the MMP SNPs and cancer risk, although 5A-allele 
carriers of the MMP-3 5A/6A polymorphism might have a worse prognosis. Although some 
studies concerning CRC report a correlation between cancer incidence and the MMP-1 
1G/2G, MMP-2 -1306 C/T, MMP-7 -181A/G and MMP-9 -1562 C/T polymorphism, the only 
association that was found to be significant in a meta-analysis was a higher cancer risk in 
2G allele carriers of the MMP-1 1G/2G polymorphism87. Sometimes, as for the MMP-7 -181 
A/G polymorphism in gastric cancer, the variability in results between the different studies is 
likely to be explained by ethnic differences between the study groups. Different genotype 
distributions of MMP-2 and MMP-9 SNPs have been reported in Caucasians and African-
Americans, which seem to be associated with differences in prevalence of cancer and 
cardiovascular disease115. The diverse results in the publications described in this review 
emphasize the need for studies on larger numbers of patients before definite associations 
between genetic polymorphism and susceptibility to cancer or with the course of the 
disease in affected individuals can be established. There is a need for large cohorts of 
patients who are genotyped, and information about disease progression, lymph node 
metastases, distant metastases and prognosis needs gathered. In the meantime meta-
analyses rather than single studies are the best indicators of the practical value of single 
SNPs. The recent meta-analysis of Zhou et al116 including almost 3000 breast carcinoma 
patients, suggested MMP-2 -1306 C/T as a potential indicator, whereas the SNPs of MMP-
1, MMP-3 and MMP-9 were not indicative.  
Genome-wide association studies (GWAS) may further highlight the genes that are 
important in identifying people at high risk for the development of cancer or patients who are 
likely to have an unfavorable outcome of their disease. To date, fourteen loci identified by 
GWAS analysis have been shown to influence the risk of developing colorectal cancer117. 
None of them is located in any of the MMP genes. However, in an extensive mutation 
analysis of the human genome in which 13.023 genes were involved, Sjöblom et al118 
identified MMP-2, ADAM29 and three ADAMTS family members among the 69 CAN genes 
that are often mutated in colorectal cancer.  
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CONCLUSION 
 
To predict the cancer risk in a population and the outcome of the disease in affected 
individuals, a genomic profile including functional SNPs of several genes would probably be 
a better tool than the use of a single SNP. Being key players in the process of cancer 
development and progression, SNPs of selected MMPs or TIMPs could be included in such 
a profile to predict disease susceptibility and/or the course of a disease. Because of the 
heterogeneity of previous studies that have included a relatively small number of patients, 
further research on large cohorts of cancer patients and healthy controls is needed before a 
definite conclusion can be drawn about the impact of these genes on gastro-intestinal 
cancer risk and prognosis.  
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The prognostic significance of single-nucleotide polymorphisms (SNPs) and tumour 
protein levels of MMP-2 and MMP-9 was evaluated in 215 colorectal cancer patients. 
Single- nucleotide polymorphism MMP-2 -1306 C/T and high MMP-2 levels were 
significantly associated with worse survival. Extreme tumour MMP-9 levels were associated 
with poor prognosis but SNP MMP-9 -1562 C/T was not. Tumour MMP levels were not 
determined by their SNP genotypes. 
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INTRODUCTION
 
Enhanced tumour matrix metalloproteinase (MMP) levels have been correlated to 
decreased patients’ survival in various types of cancer1-5. Next to sheer degraders of 
extracellular matrix, MMPs are presently regarded as general molecular switches in the 
microenvironment6. For instance, MMPs function as major regulators of tumour growth by 
catalysing the release or activation of growth factors, activation or shedding of membrane 
receptors, or cleavage of matrix/membrane-bound substrates involved in cell proliferation7. 
A subgroup of MMPs, the gelatinases (MMP-2 and MMP-9), have been particularly 
implicated in progression, angiogenesis and metastasis of various cancer types8. In the 
present study, we evaluated the association between, and the prognostic relevance of 
tissue protein levels of MMP-2 and MMP-9 and their gene promoter single-nucleotide 
polymorphisms (SNPs) in a cohort of 215 Dutch colorectal cancer patients. 
MATERIALS AND METHODS
  
Patients and study design 
Representative, nonnecrotic samples of cancer tissue were collected from 215 patients 
with colorectal cancer, operated in the Leiden University Medical Centre (December 1983 - 
September 1991). Tissues were snap-frozen and stored at -70°C. Clinical data and follow-
up were available for at least 10 years. Macroscopic and microscopic parameters were 
obtained from the pathology reports. The study was performed according to the instructions 
and guidelines of the LUMC Medical Ethics Committee. 
 
Tissue preparation and protein concentration 
Tissues were homogenised in 0.1 M Tris-HCL (pH 7.5) with 0.1% (v/v) Tween 80 buffer 
and centrifuged twice all at 4°C, as described before9, the protein concentrations were 
determined10 and the supernatants were aliquoted and stored at -70°C. Storage-induced 
degradation of MMP-2 and MMP-9 was checked by western blots and gelatin zymography 
prior to ELISA measurements11. 
Determination of MMP-2 and MMP-9 in tissue homogenates 
The MMP-2 and MMP-9 levels were determined by previously described ELISAs12. 
Polyclonal anti-MMP-2 or monoclonal anti-MMP-9 antibodies were used as catching 
antibody, incubated with appropriately diluted samples (o/n, 4°C), and polyclonal anti-MMP-
2/biotin-labelled goat anti-rabbit-IgG and biotin-labelled polyclonal anti-MMP-9 antibodies 
for immunedetection combined with avidin-peroxidase and the 3,3΄,5,5΄-tetramethyl 
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benzidine/H2O2 substrate solution, and the absorption was read at 450 nm. Sample MMP 
concentrations were calculated from standard curves and expressed in ng per mg protein. 
 
Single-nucleotide polymorphism analysis 
Tissue DNA was isolated using the salting out method13. Single-nucleotide 
polymorphism (SNP) analysis for MMP-2 -1306 C/T and MMP-9 -1562 C/T was performed 
by tetraprimer ARMS PCR, involving four oligonucleotide primers but no restriction 
enzymes, or RFLP-PCR, as described earlier14, 15. 
 
Statistical analysis 
Statistical analyses were performed using SPSS 12.0 Statistical Package (2004, SPSS 
Inc., Chicago, IL, USA). Expression differences between groups were calculated using the 
Mann-Whitney’s U-test. Log rank statistics was used for optimal cutoff point analysis. 
Hardy-Weinberg’s analysis was performed using χ2 or Fisher’s exact test to examine 
differences in the distribution of alleles and genotypes. Correlations between parameters 
were according to Pearson or Spearman, where appropriate. Overall survival curves were 
according to Kaplan and Meier. Univariate and multivariate survival analyses were 




The genotype distributions of the SNPs for MMP-2 and MMP-9 in 215 colorectal cancer 
patients are shown in Table 1. The distribution of the polymorphisms in the patients was 
according to the predicted Hardy-Weinberg’s distribution. Both SNPs showed a weak but 
significant association with TNM stage (Table 1) and MMP-2 -1306 C/T also with survival 
(Figure 1A). All other clinicopathological parameters did not show an association with either 
SNP MMP-2 -1306 C/T or MMP-9 -1562 C/T, and the latter was also not associated with 
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LR 6.36, P=0.04 
TT vs. CC/CT, P=0.01 















LR 1.26, P=0.53 
TT vs. CC/CT, P=0.26 
TT, 9/7† 
Table 1. Genotype distribution of single-nucleotide polymorphisms (SNPs) for MMP-2 and MMP-9 in 215 colorectal 
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MMP = matrix metalloproteinase *χ2 values for TNM stage distribution of MMP-2 and MMP-9 were, respectively, 15.9 
(P = 0.01) and 14.9 (P = 0.02).  
 
           














   
Figure 1: Kaplan-Meier’s 10-year survival curves of 215 colorectal cancer patients grouped by their genotype for SNP 
MMP-2 -1306 C/T (A) and MMP-9 -1562 C/T (B). The total number of patients and the deceased patients (†) are 
indicated per subgroup.  
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Table 2: Univariate and multivariate Cox’s proportional hazard 10-year survival analysis of 215 colorectal cancer 
patients 
     
Univariate 
   
Multivariate 
 



























 Age < 65 years > 73-142 2.123 1.448-3.113 0.000 2.390 1.625-3.516 0.000
 TNM 1/2 vs 3/4 120-95 2.316 1.662-3.228 0.000 2.548 1.822-3.564 0.000
 Localization Right vs rest 75-140 1.023 0.726-1.442 0.896  Not included  
 Diameter <5 cm > 92-123 1.310 0.936-1.834 0.116  Not included  
 Differentiation Good vs rest 38-174 1.129 0.789-1.614 0.506  Not included  
 
MMP Proteins
        
 MMP-2 <18.5ng/mg> 158-56 1.504 1.048-2.158 0.027 1.417 0.982-2.043 0.062
























MMP SNPs         
 MMP-2 CC/CT vs TT 203-12 1.471 1.079-2.006 0.015 1.395 1.019-1.911 0.038
 MMP-9 CC/CT vs TT 206-9 1.239 0.847-1.813 0.270 1.114 0.757-1.638 0.584 
CI = confidence interval; HR = hazard ratio; MMP = matrix metalloproteinase. Multivariate analysis was performed by 
adding every single MMP-related parameter to the dichotomised, prognosis-associated clinicopathological 
parameters gender, age and TNM stage. Entries in bold indicate significant, or in case of MMP-2 almost significant P-
values.
 
The MMP-2 and MMP-9 protein levels in the colorectal cancer homogenates did not 
correlate with their respective SNP genotypes. The median values for MMP-2 -1306 C/T 
were 10.9, 9.5, and 11.6 ng mg-1 for genotypes CC, CT and TT respectively. Even an 
apparent enhancement of MMP-9 protein associated with the TT genotype of SNP MMP-9 -
1562 C/T in tumours did not reach significance (CC/CT vs TT, medians 36.5/26.3 vs 44.4 
ng mg-1, P = 0.28). 
Univariate Cox’s survival analyses confirmed the association of the MMP-2 SNP and the 
protein levels of MMP-2 and MMP-9 with survival (Table 2). Multivariate analysis against the 
prognosis-associated parameters gender, age and TNM classification showed that the 
MMP-2 SNP was independently associated with survival, whereas the tumour protein levels 
of MMP-2 just lost and MMP-9 completely lost their significance.
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The protein levels of MMP-2 (median 10.6; range: 0.0-76.6 ng per mg protein) and 
MMP-9 (median 37.3; range: 0.5-201.9 ng per mg protein) in the colorectal carcinomas 
were found not to be related to any of the clinicopathological parameters, although for 
MMP-2 a stepwise increase with TNM stage was discernable (not shown). For the survival 
analysis, an optimised cutoff point value was identified for the tumour MMP-2 level (18.5 ng 
per mg protein, LR 5.07, P = 0.024, Figure 2A). The same approach for MMP-9 resulted in 
two differently oriented cutoff points; a low MMP-9 value (11.2 ng per mg protein, LR 9.18, 
P=0.010) and a high value (125.0 ng per mg protein, LR 5.31, P = 0.021), both associated 


























Figure 2: Optimal cutoff point analysis and corresponding Kaplan-Meier‟s 10-year survival curves for MMP-2 (A) and 
MMP-9 (B) in tumour tissue homogenates from 215 colorectal cancer patients. The optimal cutoff points are indicated 
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Table 2: Univariate and multivariate Cox‟s proportional hazard 10-year survival analysis of 215 colorectal cancer 
patients 
     
Univariate 
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Age < 65 years > 73-142 2.123 1.448-3.113 0.000 2.390 1.625-3.516 0.000
TNM 1/2 vs 3/4 120-95 2.316 1.662-3.228 0.000 2.548 1.822-3.564 0.000
Localization Right vs rest 75-140 1.023 0.726-1.442 0.896  Not included  
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adding every single MMP-related parameter to the dichotomised, prognosis-associated clinicopathological 
parameters gender, age and TNM stage. Entries in bold indicate significant, or in case of MMP-2 almost significant P-
values.
 
The MMP-2 and MMP-9 protein levels in the colorectal cancer homogenates did not 
correlate with their respective SNP genotypes. The median values for MMP-2 -1306 C/T 
were 10.9, 9.5, and 11.6 ng mg-1 for genotypes CC, CT and TT respectively. Even an 
apparent enhancement of MMP-9 protein associated with the TT genotype of SNP MMP-9 -
1562 C/T in tumours did not reach significance (CC/CT vs TT, medians 36.5/26.3 vs 44.4 
ng mg-1, P = 0.28). 
Univariate Cox‟s survival analyses confirmed the association of the MMP-2 SNP and the 
protein levels of MMP-2 and MMP-9 with survival (Table 2). Multivariate analysis against the 
prognosis-associated parameters gender, age and TNM classification showed that the 
MMP-2 SNP was independently associated with survival, whereas the tumour protein levels 
of MMP-2 just lost and MMP-9 completely lost their significance.
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DISCUSSION 
 
MMP-2 and MMP-9 are proteinases implicated in cancer progression. We showed 
previously that high tumour levels of MMP-2 in gastric carcinomas were consistently 
associated with a worse survival3, 11. For enhanced MMP-9 levels the relation with survival 
was more ambivalent3, 14. Also in our present cohort of colorectal carcinoma patients, we 
found that MMP-2 and MMP-9 levels within the tumours are of significance to survival. The 
cutoff point analysis showed a broad range of MMP-2 levels with a significant and 
unidirectional relation with survival outcome: high tumour MMP-2 levels are unfavourable for 
the patients’ prognosis. Our ELISA-derived MMP-2 data correspond very well with a recent 
immunohistochemical study in a group of 351 colorectal cancer patients, showing that high 
expression of MMP-2 in malignant epithelium as well as in the surrounding stroma was 
associated with reduced survival2. Similar analysis on our tumour MMP-9 data revealed that 
not only patients with the highest, but also those with the lowest levels had a worse survival 
than patients with intermediate levels. Duality of tumour MMP-9 levels with respect to 
survival has been recognised before in immunohistochemistry-based studies. For example, 
extensive MMP-9 staining in ovarian cancer cells was associated with a longer survival, as 
opposed to a shorter survival with a higher stromal expression of MMP-916. Earlier 
morphometric studies indicated that the degree of MMP-9 expression in tumour-associated 
lymphocytes, macrophages and neutrophils was inversely associated with invasion and 
metastasis in colorectal cancer17. These observations are relevant to our findings because a 
low level of MMP-9 in the tumour homogenates might indicate a lack of infiltration of the 
tumours with MMP-9 containing leukocytes, known to exert anticancer effects18, 19, leading 
to an adverse prognosis. In addition, MMP-9- mediated cleavage of extra-cellular matrix 
components is also known to generate antiangiogenesis inhibitors like angiostatin20. Low 
MMP-9 expression in the tumour, leading to insufficient production of antiangiogenic factors, 
could also contribute to the worse prognosis of these patients21. However, MMP-9 has a 
wide range of substrates, including various growth factors and several types of collagen, 
which after cleavage contribute to the process of invasion, angiogenesis, and metastasis of 
tumours, explaining why high tumour levels of MMP-9, in general, are associated with a 
poor prognosis.  
Differences in expression of metalloproteinases might, in part, be explained by genotypic 
variation. Because the investigated SNPs of MMP-2 and MMP-9 are located in the promoter 
region of the gene, a correlation between polymorphism and protein expression might be 
expected. The CT transition at the -1306 position of the MMP-2 gene promoter prevents 
binding of the stimulating Sp1 transcription factor whereas a change at the -1562 position of 
the MMP-9 gene decreases binding of a repression factor22, 23. In vitro MMP-2 expression 
levels by colon cancer cell lines containing the CC genotype were indeed higher compared 
with cells with the CT genotype24. In our cohort of patients, however, we found no 
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relationship between MMP-2 and MMP-9 polymorphisms and the tumour protein levels, 
likely caused by the complicated regulatory posttranslational mechanisms for proteinases in 
multicellular tumour tissues. Nevertheless, we did find significant associations between 
MMP-2 -1306 C/T and TNM stage and survival, that is, worse prognosis in patients with the 
TT genotype. This association with the outcome of the patients support the recent 
confirmation of MMP-2 as one of the candidate cancer genes (CAN-genes) by the number 
and nature of mutations and pathways in colorectal cancer25. Our results for SNP MMP-9 -
1562 C/T correspond well with data from Asiatic patients26, indicating that this 
polymorphism is not directly involved in the process of colorectal carcinogenesis. 
Summarising, we showed that MMP-9, mechanistically probably the most interesting of 
the gelatinases, is not a likely candidate as a simple prognostic indicator. Despite the 
absence of a correlation between promoter-located SNP -1306 C/T in the MMP-2 gene with 
tumour MMP-2 levels, both parameters were significantly associated with survival, 
indicating MMP-2 as a consistent independent prognostic factor in colorectal cancer. 
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Background: Upregulation of the matrix metalloproteinases MMP-2 and MMP-9 in various 
cancers has been associated with worse survival of the patients.  
Methods: We assessed MMP-2 and MMP-9 levels in normal colorectal mucosa from 
colorectal cancer patients in relation to the course of the disease.  
Results: A high protein expression of MMP-2 as well as MMP-9 in normal mucosa was 
found to be correlated with worse 5-year survival. The combination of both parameters was 
an even stronger prognostic factor. These protein levels were found not to be related to the 
corresponding single-nucleotide polymorphisms of MMP-2 (-1306C>T) and MMP-9 (-
1562C>T). Multivariate analyses indicated that the MMP-2 and MMP-9 levels in normal 
mucosa are prognostic for survival, independent of TNM classification.   
Conclusion: MMP-2 and MMP-9 levels in normal mucosa are indicative of the course of 
disease in colorectal cancer patients. 
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INTRODUCTION
 
The gelatinases MMP-2 and MMP-9 are implicated in the process of colorectal cancer 
progression, angiogenesis and metastasis1. We previously reported that MMP-2 genotype 
and high levels of tumour MMP-2 are associated with a poor survival in colorectal cancer 
patients. For MMP-9 we found a bivalent correlation between MMP-9 expression and 
survival, that is, patients with either very low or very high MMP-9 tumour protein levels have 
worse survival compared with patients with intermediate MMP-9 expression2. In contrast, 
little is known about the impact of MMP expression in normal mucosa of cancer patients. 
We hypothesised that the expression of MMP-2 and MMP-9 in normal mucosa of colorectal 
cancer patients could be relevant as well to the outcome in colorectal cancer. The aim of 
the present study was to evaluate the relation of the genotype and phenotype of MMP-2 
and MMP-9 in normal appearing mucosa with outcome of patients with colorectal cancer.  
 
MATERIALS AND METHODS 
 
Patients and study design 
Tumour tissue and normal appearing mucosa at a distance of 5-10 cm from the tumour 
was collected from 198 consecutive patients (85 female and 113 male) who underwent 
surgery for colorectal cancer between 1983 and 1991 at Leiden University Medical Centre. 
All patients from whom tissue was obtained and data collection was complete were included 
in this retrospective study of prospectively collected tissues. None of the patients received 
(neo-) adjuvant chemo- and/or radiotherapy. The surgical procedure consisted of removal of 
the tumour with en bloc resection of the lymph nodes. Tissue samples were snap frozen 
and stored at -70°C until use. Macroscopic and microscopic parameters were obtained from 
the pathological reports, including TNM classification. Clinical data and follow-up 
information was available for a period of at least 5 years. The primary end point was 
survival at 5 years after surgery. Patient characteristics were as follows: 67% of patients 
was >65 years of age, TNM classification was stage 1 in 17%, stage 2 in 40%, stage 3 in 
29% and stage 4 in 14% of the patients. The tumour was localised in the right hemicolon in 
36% of the patients, 42% had left-sided cancer and in 22% the tumour was localised in the 
rectum. In 42% of the patients the tumour was smaller than 5 cm in diameter and in 23% 
there was a mucinous component in the histology. Histological differentiation grade was 
poor in 13% of the patients, moderate in 70% and good in 17% of the patients. Parameters 
considered for inclusion in the multivariate analysis were: MMP-2 and MMP-9 in normal 
mucosa, tumour stage, age and gender. The study was performed according to the 
instructions and guidelines of the LUMC Medical Ethics Committee and in accordance with 
the Helsinki Declaration. 
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Tissue preparation and protein concentration 
Tissue homogenates were prepared in 0.1 M Tris-HCL (pH 7.5) with 0.1 % (v/v) Tween 
80 extraction buffer as previously described3. The protein concentration was determined4. 
 
Determination of MMP-2 and MMP-9 in tissue homogenates 
Levels of MMP-2 and MMP-9 were determined in homogenates by previously described 
ELISAs5. In short, polyclonal anti-MMP-2 or monoclonal anti-MMP-9 antibodies were used 
as catching antibody and appropriately diluted samples were incubated overnight at 4°C. 
Immune-detection was performed using polyclonal rabbit anti-MMP-2 followed by biotin-
labelled goat anti-rabbit-IgG for MMP-2 and biotin-labelled polyclonal anti-MMP-9 antibodies 
for MMP-9. After incubation with avidinperoxidase, the chromogenic substrate 3,3΄,5,5΄-
tetramethyl benzidine was added in the presence of hydrogen peroxide. The reaction was 
stopped with H2S04 and the absorption was measured at 450 nm. The amount of MMP was 
calculated from parallel incubated standard curves of MMP-2 or MMP-9 and expressed in 
ng per mg protein of the homogenate. 
 
Single-nucleotide polymorphism (SNP) analysis  
Genomic DNA was isolated from the tissues using the salting out method6. The SNP 
analysis for MMP-2-1306C>T  and MMP-9-1562C>T was performed by restriction fragment length 
polymorphism – polymerase chain reaction as described earlier7, 8 or by tetra primer ARMS 
PCR, involving four oligonucleotide primers but no restriction enzymes7. Genotype 
frequencies for MMP-2-1306C>T were CC: n=108: CT: n=79 and TT: n=11, and for MMP-9-
1562C>T CC: n=139; CT: n=50 and TT: n=9. 
 
Statistical analyses 
Statistical analyses were performed using SPSS 17.0 Statistical Package (SPSS Inc., 
Chicago, IL, USA). Expression differences between groups were calculated using the 
Mann-Whitney U-test. Log Rank statistics (LR) was used for optimal cut point analysis9. 
Hardy-Weinberg analysis was performed using chi-square or Fisher’s exact test to examine 
differences in the distribution of alleles and genotypes. Multivariate analyses were 
performed by adding every single MMP-related parameter to the dichotomised, prognosis-
associated clinico-pathological parameters gender, age and TNM stage.  Correlations 
between parameters were calculated according to Pearson’s correlation test. P-values 
smaller than 0.05 were considered significant. 
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RESULTS
  
The median protein level of MMP-2 and MMP-9 in the normal mucosa of the 198 
colorectal cancer patients was 4.8 ng mg-1 protein (range 0 - 30.5) for MMP-2 and 3.2 ng 
mg-1 protein (range 0.2-164.7) for MMP-9. As expected, MMP expression in normal mucosa 
was lower than in carcinoma tissue: 2-fold lower for MMP-2 (Figure 1A, median carcinomas 
10.6 ng mg-1 protein) and 12-fold lower for MMP-9 (median carcinomas 36.7 ng mg-1 
protein). The MMP-2 levels in the normal mucosa correlated significantly with the levels in 
cancer tissue (R = 0.489, P ≤ 0.0001 for all genotypes together; results per genotype are 
shown in figure 1A), whereas the MMP-9 levels did not (R = 0.034, P = 0.637).  The highest 
levels of MMP-2 and MMP-9 were found in mucosa from TNM stage IV patients, but the 
differences with and between the other stages were not statistically significant (data not 
shown). Optimal cutoff point analyses of mucosal MMP-2 and MMP-9 protein levels divided 
the patients in subgroups with significant differences in survival. High levels of MMP-2 
(cutoff 8.7 ng mg-1 protein, LR 12.82, P < 0.001, Figure 1B) or MMP-9 (cutoff 1.6 ng mg-1 
protein, LR 10.41, P = 0.001, Figure 1C) were associated with poorer 5-year survival. The 
combination of both mucosal MMP-based parameters appeared a highly significant 
discriminator (LR 20.30 P < 0.0001) for subdivision of patients into good, intermediate, and 










Figure 1. (A) Correlation between the tissue MMP-2 levels (in ng mg-1 protein) in normal mucosa and corresponding 
carcinoma tissue obtained from 198 colorectal cancer patients. The left panel shows the correlation in patients with a 
CC genotype, the middle panel in patients with a CT genotype and the right panel shows the correlation in patients 
with a TT genotype of the -1306 CT polymorphism of MMP-2. Indicated are the Pearson’s correlation coefficients for 
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Figure 1. (D) Kaplan Meier 5-year survival curves for combination of MMP-2 and MMP-9 in normal mucosa (both 
MMP-2 and MMP-9 high (lower, thick line), both MMP-2 and MMP-9 low (upper, dashed line), either MMP-2 high and 
MMP-9 low or MMP-2 low and MMP-9 high (intermediate, thin line); for cutoff points see B and C). The total number 




The genotypes of the MMP-2-1306C>T and MMP-9-1562C>T polymorphism were 
distributed according to the Hardy-Weinberg equilibrium (MMP-2 χ2=0.49, P = 0.48; MMP-9 
χ2=2.5, P = 0.11) and there was no association between the different genotypes and the 
levels of MMP-2 and -9 in normal mucosa (data not shown). 
Univariate Cox analysis confirmed the association of the tissue levels of MMP-2 and 
MMP-9 with survival (Table 1). Multivariate Cox analysis, including the clinical parameters 
gender, age and TNM stage of the tumour, showed both mucosal MMPs to be independent 
indicators of prognosis (hazard ratios >1.7, P = 0.009). A separate multivariate analysis of 
the MMP-2/MMP-9 combination indicated a highly significant hazard ratio for patients with 
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Figure 1. (B and C): Optimal cutoff point analysis and corresponding Kaplan-Meier 5-year survival curves for 
dichotomized (high/low) levels of MMP-2 (B) and MMP-9 (C) in normal mucosa. The optimal cutoff points are 
indicated with arrows. In the survival curves, the total number of patients and the deceased patients (†) are indicated 
per subgroup. 
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Figure 1. (B and C): Optimal cutoff point analysis and corresponding Kaplan-Meier 5-year survival curves for 
dichotomized (high/low) levels of MMP-2 (B) and MMP-9 (C) in normal mucosa. The optimal cutoff points are 
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at longer distances from the tumour enhanced calcium levels and increased numbers of 
aberrant crypts are detected, indicating differences with mucosa from healthy controls11, 12. 
Some of these changes are clearly related to changes in the endothelium. ‘Normal’ mucosa 
adjacent to larger, more invasive tumours showed enhanced microvessel densities 
compared with less invasive tumours, which was associated with increased levels of the 
angiogenic factors vascular endothelial growth factor (VEGF), interleukin-8, and factor VIII-
related antigen13. These differences in the normal mucosa were not related to the survival of 
the patients. We have previously shown that low levels of the endothelium-derived serine 
proteinase tissue-type plasminogen activator (tPA) in normal appearing mucosa of 
colorectal and gastric cancer patients is also associated with poor prognosis14, 15. The 
correlation of high protein levels of MMP-2 and MMP-9 in mucosa adjacent to colorectal 
cancer tissue with worse survival, as we found, is probably also more, but not exclusively, 
related to endothelial cells in combination with epithelial cells and/or leukocytes. Previously 
we showed that MMP-2 in the intestinal mucosa of colorectal cancer patients is 
predominantly expressed in the submucosal extracellular matrix and MMP-9 in the mucosal 
macrophages and neutrophils5. We hypothesised previously that the poor prognosis found 
for patients with very low tumour MMP-9 levels is possibly due to the lack of infiltrating 
leukocytes, which may possess anti-cancer effects2. Diffuse staining of a subset of 
microvessels in tumour-adjacent mucosa of the oesophagus by CD105/endoglin, a 
neovascularisation marker, has been found to correlate statistically with worse overall 
survival of the patients16. Interestingly, we previously observed that MMP-9 is involved in 
the VEGF-mediated neoangiogenesis in colorectal cancer and that MMP-mediated endoglin 
mobilisation is involved in the regulation of the angiogenic potential of endothelial cells in 
colorectal cancer17, 18. Angiogenesis in the adjacent mucosa might very well enhance the 
development of multi-focal tumours or regional metastasis, which could explain the 
correlation with survival. 
We have previously shown that there is no association between SNPs of MMP-2 and 
MMP-9 and the amount of corresponding protein in colorectal carcinomas2. But in a tumour 
environment the final concentration of MMP-2 and -9 would depend on many different cell 
types, mechanisms and interactions. Therefore, one could speculate that an association 
between the SNP and the amount of MMP protein in normal mucosa would be more likely. 
T allele carriers of the MMP-2-1306C>T polymorphism have lower promoter activity due to 
disruption of an Sp-1-binding site19, while T allele carriers of the MMP-9-1562C>T 
polymorphism have increased transcriptional activity due to preferential binding of a 
transcription suppressor protein to the C allele20. Although normal mucosa MMP-2 levels 
correlated significantly with their corresponding tumour levels, this was not restricted to or 
within a specific genotype.  The tissue levels of MMP-9, either from normal mucosa or 
tumour did not correlate and were also independent from the genotypic background. In a 
recent review about SNPs of MMPs and gastrointestinal cancer we already emphasised 
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Table 1. Univariate and multivariate Cox proportional hazard analysis for 5-year survival in normal appearing mucosa 
from 198 patients with colorectal cancer 
     
Univariate 
   
Multivariate 
 n  HR CI 95% P HR CI 95% P
   
Parameter  

























   Age  <65yrs>  66-132 1.861 1.230-2.815 0.003 2.003 1.322-3.035 0.005
    TNM I+II-III+IV 113-85 2.972 2.056-4.297 0.000 3.083 2.129-4.465 0.000
 
MMP mucosal
       
   MMP-2 <8.7> 154-44 1.898 1.273-2.828 0.002 1.718 1.145-2.578 0.009
   MMP-9 <1.6> 48-150 2.323 1.421-3.796 0.001 1.948 1.184-3.204 0.009 
 
   MMP-2/MMP-9 
































CI = confidence interval; F-M = female-male; HR = hazard ratio; MMP = matrix metalloproteinase; Ref = reference 
group. aIn the multivariate analysis for the MMP-2/MMP-9 combination, the separate variables MMP-2 and MMP-9 
protein were not included. <,< = MMP-2<8.7 ng mg -1 protein and MMP-9<1.6 ng mg -1 protein; >,> = MMP-2>8.7 ng 
mg -1 protein and MMP-9>1.6 ng mg -1 protein. Multivariate analysis was performed by adding every single MMP-
related parameter to the dichotomised, prognosis-associated clinico-pathological parameters gender, age and TNM 





In the present study we found high protein levels of MMP-2 and MMP-9 in mucosa 
adjacent to colorectal cancer tissue to be indicative for the course of disease, that is, 
independently associated with a worse survival of the patients. Mucosa immediately 
adjacent to colon cancer (within 2 cm) shares histochemical, ultrastructural and biological 
features with the corresponding tumour and is referred to as transitional mucosa10. But even 
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aberrant crypts are detected, indicating differences with mucosa from healthy controls11, 12. 
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compared with less invasive tumours, which was associated with increased levels of the 
angiogenic factors vascular endothelial growth factor (VEGF), interleukin-8, and factor VIII-
related antigen13. These differences in the normal mucosa were not related to the survival of 
the patients. We have previously shown that low levels of the endothelium-derived serine 
proteinase tissue-type plasminogen activator (tPA) in normal appearing mucosa of 
colorectal and gastric cancer patients is also associated with poor prognosis14, 15. The 
correlation of high protein levels of MMP-2 and MMP-9 in mucosa adjacent to colorectal 
cancer tissue with worse survival, as we found, is probably also more, but not exclusively, 
related to endothelial cells in combination with epithelial cells and/or leukocytes. Previously 
we showed that MMP-2 in the intestinal mucosa of colorectal cancer patients is 
predominantly expressed in the submucosal extracellular matrix and MMP-9 in the mucosal 
macrophages and neutrophils5. We hypothesised previously that the poor prognosis found 
for patients with very low tumour MMP-9 levels is possibly due to the lack of infiltrating 
leukocytes, which may possess anti-cancer effects2. Diffuse staining of a subset of 
microvessels in tumour-adjacent mucosa of the oesophagus by CD105/endoglin, a 
neovascularisation marker, has been found to correlate statistically with worse overall 
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mobilisation is involved in the regulation of the angiogenic potential of endothelial cells in 
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that due to the complicated regulatory processes after transcription, SNPs are not very 
strong effectors of overall synthesis/presence of the corresponding MMP in vivo21. 
In conclusion, this study shows that increased MMP-2 and MMP-9 protein expression in 
normal mucosa at some distance of colorectal tumours is strongly related to the course of 
disease, that is, independently associated with a poor prognosis of colorectal cancer 
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Background and aim of the study: Matrilysin (or MMP-7) is a metalloproteinase (MMP) 
abundantly produced by (pre)malignant epithelial cells and associated with invasion and 
metastasis. The aim of the present study was to investigate whether the levels of total and 
active matrilysin in the adenoma-carcinoma sequence were altered and to study the 
relationship between the MMP-7 genotype, matrilysin level and activity with the outcome of 
colorectal cancer patients. 
Methods: The tissue level and activity state of matrilysin was evaluated in 58 colorectal 
adenomas and in normal mucosa and tumour tissue from 174 patients with colorectal 
cancer. Matrilysin protein levels and the MMP-7 SNPs -153 C/T and -181 A/G were 
determined, respectively, by a specific activity assay detecting total and active matrilysin 
and RFLP-PCR-based techniques.  
Results: Total matrilysin level was found to increase gradually in the normal tissue – 
adenoma – carcinoma sequence, and in the adenomas in association with dysplasia. 
Matrilysin activity, however, was only enhanced in the carcinomas. SNP -153 C/T correlated 
with active matrilysin in cancer tissue, but not with the total amount of MMP-7. Matrilysin 
activity and the SNP -153 C/T were found to be independently associated with the overall 
survival of the cancer patients.  
Conclusion: Matrilysin up-regulation was associated with dysplasia in adenomas and 
therefore seems to be an early event in colorectal carcinogenesis. Enhanced MMP-7 
activity, however, was only present in the more advanced stages of colorectal cancer 
development. A high level of either total or active MMP-7 in the carcinoma is associated 
with worse 10-year survival, but only active MMP-7 was independently associated with the 
outcome of the patients. MMP-7 SNP -153 C/T was not accompanied by enhanced tumour 
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INTRODUCTION  
 
Matrix metalloproteinases (MMPs) consist of a family of proteinases implicated in 
(patho)physiological processes like cell migration and neo-angiogenesis. The smallest 
family member, MMP-7 or matrilysin, is considered the most promising candidate for 
cancer-associated diagnostic purposes, because of a number of specific properties: 1] 
Matrilysin is able to degrade a variety of tumour-associated extracellular matrix 
components, like elastin, collagen type IV, fibronectin, vitronectin, aggrecan and 
proteoglycans1. 2] Through active cleavage and via activation of other matrix 
metalloproteinases, matrilysin is involved in the shedding of a range of trans-membrane 
proteins like E-cadherin, FasL and TNF-alpha precursor1. 3] Unlike other MMPs, matrilysin 
is mainly produced by epithelial cells, implicating an active role of matrilysin at the level of 
the invading malignant cells2. Matrilysin over-expression is associated with mutational 
activation of the Apc/Wnt signalling pathway and is therefore considered an early event in 
carcinogenesis3, 4. The transformation from normal colon mucosa to cancer is a multi-step 
process, where consequent mutations in oncogenes and tumour suppressor genes lead to 
the development of aberrant crypt foci, adenomatous polyps, carcinoma and eventually 
colorectal metastasis5. Enhanced levels of matrilysin have previously been found in 
adenomas as well as carcinomas, mainly in immunohistochemical studies6-9. Furthermore, 
matrilysin has been associated with a poor prognosis of cancer patients6, 7, 10-12.  
In the present study we assessed the association of matrilysin with the multi-step model 
for colorectal cancer by including adenomas and by measuring not only the total level of 
matrilysin, but focusing especially on the activity state of matrilysin in the successive stages. 
Furthermore, the association of two promoter-located gene polymorphisms (MMP-7 SNPs) 
with matrilysin tissue levels (total/active) was determined. The MMP-7 SNP variants and 
carcinoma matrilysin levels were also evaluated for their prognostic value for the overall 
survival of the patients.  
 
PATIENTS AND METHODS 
 
Patients
Tissue was collected from 174 patients with colorectal cancer, operated in the Leiden 
University Medical Center between December 1983 and September 1991. Samples from 
the non-necrotic mid-central part of the tumour and normal mucosa at a distance of 5 to 10 
cm were obtained from the surgical specimen immediately after resection. In the same 
period, tissue samples from 58 endoscopically removed colonic adenomas were collected. 
In these adenomas, the degree of dysplasia was classified as mild in 19, moderate in 23, 
severe in 10 and unknown in 6 adenomas. All tissues were frozen and stored at -70°C until 
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use. Clinical data and follow-up was available for a period of at least 10 years. Macroscopic 
and microscopic data were obtained from pathology reports, including localization, 
diameter, histological type, grade of dysplasia and differentiation according to the WHO 
classification, and classification of the carcinomas according to the TNM classification. All 
human samples were collected according to the guidelines of the Medical Ethics Committee 
of the Leiden University Medical Center and in accordance with the Helsinki declaration. 
Tissue preparation and protein concentration 
Homogenates were prepared by adding 1 ml of ice-cold 0.1 M Tris-HCL (pH 7.5) with 
0.1 % (vol/vol) Tween 80 extraction buffer per 60 mg tissue sample. The tissues were 
homogenized on ice for two minutes in a Potter S (B Braun). Homogenates were 
centrifuged twice at 8000 x g for 2.5 minutes at 4°C and the supernatants were stored at -
70°C (15). The protein concentrations in the homogenates were determined according to 
the method of Lowry et al13. 
 
Matrix metalloproteinase-7 activity assay 
An immunocapture bioactivity assay (BIA) for MMP-7 was performed as recently 
described by Hawinkels14. Briefly, MaxiSorp 96-well plates (Nunc) were coated with 
matrilysin-specific antibodies for 2 hours at 37°C, blocked and washed (3x) with PBS/0.05% 
Tween-20. Appropriately diluted samples or human recombinant matrilysin (R&D Systems 
Europe, Abingdon, UK) were incubated overnight at 4°C in assay buffer. After washing (4x), 
samples were incubated with 1mM APMA or assay buffer for determination of total or 
endogenously active MMP-7 levels, respectively. MMP-7 activity was detected using 
modified MMP-sensitive pro-urokinase in combination with peptide substrate S-2444. 
Colour development was detected by kinetic OD450 readings during 7 hours. MMP-7 
concentrations were calculated from the standard curves and expressed in ng MMP-7/mg 
protein. 
MMP-7 SNP analysis 
Tissue DNA was isolated using the salting out method15. Analyses for matrilysin SNP -
181 A/G and -153 C/T were performed by Restriction Fragment Length Polymorphism – 
Polymerase Chain Reaction as described earlier16, 17. For SNP -181A/G the following 
primers were used: forward primer TGGTACCATAATGTCCTGAATG, reverse primer 
TCGTTATTGGCAGGAAGCACACAATGAATT. The primers for SNP -153 C/T were: 
forward primer ACGAATACATTGTGTGCTTCCTGCCAATCA and reverse primer  
TTTATATAGCTTCTCAGCCTCG (reverse). Deliberate mismatches in primers are 
underlined. PCR conditions were: annealing at 55°C, cycle number 35, BP 150, Restriction 
enzyme EcoRI for MMP-7 -181 A/G and annealing at 55°C, cycle number 30, BP 158, 
Restriction enzyme NIaIII for MMP-7 -153 C/T. 
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Statistical analysis 
Statistical analyses were performed using SPSS 17.0 Statistical Package (SPSS Inc., 
Chicago, IL, USA). Hardy-Weinberg analysis was performed using chi-square (χ2) or 
Fisher’s exact test to examine differences in the distribution of alleles and genotypes. 
Differences between groups and group means were calculated using the chi-square (χ2) or 
Fisher’s exact test, Mann-Whitney U-test or Wilcoxon’s signed rank test for related samples 
(N/T pairs). Correlations between parameters were calculated with Pearson’s rank test 
(Rho). Uni- and multivariate analyses were performed according to the Cox proportional 
hazard model.  
RESULTS 
Patient characteristics 
The clinicopathological characteristics of the patients are presented in table 1, also 
showing the correlation of these parameters with the 10-year overall survival. The majority 
of the tumours were of TNM stage 2 or 3. TNM stage and older age were significantly 
associated with survival, whereas tumour localization, size, differentiation grade and 
histology were not. 
 















































































































* data for 2 patients not available. Statistical significant P-values are bold. 
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* data for 2 patients not available. Statistical significant P-values are bold. 
















Figure 1C) total (left panel) and active (right panel) matrilysin levels in colorectal adenomas, subdivided by grade of 
dysplasia. Significant differences between groups are indicated. 
Single-nucleotide polymorphisms for matrilysin
The genotype distributions of the promoter-located SNPs MMP-7 -181 A/G (AA: n=54, 
AG: n=85 and GG: n=35) and MMP-7 -153 C/T (CC: n=159, CT: n=14 and T: n=1) were 
both according to the Hardy-Weinberg prediction. There was no relation between these 
matrilysin SNPs and the TNM stage, diameter, localization and differentiation grade of the 
tumour (data not shown). Evaluation of both matrilysin genotypes with the total and active 
protein levels in homogenates from the corresponding cancer tissue and adjacent normal 
mucosa revealed a weak but statistically significant correlation between SNP -153 C/T and 
matrilysin activity in cancer tissue (χ2 = 7.0, P = 0.03). Because the MMP-7 -153T/-181G 
haplotype was reported to be associated with increased MMP-7 expression in vitro, we 
analyzed the MMP-7 levels in this group of patients (n=15) compared to the rest of the 
patients (n=159), but did not find any difference in MMP-7 expression in the colorectal 
carcinomas or corresponding normal mucosa between the two groups (data not shown).  
Survival analyses
Figure 2A shows that SNP -153 C/T was significantly associated with 10-year survival: 
better survival of patients with the CC genotype compared to those with a CT or TT 
genotype (LR 14.0, P < 0.001), and that the SNP -181 A/G was not related to survival in 
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Matrilysin protein and activity levels 
Matrilysin total protein level and activity in colorectal carcinomas and their corresponding 
normal mucosa and in adenomas is shown in figure 1. The total group of carcinomas 
contained significantly more matrilysin protein (Figure 1A) and activity (Figure 1B) than 
normal mucosa (medians respectively 3.37 versus 1.19 and 1.59 versus 0.59 ng/mg 
protein, n=174, both P ≤ 0.001). The adenomas (n=58) contained significantly more 
matrilysin than normal mucosa (2.97 ng/mg, P ≤ 0.001) but similar levels to the carcinomas 
(P = 0.161), whereas the matrilysin activity level of the adenomas (0.35 ng/mg, n=58) was 
similar to that in the normal mucosa but significantly lower compared to the carcinomas (P ≤ 
0.001). In the adenomas, a trend towards higher levels of both total and active matrilysin in 
adenomas with moderate or severe dysplasia compared to the adenomas with mild 
dysplasia was observed (Figure 1C). The correlation between total versus active matrilysin 
in all tissue samples was high (Rho = 0.609, P < 0.001, n=414).  
 
 



















Figure 1. Matrilysin levels in normal appearing mucosa at 5 to 10 cm from the carcinomas, adenomatous polyps and 
colorectal carcinomas. A) total matrilysin in ng/mg protein and B) active matrilysin in ng/mg protein. The box-plots 
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Figure 1C) total (left panel) and active (right panel) matrilysin levels in colorectal adenomas, subdivided by grade of 
dysplasia. Significant differences between groups are indicated. 
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patients (n=159), but did not find any difference in MMP-7 expression in the colorectal 
carcinomas or corresponding normal mucosa between the two groups (data not shown).  
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Figure 2. Kaplan-Meier 10-year overall survival curves of 174 colorectal cancer patients subdivided by A) MMP-7 









P = 0.0009 
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Optimized cut off stratification, dividing the patients in 2 groups, revealed a carcinoma 
cut-off point of 2.25 ng/mg for total matrilysin (Figure 3A). The Kaplan-Meier curve shows 
that patients with a low total matrilysin level had a significantly better survival than patients 
with higher levels (LR 9.23, P = 0.002). The same procedure for active matrilysin revealed a 























Figure 3. Optimal cut-off point analysis and corresponding Kaplan-Meier 10-year survival curves for dichotomized 
(high/low) levels of total matrilysin (A) and active matrilysin (B) in carcinoma. The optimal cut-off points are indicated 
with arrows. In the survival curves, the total number of patients and the number of deceased patients(†) are indicated 
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DISCUSSION 
Tumour development from normal mucosa to colorectal cancer is a multistep process5. 
Our results show that matrilysin (or MMP-7), which is normally only present in small 
amounts in paneth cells of normal colonic mucosa, is already strongly up-regulated in 
colorectal adenomas. The total levels of matrilysin hardly increased further in more 
advanced stages of the adenoma-carcinoma sequence. Although the mechanism is not 
entirely cleared, early mutations in WNT/Apc, K-ras and E1AF are reported to be involved in 
matrilysin up-regulation4, 18, 19. Besides by mutations in regulating pathways of (pre)-
malignant cells, the up-regulation of matrilysin could also originate from SNP variations in 
the promoter part of the MMP-7 gene. Although SNP -153 C/T was associated with patients’ 
survival in this study, we could not establish a clear correlation with up-regulated levels of 
matrilysin, neither in the carcinomas nor in the normal mucosa. Also patients with the MMP-
7 -153T/-181G haplotype, which has been shown to increase MMP-7 expression in vitro16, 
did not have elevated MMP-7 levels compared with the rest of the patients. In contrast to 
the overall level, the activity of matrilysin was weakly but significantly correlated with MMP-7 
SNP -153 C/T, which cannot easily be explained. Being genotypic variations, MMP-7 SNP 
derived up-regulation would not be restricted to (pre)malignant epithelial cells and therefore 
the activity could as well originate from matrilysin expressing stromal cells within the tumour 
in the individuals carrying the SNP variants. Other studies that reported association of 
MMP-7 SNPs with invasive properties of colon or other gastrointestinal cancers or with 
worse survival of the patients did not establish a clear relation with matrilysin levels either20-
25. 
Adenomas greater than 1 cm in diameter and/or with villous components and/or with 
severe dysplasia are regarded as advanced adenomas, because they are at increased risk 
for transforming into an invasive carcinoma26, 27. An immunohistochemical study has 
demonstrated an increase in MMP-7 expression with a more advanced histology stage of 
colorectal adenomas, that is, tubular adenomas had the lowest level of MMP-7 expression, 
villous adenomas the highest and tubulovillous adenomas were in between the other two 
groups7. In the present study we have looked into the correlation between the degree of 
dysplasia (mild/moderate/severe) and levels of (total and active) matrilysin. We noticed a 
trend towards increased MMP-7 levels in the adenomas with more advanced (moderate, 
severe) grades of dysplasia compared to the adenomas with mild dysplasia. A similar trend 
was observed for MMP-7 activity, although the absolute levels of active MMP-7 were within 
the same range as in the normal mucosa. 
The association between up-regulation of MMP-7 in the colorectal cancer sequence and 
poor outcome of colorectal cancer patients has been described before in 
immunohistochemical and tissue microarray studies10, 28. Whereas Koskensalo et al. 
observed a difference in survival between patients with high and low immunohistochemical 
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 The matrilysin-derived variables were evaluated for their association with 10-year 
survival using univariate and multivariate Cox analyses (Table 2). In the univariate analysis, 
patients with a CT or TT genotype of the -153 C/T polymorphism, or those with high levels 
of matrilysin protein or matrilysin activity showed a significantly worse 10-year overall 
survival. From these parameters only matrilysin activity (P = 0.004) and the MMP-7 -153 
C/T SNP (P = 0.05) proved to be independent prognostic markers in the multivariate 
analyses, next to TNM stage of the carcinomas and age of the patients, whereas the level 
of total MMP-7 just lost its prognostic significance (P = 0.051). 
 
 
Table 2. Univariate and multivariate Cox‟s proportional hazard 10-year survival analyses of 174 colorectal cancer 
patients. Statistical significant P-values are bold, * indicates missing data. 























Age < 65 yr ≥ 53/121 1.952 1.270-2.999 0.002 2.228 1.431-3.469 0.000
TNM 1,2 vs 3,4 102/72 2.620 1.817-3.777 0.000 2.763 1.880-4.060 0.000
Localization Right vs rest 62/112 0.958 0.661-1.389 0.820 1.171 0.788-1.739 0.435 
Diameter < 5 cm ≥ 75/99 1.268 0.877-1.832 0.207 1.097 0.741-1.622 0.644 
Differentiation Good vs rest 31/141* 1.305 0.798-2.133 0.298 1.063 0.639-1.767 0.815 
         
Matrilysin SNPs         
SNP -153 C/T CC vs CT,TT 159/15 2.487 1.412-4.381 0.002 1.798 1.000-3.232 0.050
SNP -181 A/G 
 
Matrilysin proteins
AA vs AG,GG 54/120 1.258 0.845-1.871 0.258 1.263 0.841-1.896 0.261 
Total protein  <2.25≥ 59/115 1.886 1.261-2.821 0.002 1.519 0.998-2.312 0.051 
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DISCUSSION 
Tumour development from normal mucosa to colorectal cancer is a multistep process5. 
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Adenomas greater than 1 cm in diameter and/or with villous components and/or with 
severe dysplasia are regarded as advanced adenomas, because they are at increased risk 
for transforming into an invasive carcinoma26, 27. An immunohistochemical study has 
demonstrated an increase in MMP-7 expression with a more advanced histology stage of 
colorectal adenomas, that is, tubular adenomas had the lowest level of MMP-7 expression, 
villous adenomas the highest and tubulovillous adenomas were in between the other two 
groups7. In the present study we have looked into the correlation between the degree of 
dysplasia (mild/moderate/severe) and levels of (total and active) matrilysin. We noticed a 
trend towards increased MMP-7 levels in the adenomas with more advanced (moderate, 
severe) grades of dysplasia compared to the adenomas with mild dysplasia. A similar trend 
was observed for MMP-7 activity, although the absolute levels of active MMP-7 were within 
the same range as in the normal mucosa. 
The association between up-regulation of MMP-7 in the colorectal cancer sequence and 
poor outcome of colorectal cancer patients has been described before in 
immunohistochemical and tissue microarray studies10, 28. Whereas Koskensalo et al. 
observed a difference in survival between patients with high and low immunohistochemical 
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staining for MMP-7 after 5 but not after 10 years, the difference in survival in our cohort was 
still present 10 years after the surgical intervention for the cancer. The technique that was 
used in the present study, an MMP-7 activity assay, provides insight in the impact of MMP-7 
activity during colorectal carcinogenesis and prognosis. We have demonstrated that not 
only the total amount of MMP-7 within a tumour, but also the activity state of MMP-7, is an 
important prognostic parameter. Others have demonstrated that MMP-7 is present in the 
circulation of colorectal cancer patients and that patients with higher serum MMP-7 levels 
are more likely to relapse compared to patients with lower levels29, 30. Even in patients with 
advanced colorectal cancer who have been treated with anti-EGFR therapy as a third line 
therapy, those patients who had the highest serum MMP-7 levels had the poorest overall 
and progression-free survival31. These findings suggest that MMP-7 might be used as a 
(serological) prognostic marker and may even serve as a target for therapy. 
Our data clearly show that despite the overall enhanced protein levels of matrilysin in all 
stages of adenomas and carcinomas, the activity is only enhanced in carcinomas. 
Apparently, next to over-expression, also an up-regulated activation mechanism is essential 
for biological activity. This phenomenon has been shown before for other proteinases and 
tumour promoting growth factors32-34. Besides the fact that immunohistochemical staining of 
matrilysin is found mainly in the cytoplasm and therefore presumably represents inactive 
pro-matrilysin, activation of pro-matrilysin outside the cell is a complex mechanism 
depending on the presence of pro-matrilysin activators and MMP inhibitors such as TIMP-1 
and TIMP-235. Also local binding of released (pro-)matrilysin to the surface of the cells might 
play a substantial role. Soluble pro-matrilysin is susceptible to auto-cleavage, resulting in 
uncontrolled activation35. Docking of pro-matrilysin to CD151, a cell-surface trans-
membrane protein present on epithelial cells36, prevents auto-activation of MMP-737. Down-
regulation of CD151 expression by hypoxic conditions in colorectal cancer was reported to 
promote migration of malignant epithelial cells38. Hypoxia and the subsequent loss of 
CD151, in combination with the gain of other alternative sites for (pro)-matrilysin protection 
against TIMPs39, may therefore be factors stimulating uncontrolled auto-activation around 
malignant cells. These observations might provide an explanation why high amounts of pro-
matrilysin but concomitant low activity levels are present in adenomas and high levels of 
activated MMP-7 are present in the more hypoxic carcinomas. Further studies are needed 
to investigate whether this hypothesis is correct. 
In conclusion, we found enhanced matrilysin levels in most neoplastic colorectal tissues. 
Especially the active form of MMP-7 correlated with more advanced stages of the disease. 
MMP-7 activity as well as the MMP-7 -153 C/T SNP were independently associated with 10-
year survival of the carcinoma patients, whereas the total amount of MMP-7 just lost its 
prognostic significance. There was a weak correlation between matrilysin activity and the 
MMP-7 SNP -153 C/T genotype in the carcinomas. In conjunction with earlier mRNA 
studies reporting that matrilysin levels were increase with enhancing Dukes stage40, related 
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to the presence of distant metastases41, and were also measurable in the circulation29, 30, 42-
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Colorectal cancer is the second leading cause of cancer death in the Netherlands and 
the fourth worldwide. Understanding the underlying mechanisms in cancer development 
and cancer progression is crucial for the development of more effective treatment 
strategies, especially in those patients who have an increased risk of developing cancer or 
who already developed either lymph node or distant metastasis. In this thesis, the focus is 
on the clinical impact of matrix metalloproteinases (MMPs) in the different stages of 
colorectal cancer development and metastasis. 
Matrix metalloproteinases in the colorectal cancer sequence 
To better understand the potential involvement of MMPs in the different phases of 
colorectal cancer development, the degree of expression of MMP-2, -8, -9 and neutrophil 
granulocyte-associated lipocalin (NGAL) was studied in the different phases of colorectal 
carcinogenesis. NGAL is a 25 kDA glycolylated protein that prevents inactivation of MMP-9 
by the formation of heterodimers with the 92 kDa gelatinase and thereby preventing its 
degradation1. Chapter 2 describes the results of enzyme-linked immunosorbent assay 
(ELISA) and bio-immunoassay (BIA) measurements of these proteins in tissues from 
various stages of colorectal cancer progression, that is, normal colorectal mucosa, 
adenomatous polyps, adenocarcinomas and liver metastases. Samples of normal liver 
tissue were included to serve as a standard for the liver metastases. MMP-8 (2-fold 
increase in adenoma, 8-fold increase in cancer), and NGAL (4-fold increase in adenoma, 8-
fold increase in cancer) showed a significant stepwise up-regulation in the development 
from normal mucosa to adenoma and subsequent colorectal cancer development, a trend 
that was also observed for MMP-9. In carcinomas and liver metastases, these results were 
persistent after correction for the degree of inflammation, whereas in adenomas the 
increase of MMP-8, -9 and NGAL could be ascribed entirely to this increase in inflammation. 
MMP-2 up-regulation was observed only in the later phases of colorectal carcinogenesis, 
once cancer had developed. These data provided insight in the expression of MMPs 
throughout the process of colorectal cancer development, which needs to be taken into 
account when developing and choosing MMP-inhibitors as a therapy to intervene in this 
process, as will be discussed later in this chapter.  
MMP-2 and MMP-9 as biomarkers for colorectal cancer 
The follow-up of colorectal cancer patients has become more important now that more 
advanced treatment options are available. To be able to evaluate the possibility of the use 
of MMP-2 and MMP-9 as biomarkers, the presence of these MMPs in easily accessible 
biofluids like urine and plasma needs to be demonstrated. This had so far not been done for 
MMP-2 and MMP-9 in the urine of colorectal cancer patients. In a cohort of 49 patients who 
were operated because of colorectal cancer, MMP-2 and MMP-9 levels were measured in 
plasma, urine and in tissue and correlated with the clinical and surgical outcome (chapter 
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3). Different techniques (zymography, ELISA and BIA) were used to measure the MMPs in 
the different specimens. The presence of measurable amounts of MMP-2 and MMP-9 in the 
urine of colorectal cancer patients was demonstrated for the first time. Plasma and urine 
MMP-9 levels showed a peak value shortly after surgery, most probably reflecting the 
process of wound healing after major surgery. Especially urinary MMP-2 levels, when 
measured by zymography, were associated with a poor clinical and surgical outcome. High 
preoperative plasma MMP-9 levels were also predictive of poor clinical outcome, but this 
correlation only appeared to be modest. 
Currently, carcinoembryonic antigen (CEA) is used as a serum marker in the follow-up of 
patients who have undergone surgery for colorectal cancer. The sensitivity for this marker to 
predict recurrent disease after curative resection varies from 58 to 89%2, 3. However, thirty 
to forty percent of colorectal cancers do not produce CEA and in those patients who 
consequently did not have preoperatively elevated CEA levels, the sensitivity of CEA for the 
detection of recurrent disease is only about 40%2, 4. The treatment options for recurrent and 
even metastatic colorectal cancer have increased over the last decades5. Because early 
detection of limited liver metastases creates the possibility of surgical metastasectomy and 
increases long-term disease-free survival, it would be useful to have disposition of an 
additional biomarker to predict recurrent disease. Circulating MMP-2 levels are unsuitable 
tools for CRC follow-up, as several studies have demonstrated that those levels are lower in 
colorectal cancer patients compared to healthy controls6, 7. Plasma MMP-9 levels have 
been shown to be increased in CRC patients compared to healthy individuals8-14 and might 
therefore be more useful in the follow-up of these patients. However, in one study of 61 
postoperative CRC patients in whom plasma MMP-9 levels were measured three-monthly 
over a two year follow-up period, MMP-9 levels were not able to predict recurrent disease.  
As both MMP-2 and MMP-9 are detectable in the urine of colorectal cancer patients, 
whereas they are hardly detectable in the urine of healthy controls, urine levels of the 
gelatinases might be more useful as biomarkers in the follow-up. A problem that occurs in 
this context is the aspecificity of MMP-elevation in urine, as elevated urine levels of the 
gelatinases can also be found in a number of other malignant (e.g. bladder cancer, prostate 
cancer, brain tumours) as well as benign (e.g. kidney disease, endometriosis) diseases15-21. 
Still, in patients without significant comorbidity, it might be worth investigating whether 
urinary MMPs could be of additional value in the follow-up after surgery for colorectal 
cancer.  
Single-nucleotide polymorphisms of matrix metalloproteinases in gastrointestinal cancer 
The most common type of genetic variation is single-nucleotide polymorphism (SNP). 
The replacement of one single nucleotide by another can occur in either the coding or non-
coding region of the gene. To be considered a SNP, the gene frequency of the minor allele 
needs to be at least 1%. SNPs can be associated with, for example, disease susceptibility 
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(i.e., a particular genotype is more or less prevalent in diseased than in healthy controls), 
the course of a disease or the response of an individual to drug treatment. One or more of 
the known SNPs of MMP-1, -2, -3, -7, -8, -9, -12, -13 and -21 have been studied in 
oesophageal cancer (both adenocarcinoma and squamous cell cancer), gastric cancer, 
hepatocellular carcinoma and colorectal cancer. Chapter 4 gives an overview of these 
studies. Some of the SNPs in the MMP-genes are associated with cancer susceptibility, and 
in some cases there was a correlation with clinicopathological parameters and/or the 
outcome of disease in patients with gastrointestinal (GI) cancer. Probably due to differences 
in ethnicity, sample size or environmental factors, there was quite some heterogeneity 
between the results of the different studies that were included in this overview. The same 
diversity in results has been reported in lung and breast cancer22. Some of the most 
consistent results are the association between the -1306 C/T MMP-2 polymorphism and 
oesophageal cancer (increased cancer risk in CC carriers) and between the MMP-7 -181 
A/G polymorphism and gastric as well as oesophageal cancer (increased cancer risk in G-
allele carriers, in the Asian population only). Some studies report an association between 
colorectal cancer susceptibility and the MMP-1 -1607 1G/2G, MMP-2 -1306 C/T, MMP-7 -
181 A/G and MMP-9 -1562 C/T polymorphism; however, in two large meta-analyses only 
the correlation between 2G allele carriers of the MMP-1 1G/2G polymorphism and an 
increased risk for development of colorectal cancer remained significant23, 24. Studies that 
actually looked at the correlation between SNPs and protein levels of MMPs are scarce and 
the few studies that did investigate this correlation yielded negative results25, 26.  
Almost all known functional SNPs of MMPs are located in the promoter region of the 
gene and have been demonstrated to influence gene expression in vitro. For example, C to 
T substitution at the -1306 position of the MMP-2 gene leads to disruption of a binding site 
for the Sp1 transcription factor and as a result a decreased promoter activity in vitro27, 
whereas the activity of the MMP-9 promoter is increased in T-allele carriers of the -1562 C/T 
polymorphism as a result of decreased binding of a repression factor28. For MMP-7, two 
functional SNPs have been identified in the promoter of the gene, namely the -181 A/G and 
-153 C/T polymorphisms29. Nuclear proteins bind with higher affinity to the G-allele than to 
the A-allele at the -181 position of the MMP-7 gene. The T-allele at the -153 position binds 
additional nuclear proteins compared to the C-allele, but those proteins that bind to both 
alleles have a higher affinity for the C-allele than for the T-allele. The overall effect is a two- 
to three-fold increase in in vitro transcriptional activity in carriers of both minor alleles (-
181G and-153T) compared to carriers of at least one of the major alleles (i.e. -181A and/or -
153C carriers)29. The (cor)relation of the MMP-2, -7 and -9 polymorphisms with protein 
levels and outcome of colorectal cancer patients will be discussed in the next two 
paragraphs.   
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Figure 1. The matrix metalloproteinases MMP-2, -7, -8 and -9 that have been studied in this thesis are expressed by 
different cell types present in the tumour microenvironment. Adapted from Kessenbrock et al (2010)30 and Langers et 
al (2011; chapter 4). 
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Gelatinases in colorectal cancer 
Because of their involvement in angiogenesis, regulation of inflammation, metastatic 
niche formation, tissue invasion and cell growth30, MMP-2 and MMP-9 have received 
particular interest in cancer research. Both gelatinases have indeed been shown to be 
implicated in the progression and metastasis of various solid tumours31. In the studies 
described in chapter 5, the questions were addressed whether functional SNPs of MMP-2 
and MMP-9 and/or their protein levels in peroperatively obtained carcinoma tissue are 
associated with survival in a cohort of 215 colorectal cancer patients, and whether there is a 
correlation between the functional polymorphisms and tissue levels of MMP-2 and MMP-9. 
For the MMP-2 -1306 C/T and the MMP-9 -1562 C/T polymorphisms, no correlation 
between SNP and tumour level of MMP-2 or MMP-9 was found. The absence of this 
correlation could be explained by the fact that protein levels not only depend on the 
transcription levels of the MMP-gene, but also on producing cell type, activation and 
clearing of the protein. Some of the cell types expressing the metalloproteinases that have 
been studied in this thesis are shown in figure 1. Especially in a tumour microenvironment, 
many different cell types, mechanisms and interactions determine the final concentration of 
MMPs. Therefore, it would be more rational to look at the association between genotype 
and protein levels of MMPs in normal colorectal mucosa, which was actually done in the 
study described in chapter 6. In 198 of the 215 colorectal cancer patients described in 
chapter 5, tissue derived from normal colon at a distance of 5-10 centimetres from the 
tumour site was available for analysis. MMP-2 and MMP-9 levels in normal mucosa were 
determined by ELISA and compared to the different genotypes of MMP-2 (-1306 C/T 
polymorphism) and MMP-9 (-1562 C/T polymorphism). Also in normal mucosa no 
association between the protein levels of the gelatinases and their promoter genotypes was 
found. In spite of the lack of a correlation between the SNPs and protein levels, patients 
with a TT genotype of either the MMP-2 -1306 C/T polymorphism or the MMP-9 -1562 C/T 
polymorphism were found to have a more advanced TNM stage than C-allele carriers. 
Furthermore, a multivariate Cox’s analysis demonstrated that the MMP-2 -1306 C/T SNP 
(but not the MMP-9 -1562 C/T SNP) was independently associated with survival of the 
patients.  
At the protein level, there was a significant association between MMP-2 levels in 
carcinoma tissue and survival. Patients with a tumour MMP-2 level of higher than 18.5 
ng/mg protein had a worse 10 year survival that those patients with MMP-2 levels below this 
cut-off point. Interestingly, patients with either very low (<11.2 ng/mg protein) or very high 
(>125 ng/mg protein) tumour levels of MMP-9 had a worse survival compared to those 
patients with intermediate tumour MMP-9 levels. These somewhat surprising results could 
be explained by putative pro- and anti-tumour effects of MMP-9, especially concerning its 
ambivalent role in angiogenesis. The pro-angiogenic effects of MMP-9 are well established, 
as is illustrated by the MMP-9 induced increase of Vascular Endothelial Growth Factor 























Figure 1. The matrix metalloproteinases MMP-2, -7, -8 and -9 that have been studied in this thesis are expressed by 
different cell types present in the tumour microenvironment. Adapted from Kessenbrock et al (2010)30 and Langers et 
al (2011; chapter 4). 
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Gelatinases in colorectal cancer 
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(VEGF) and basic Fibroblast Growth Factor (FGF-2) bioavailability 32, 33. On the other hand, 
MMP-9 generates anti-angiogenic factors like angiostatin, endostatin and tumstatin, which 
inhibit angiogenesis34-37. Furthermore, very low levels of MMP-9 within the tumour might 
reflect a lack of influx of MMP-9 generating cells (like neutrophilic leukocytes) into the 
tumour, which has been associated with decreased survival and a higher rate of local 
recurrence38-42.  
In normal mucosa, gelatinase expression is lower than in carcinoma tissue. This 
difference is more pronounced for MMP-9 (12-fold lower protein levels in normal mucosa 
compared to carcinomas) than for MMP-2 (2-fold lower levels). Survival of patients with low 
MMP-2 (<8.7 ng/mg) or low MMP-9 (<1.6 ng/mg) levels in normal mucosa was better than 
in patients with higher levels, and the combination of both mucosal gelatinases provided an 
even stronger instrument to classify patients as good, intermediate and poor survivors. 
These results were confirmed by a uni- and multivariate analysis, which identified both 
mucosal MMPs as independent prognostic variables and their combination as the strongest 
independent prognostic parameter. The fact that MMP-2 and MMP-9 in normal colorectal 
tissue corresponded even better with patient outcome than their levels in tumour tissue, is 
an interesting phenomenon that cannot easily be explained. Because the samples of normal 
tissue were obtained at a distance of 5-10 cm from the primary tumour, they should be 
regarded as distant mucosa and should therefore not display the changes that might be 
expected in mucosa immediately adjacent to the tumour43. However, also in mucosa not 
immediately adjacent to the tumour mucosal changes have been observed, like for example 
aberrant crypts and enhanced calcium levels44, 45. The strong correlation with higher 
gelatinase-levels and worse outcome suggests that this is either a response to the presence 
of a tumour elsewhere in the colon, or there might be some kind of “field defect” in which 
these changes in MMP profile occur even before cancer develops. To be able to better 
answer this question, it would be interesting to look at MMP-levels in normal colorectum of 
patients who are at an increased risk of CRC development or who have developed 
dysplasia in the context of an inflammatory bowel disease. Processes like neo-angiogenesis 
and breakdown of the basement membranes are limited to the site of malignancy and do 
not take place at distance of the tumour. Still, some microvascular changes have been 
observed in normal mucosa adjacent to large invasive colorectal tumours, like enhanced 
microvessel density associated with increased levels of vascular endothelial growth factor 
(VEGF) and interleukin 846. The changes that were observed in the normal mucosa could 
reflect the creation of a tumour-friendly environment (even at distant sites from the tumour) 
that promotes local spread of the tumour and, once the tumour reaches this area, could 
facilitate dissemination and enhance the development of multifocal tumours, which could 
subsequently explain the worse prognosis in patients with high mucosal MMP-levels.  
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Matrilysin in colorectal cancer  
Because of its ability to induce angiogenesis, increase cell survival, create resistance to 
apoptosis, degrade ECM components and to activate other MMPs, MMP-7 (or matrilysin) is 
probably one of the most important MMPs in colorectal carcinogenesis47. Chapter 7 
focuses on the genotype and phenotype of matrilysin in relation to outcome of CRC 
patients. Furthermore, MMP-7 expression and activity were examined throughout the 
colorectal carcinoma sequence.  No correlation between either of the two promoter-located 
functional SNPs of MMP-7 (–181A/G and -153C/T) and protein levels of MMP-7 was found. 
However, there was a small but significant association between the -153 C/T SNP and 
MMP-7 activity, and this polymorphism also correlated with the survival of the patients. 
Matrilysin levels were increased in colorectal adenomas, especially in those with moderate 
or severe dysplasia, as well as in colorectal carcinomas. This suggests that MMP-7 is 
already involved in the early stages of colorectal carcinogenesis, which is in line with the 
finding that MMP-7 overexpression is associated with mutational activation of the APC/Wnt 
signalling pathway which is also involved in the early stages of colorectal cancer 
development.48, 49. Activation of MMP-7 was particularly seen in colorectal carcinomas and 
thus seems to take place later in the colorectal carcinogenesis process. High tumour levels 
of either total matrilysin or matrilysin activity were associated with poor 10-year survival, but 
only matrilysin activity proved to be an independent prognostic parameter. These data 
provide further insight in the implication of MMP-7 throughout the colorectal cancer 
sequence and suggest that it might be useful as a prognostic tool and maybe even as a 
target for therapy, as will be discussed in the next paragraph. 
Therapeutical options for matrix metalloproteinase inhibitors 
The fact that MMP expression is increased in various types of cancer50, combined with 
the fact that increased MMP expression is often associated with poor outcome of these 
patients, provided the rationale for the use of MMP inhibitors as therapeutics in cancer51. In 
the APCMin/+ mouse, which is a model of intestinal cancer development, treatment with 
broad spectrum MMP inhibitors led to a more than 50% decrease in polyp count52, 53. 
However, the results of MMP-inhibitors (MMPIs) in humans have been disappointing. One 
of the reasons for this lack of success is the occurrence of side effects (in particular 
musculoskeletal complaints)51. Furthermore, the first generation of MMPIs that have been 
used in patients were all broad spectrum MMPIs. The original concept that all MMPs 
promote tumour progression has proven to be incorrect and what makes things even more 
complicated is that one particular MMP can be harmful in one situation, but beneficial under 
different circumstances. Even in one particular disease, the role of MMPs can be positive or 
negative depending on the stage of progression, as has been shown for MMP-2 and MMP-9 
in a mouse model of the Alport syndrome54. These observations illustrate that to design 
MMP inhibiting therapies, not only knowledge is required about the (either beneficial or 
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detrimental) role of a particular MMP in the progression of a certain tumour, but also the 
stage of disease should be taken into account when determining the optimal profile for MMP 
inhibition as anti-cancer therapy. Furthermore, concomitant therapy, like surgery, for 
colorectal cancer will be followed by a period of wound healing, a process in which MMPs 
are involved under physiological circumstances and where MMP inhibition may be harmful. 
Increased knowledge of the role of individual MMPs in the different stages of cancer 
development, combined with the development of antibodies against specific MMPs, might 
open the road to directed anti-MMP therapy in the future55. If MMPIs would be considered 
as chemoprotective agents to prevent adenoma formation and/or progression in individuals 
at high-risk for colorectal cancer development, the need to understand and overcome the 
side-effects becomes even more important.  
Conclusions and future perspectives 
The studies described in this thesis provide further evidence for the role of MMPs in 
colorectal cancer development and identifies MMPs (both at a SNP and protein level) as 
predictors of outcome in patients with colorectal carcinoma. MMP-2 and -9 levels in normal 
mucosa of CRC patients are an even stronger predictor of survival than their levels in 
tumour tissue. Whereas the MMP-2 -1306 C/T SNP, the MMP-7 -153 C/T SNP, high tumour 
MMP-2 and MMP-7 levels and tumour MMP-7 activity are associated with poor survival, 
MMP-9 shows a bidirectional association, with poor 10 year survival in patients with either 
very low of very high tumour levels of MMP-9. For the first time ever, measurable levels of 
MMP-2 and MMP-9 have been shown to be present in urine of colorectal cancer patients 
and, in case of MMP-2, also to correlate with clinical and surgical outcome of the patients. 
MMP-7, MMP-8 and probably also MMP-9 are involved in the early stages of 
carcinogenesis, that is, in colorectal adenomas, whereas MMP-2 levels and MMP-7 activity 
are only enhanced once cancer has developed. 
The development of genome-wide association studies (GWAS) and whole genome 
sequencing allows to search a large number of genetic variations throughout the genome or 
even to sequence the entire genome of an individual. As these constantly improving 
technologies become available at lower costs, they will probably replace the individual SNP 
determinations, causing a shift from hypothesis-driven research towards a non-hypothesis 
based collection of a large number of genetic data. These data then need to be linked to 
information about disease susceptibility and/or disease outcome, with the intrinsic and 
problematic ethical implications, in order to be able to draw conclusions about the presence 
or absence of a genotype-phenotype association. So far, the GWAS studies did not locate 
any of the colorectal cancer susceptibility loci in one of the MMP genes56. However, the 
MMP-2 gene was identified as one of the CAN genes that are often mutated in colorectal 
cancer57. Whether the results of the whole genome sequencing will identify the MMP-genes 
as pivotal genes in colorectal cancer susceptibility and/or progression, remains to be seen. 
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Since the role of MMPs in cancer progression has been well established, this would not be 
very surprising. 
Personalized medicine is evolving, and MMP inhibiting therapies could be part of such 
an individualized treatment approach, especially in those patients with elevated tissue levels 
of MMP-2, MMP-7 or other MMPs that have shown to have detrimental effects on tumour 
progression and/or are associated with a poor outcome. MMP-9 inhibition would be less 
obvious as a target for therapy, because of the negative effect on survival of very low 
tumour MMP-9 levels. The major drawbacks of MMP directed therapy have been described 
before, but with detailed knowledge of the role of the different MMPs in the various stages 
of cancer progression and the possibility to aim directly at targeted MMPs, could reopen the 
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In Nederland wordt jaarlijks bij meer dan 12.000 personen de diagnose darmkanker 
gesteld. Onder darmkanker, ook wel colorectaal carcinoom (Engels: colorectal cancer, 
afgekort CRC) genoemd, wordt in de praktijk een kwaadaardige (maligne) tumor van de 
dikke darm en/of de endeldarm verstaan. Dikke darmkanker ontstaat bijna altijd uit een 
darmpoliep; dit is een goedaardige afwijking die, indien tijdig opgespoord, verwijderd kan 
worden door middel van een endoscopie. Bijna de helft van de darmkankerpatiënten zal 
uiteindelijk aan de ziekte overlijden, meestal ten gevolge van de aanwezigheid van 
uitzaaiingen (metastasen). Bij het ontstaan van uitzaaiingen worden de natuurlijke barrières, 
zoals de basaalmembraan van het darmslijmvlies, door de tumorcellen doorbroken. Dit leidt 
tot doorgroei in de diepere lagen van de darmwand (invasie), waardoor het enerzijds 
mogelijk wordt dat de tumorcellen doorgroeien in de lymfevaten en via het lymfevat-stelsel 
kunnen uitzaaien (lymfogene metastasering); anderzijds kan doorgroei tot in de bloedvaten 
leiden tot uitzaaiingen in andere organen (hematogene metastasering). Andere belangrijke 
factoren in het proces van metastasering zijn de vorming van bloedvaten (angiogenese) 
door en naar de tumor en het “voorbereiden” van de organen waarin de uitzaaiingen 
kunnen ontstaan door het creëren van een zogenaamde “metastatische niche”. Dit laatste 
houdt in dat er in het orgaan waarin de uitzaaiingen kunnen gaan optreden, meestal in de 
lever, veranderingen plaatsvinden die het mogelijk maken dat tumorcellen die zich via de 
bloedbaan hebben verplaatst, zich kunnen gaan nestelen en verder uitgroeien. Matrix 
metalloproteïnasen (MMPs) zijn eiwitsplitsende enzymen (proteasen) die een belangrijke rol 
spelen bij de progressie van tumoren. Zij zijn in staat verschillende componenten van de 
basaalmembraan af te breken, zodat de tumorcellen door de basaalmembraan heen 
kunnen breken en kunnen doorgroeien in de diepere lagen van de darmwand. Ook zijn zij 
van belang bij andere processen die meespelen in de ontwikkeling van kanker en 
vervolgens de metastasering, zoals later in dit hoofdstuk wordt beschreven. MMPs worden 
geproduceerd in een inactieve pro-vorm en moeten geactiveerd worden alvorens ze hun 
eiwitsplitsende werking kunnen uitoefenen. De MMPs die in dit proefschrift aan bod komen 
zijn MMP-2 en MMP-9, samen ook wel de gelatinases genoemd, en tevens MMP-7 en 
MMP-8. In figuur 1 wordt weergegeven door welke celtypen deze MMPs worden 
geproduceerd; tevens zijn enkele belangrijke processen aangegeven in de progressie van 
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Figuur 1. De matrix metalloproteïnasen die zijn bestudeerd in dit proefschrift, te weten MMP-2, MMP-7, MMP-8 en 
MMP-9, worden geproduceerd door verschillende celtypen die aanwezig zijn in het micromilieu van de tumor. Ze zijn 
betrokken bij diverse processen die te maken hebben met de ontwikkeling en progressie van darmkanker.  
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Rol van matrix metalloproteïnasen in het ontstaan van darmkanker 
Darmkanker ontstaat in het merendeel van de gevallen uit een darmpoliep (adenoom). 
Via een stapsgewijs proces, waarbij er in elke opeenvolgende stap (van vroege poliep, naar 
verder gevorderde poliep, naar kanker en vervolgens uitzaaiingen) bepaalde genetische 
veranderingen optreden, ontwikkelt zich uiteindelijk kanker. Dit model voor darmkanker-
ontwikkeling wordt ook wel het Vogelstein-model genoemd. De in dit proefschrift 
beschreven studies tonen aan dat sommige MMPs al vroeg in het proces betrokken zijn. Zo 
zijn MMP-7, MMP-8 en MMP-9 al in het poliepstadium in verhoogde mate aanwezig. 
Hetzelfde geldt voor neutrofiel gelatinase-geassocieerd lipocaline (NGAL). Lipocaline 
verhindert de afbraak van MMP-9 door de vorming van complexen met MMP-9. MMP-7 
blijkt al in het poliep-stadium verhoogd te zijn; activatie van MMP-7 treedt echter pas later 
op, op het moment dat zich kanker heeft ontwikkeld. Toename van MMP-2 wordt pas 
gezien op het moment dat zich reeds darmkanker heeft ontwikkeld. 
MMP-2 en MMP-9 in urine en plasma van patiënten met darmkanker 
De behandelingsmogelijkheden voor darmkanker zijn de afgelopen decennia fors 
toegenomen. Belangrijkste behandeling blijft natuurlijk het operatief verwijderen van de 
darmtumor, waar ook nieuwe technieken zijn ingevoerd. Terwijl er in het verleden weinig tot 
geen opties waren voor patiënten bij wie zich uitzaaiingen hadden ontwikkeld, zijn er nu 
voor deze patiëntengroep diverse behandelopties zoals nieuwe vormen van chemotherapie, 
maar ook bijvoorbeeld resectie van de levermetastasen. De follow-up van darmkanker 
patiënten wordt hiermee steeds belangrijker, want hoe eerder je de uitzaaiingen opspoort, 
hoe meer opties er zijn voor behandeling. Technieken die toegepast kunnen worden om 
metastasen in een vroeg stadium op te sporen zijn de echografie, de CT scan en het 
bepalen van de CEA (carcino-embryonaal antigeen) waarde in het bloed. Een stijging van 
de CEA waarde na een operatie voor darmkanker kan duiden op terugkeer van de ziekte. 
Bij 40% van de tumoren is het CEA op het moment van stellen van de diagnose niet 
verhoogd. Bij deze 40% van de patiënten is de waarde van het vervolgen van CEA dan ook 
beperkt. In dit proefschrift staat beschreven dat MMP-2 en MMP-9 meetbaar blijken te zijn 
in de urine en in het plasma van patiënten met darmkanker. Indien deze waarden gemeten 
worden door middel van zymografie (een bepaling die MMPs kan aantonen op basis van 
hun enzymatische activiteit), blijken met name patiënten met hoge MMP-2 waarden in de 
urine een slechte prognose te hebben. Tot nu toe was nog niet eerder aangetoond dat 
MMP-2 en MMP-9 meetbaar zijn in de urine van patiënten met darmkanker. Deze 
bevinding, gecombineerd met het feit dat zowel MMP-2 als MMP-9 eveneens meetbaar zijn 
in het plasma van darmkankerpatiënten, maakt dat deze MMPs mogelijk gebruikt zouden 
kunnen worden in de follow-up na een operatie. Een probleem hierbij is wel dat beide 
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Single-nucleotide polymorfismen (SNPs) van matrix metalloproteïnasen in kanker van het 
maagdarmkanaal 
De meest voorkomende vorm van genetische variatie is het single-nucleotide 
polymorfisme (SNP), waarbij één enkel nucleotide van een gen vervangen wordt door een 
ander nucleotide. SNPs als genetische kenmerken kunnen geassocieerd zijn met de 
vatbaarheid voor bepaalde aandoeningen, maar ook met het beloop van een ziekte of de 
respons op therapie. Veel van de SNPs die zijn onderzocht bij maligniteiten van het 
maagdarmkanaal zijn gelokaliseerd in de zogenaamde promoter-regio van het gen, waar 
onder andere wordt bepaald in welke mate een gen tot expressie komt. Zij hebben daarom 
mogelijk effect op de translatie (vertaling) van het gen naar eiwit en dus ook op de 
hoeveelheid en soms ook de vorm waarin een bepaald eiwit geproduceerd wordt. Bij 
slokdarmkanker, maagkanker, darmkanker en levercelkanker is onderzocht in hoeverre er 
een associatie is tussen bepaalde SNPs en het ontstaan van de genoemde tumoren. Hierbij 
worden de meest consistente resultaten gevonden bij het -1306 C/T polymorfisme van 
MMP-2 en het -181 A/G polymorfisme van MMP-7, welke geassocieerd zijn met de kans op 
de ontwikkeling van slokdarmkanker (MMP-2) danwel slokdarm- en maagkanker (MMP-7). 
Hierbij dient opgemerkt te worden dat voor de SNPs in het MMP-7 gen de correlatie alleen 
aanwezig is in de Aziatische populatie. Met betrekking tot het ontstaan van darmkanker is 
de correlatie tussen de aanwezigheid van een dubbel 2G-allel op de -1607 positie van het 
MMP-1 gen en de verhoogde kans op het ontwikkelen van darmkanker het meest 
consistent. De associatie tussen SNPs in het MMP-2, MMP-7 en MMP-9 gen en 
darmkanker-risico wordt wisselend gerapporteerd. Soms zijn deze wisselende uitkomsten 
toe te schrijven aan een verschil in etniciteit van de onderzochte studiepopulatie.  
Slechts een beperkt aantal studies heeft de relatie tussen SNPs en eiwitniveaus 
onderzocht. Van een aantal SNPs is bekend dat ze in vitro leiden tot een toegenomen 
transcriptie van het gen (d.w.z. omzetting van DNA naar messenger RNA), doordat er een 
toegenomen binding is van een transcriptiefactor. Dit is bijvoorbeeld het geval bij de MMP-7 
-181A/G SNP. Het tegenovergestelde komt ook voor: de transcriptie-activiteit neemt dan 
juist af door verstoring van een bindingsplaats van een transcriptie-factor (zoals 
bijvoorbeeld bij de MMP-2 -1306 C/T SNP). De toe- of afgenomen activiteit van de 
transcriptie-factor in vitro laat zich echter lang niet altijd vertalen in toe- of afgenomen 
eiwitniveaus in de patiënten. 
Gelatinases in darmkanker 
MMP-2 en MMP-9 worden samen ook wel de gelatinases genoemd, vanwege het feit 
dat beide in staat zijn gelatine (gedenatureerd collageen) af te breken. Tevens zijn beiden in 
staat meerdere andere componenten van de basaalmembraan af te breken, zoals 
collageen type IV, elastine en laminine. Daarnaast zijn ze betrokken bij de activatie van 
groeifactoren, chemokinen en andere pro-MMPs. MMP-2 en MMP-9 spelen een rol in onder 
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andere angiogenese, regulatie van ontsteking en vorming van de metastatische niche. Hun 
betrokkenheid bij deze processen en het feit dat zowel MMP-2 als MMP-9 een rol speelt in 
de progressie van diverse tumoren was aanleiding voor het bestuderen van de relatie 
tussen de gelatinases en de progressie en prognose van dikke darmkanker, waarvan de 
resultaten zijn weergegeven in dit proefschrift. In een groep van 215 patiënten met dikke 
darmkanker is onderzocht of weefselniveaus van MMP-2 en MMP-9 correleren met de 
overleving. Tevens is onderzocht of de functionele SNPs van MMP-2 (-1306 C/T) en MMP-
9 (-1562C/T) correleren met de desbetreffende eiwitniveaus. Dit laatste blijkt niet het geval 
te zijn. 
Aangezien er zich in het micromilieu van een tumor diverse processen tegelijkertijd 
afspelen, wordt het uiteindelijke (activiteits-)niveau van MMPs in een tumoromgeving 
bepaald door meer factoren dan door de transcriptie alleen. Het ontbreken van een relatie 
tussen SNPs en eiwitniveaus in een tumor sluit daarom niet uit dat een dergelijke relatie wel 
degelijk aanwezig is in normaal darmweefsel. Dit is onderzocht door de eiwitniveaus van 
MMP-2 en MMP-9 te meten in normale colonmucosa (darmslijmvlies) en deze waarden te 
correleren met de SNPs. Ook in de normale mucosa blijkt er geen correlatie tussen 
eiwitniveau en gen-polymmorfisme te bestaan. Ondanks de afwezige correlatie tussen SNP 
en eiwitniveaus, blijken patiënten met een TT genotype van het MMP-2 -1306 C/T 
polymorfisme of het -1562 C/T polymorfisme een verder gevorderd tumorstadium te hebben 
dan dragers van het C-allel. Tevens blijkt de MMP-2 -1306 C/T SNP een onafhankelijke 
voorspeller te zijn van de overleving van de patiënten. 
Patiënten met een laag MMP-2 eiwitniveau in het tumorweefsel hebben een significant 
betere 10-jaars overleving dan patiënten met een hoger eiwitniveau. Voor MMP-9 blijkt juist 
dat patiënten met ofwel een heel laag MMP-9 niveau in het tumorweefsel, ofwel een heel 
hoog niveau, een slechtere overleving hebben dan de groep patiënten die een gemiddeld 
MMP-9 eiwitniveau in de tumor heeft. Een mogelijke verklaring voor dit fenomeen is dat 
MMP-9 zowel pro- als anti-angiogenetische effecten heeft die potentieel afhangen van de 
concentratie waarin MMP-9 aanwezig is. Een andere verklaring kan worden gezocht in het 
feit dat zeer lage MMP-9 niveaus mogelijk veroorzaakt worden door een gebrek aan influx 
van (MMP-9 producerende) leukocyten in de tumor, hetgeen geassocieerd is met 
verminderde overleving en een hoger aantal lokale recidieven. Terwijl de eiwitexpressie van 
zowel MMP-2 als MMP-9 in normale mucosa van CRC-patiënten evident lager ligt dan in de 
tumoren, blijkt de correlatie tussen eiwitniveaus en overleving juist sterker aanwezig te zijn 
in de normale mucosa dan in de tumoren. In de normale mucosa is zowel voor MMP-2 als 
voor MMP-9 een afkappunt gevonden waarboven de patiënten een duidelijk slechtere 
prognose hebben dan de patiënten van wie de eiwitniveaus onder deze waarden liggen. De 
combinatie van de MMP-2 en MMP-9 waarden in normale mucosa is zelfs de sterkste 
voorspeller van de prognose van CRC-patiënten. 
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Matrilysine in darmkanker 
MMP-7, ook wel matrilysine genoemd, is onder andere betrokken bij de vorming van 
nieuwe bloedvaten, de overleving van de cel, het minder gevoelig maken van de cel voor 
apoptose (geprogrammeerde celdood), de afbraak van componenten van de 
basaalmembraan en het activeren van andere proMMPs. De rol van MMP-7 in de 
ontwikkeling van darmkanker is onderzocht door MMP-7 spiegels en activiteit te meten in 
normale mucosa en tumoren van 174 darmkankerpatiënten en in 58 adenomen. Terwijl in 
adenomen reeds verhoogde MMP-7 spiegels worden gemeten in vergelijking met de 
normale mucosa, treedt activatie van MMP-7 pas op in de carcinomen. De MMP-7 activiteit 
in adenomen is gelijk aan de activiteit in de normale mucosa. Er is geen correlatie tussen 
een tweetal bekende functionele SNPs van MMP-7 (SNP -181A/G en SNP -153 C/T) en de 
MMP-7 eiwitniveaus (noch in de tumoren, noch in de normale mucosa). Wel correleert de -
153 C/T SNP onafhankelijk met de 10-jaars overleving van de darmkankerpatiënten. Hoge 
MMP-7 spiegels en een hoge MMP-7 activiteit in de tumor correleren met een slechte 10-
jaars overleving; de MMP-7 activiteit is hierbij een onafhankelijke voorspeller voor de 10-
jaars prognose van darmkankerpatiënten.  
Therapeutische opties voor matrix metalloproteïnase-remmers
Gebaseerd op de feiten dat MMPs betrokken zijn bij diverse processen die een rol 
spelen in de ontwikkeling van kanker én dat hoge MMP-spiegels meestal correleren met 
een slechte uitkomst, werd in het verleden het effect van diverse anti-MMP therapieën in 
studieverband onderzocht. De resultaten van deze studies waren helaas teleurstellend. 
Deels werden deze tegenvallende resultaten veroorzaakt door de ernstige bijwerkingen van 
de MMP-remmers, met name op het gebied van spier- en gewrichtsklachten, die het 
continueren van de therapie onmogelijk maakten. Een andere belangrijke verklaring ligt in 
het feit dat de meeste van de onderzochte MMP-remmers een breed spectrum aan MMPs 
remden. Terwijl er in het verleden vanuit werd gegaan dat alle MMPs het ziektebeloop 
negatief beïnvloeden, is inmiddels duidelijk is dat sommige MMPs (ook) anti-tumor effecten 
hebben en dat het remmen van deze MMPs juist niet wenselijk is. De meeste anti-MMP 
therapieën werden toegepast in vergevorderde stadia van de ziekte, terwijl niet alle MMPs 
in elk stadium van de ziekte evenzeer betrokken zijn. De studies waarvan de resultaten zijn 
terug te vinden in dit proefschrift dragen bij aan een toenemend inzicht in welke MMPs 
betrokken zijn in de diverse fasen van darmkankerontwikkeling en metastasering. Kennis 
hiervan is essentieel bij de ontwikkeling van nieuwe, specifiekere MMP-remmers en bij het 
bepalen in welk stadium van de ziekte deze nieuwe medicijnen ingezet zouden kunnen 
worden.  
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Conclusies en toekomstperspectief 
De studies die zijn beschreven in dit proefschrift dragen bij aan een toenemende kennis 
van de rol van matrix metalloproteïnasen in de ontwikkeling van dikke darmkanker en tonen 
aan dat deze MMPs, zowel op genetisch (SNP) als op eiwitniveau, in belangrijke mate 
voorspellend zijn voor de uitkomst van patiënten met deze aandoening. MMP-2 en MMP-9 
niveaus in de normale mucosa van dikke darmkankerpatiënten blijken zelfs een sterkere 
voorspeller van de overleving van deze patiënten te zijn dan MMP-2 en MMP-9 waarden in 
tumorweefsel. Terwijl de MMP-2 -1306 C/T SNP, de MMP-7 -153 C/T SNP, hoge tumor 
MMP-2 en MMP-7 spiegels en hoge tumor-MMP-7 activiteit geassocieerd zijn met een 
slechte overleving, toont het tumor-MMP-9 niveau geen eenduidige correlatie met de 
overleving en zijn zowel zeer hoge als zeer lage tumorniveaus van MMP-9 geassocieerd 
met een slechte 10-jaars overleving. Voor het eerst is aangetoond dat MMP-2 en MMP-9 in 
meetbare hoeveelheden aanwezig zijn in de urine van darmkankerpatiënten en dat er 
mogelijk een correlatie is tussen de zymografisch bepaalde urine-MMP-2 spiegels en de 
overleving van de patiënten. Pro-MMP-7, MMP-8 en waarschijnlijk ook MMP-9 zijn reeds 
betrokken in de vroege fases van de darmkanker-ontwikkeling, d.w.z. in het poliep-stadium, 
terwijl MMP-2 en MMP-7 activiteit pas in de latere stadia verhoogd zijn. 
Met de komst van de “whole genome sequencing” wordt het mogelijk om in korte tijd het 
volledige menselijke genoom in kaart te brengen. De verwachting is dat deze nieuwe 
techniek de SNP-analyses op termijn zal vervangen. Op therapeutisch gebied is er een 
ontwikkeling gaande in de richting van geïndividualiseerde behandeling van patiënten 
(“personalized medicine”). Hierbij wordt er op basis van bepaalde tumor- en 
patiëntkenmerken de optimale therapie voor een patiënt bepaald. Gezien de betrokkenheid 
van de onderzochte MMPs in de ontwikkeling en progressie van dikke darmkanker, zouden 
MMPs in de toekomst mogelijk een rol kunnen spelen bij deze geïndividualiseerde therapie. 
Enerzijds kan deze rol bestaan uit het inschatten van de prognose van een patiënt en 
daarmee het bepalen van de noodzaak tot aanvullende behandeling; anderzijds kan 
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tot internist plaats in het Rijnland ziekenhuis te Leiderdorp (opleider: dr. F.H.M. Cluitmans), 
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als staflid op de afdeling maag-darm-leverziekten van het LUMC met als aandachtsgebied 
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NAWOORD 
 
Aan de totstandkoming van dit proefschrift heeft een groot aantal mensen bijgedragen, 
van wie ik er een aantal bij naam wil noemen. Professor Daan Hommes, promotor en tot 
recent afdelingshoofd, jij hebt me de ruimte geboden mezelf te ontwikkelen binnen de 
afdeling en binnen het onderzoek. Dank voor de kansen die je mij gegeven hebt, het 
geschonken vertrouwen en de inspirerende gesprekken. Professor Hans Vasen, 
medepromotor, we werken al jaren op een zeer prettige manier samen, je zit vol met goede 
ideeën en bent altijd enthousiast. Ik waardeer het zeer dat je de rol van mede-promotor op 
je wilde nemen. Hein Verspaget, co-promotor, jij maakte me enthousiast voor het 
onderwerp en dankzij jouw fantastische begeleiding heb ik dit proefschrift met een goed 
resultaat kunnen afronden. Je betrokkenheid, nauwgezetheid en gedrevenheid hebben mij 
en dit proefschrift heel veel goed gedaan. Je bleef vertrouwen houden in een goede afloop, 
ook als ik ergens in het traject weer helemaal werd ingenomen door de andere 
academische taken en het onderzoek even wat minder snel vorderde dan wij allebei 
hadden gehoopt. Kees Sier, co-promotor, het is ongelooflijk met welk enthousiasme je 
betrokken bent gebleven bij de in dit proefschrift verschenen manuscripten, ondanks het feit 
dat je inmiddels werkzaam was op een andere afdeling binnen het LUMC. Jouw 
begeleiding, je ideeën en je talent voor het maken van de meest prachtige illustraties 
hebben dit proefschrift zeker tot een hoger plan getild.  
De mede-auteurs, met name Frank Kubben, Luuk Hawinkels en Pim Koelink, de 
studenten en de medewerkers van het MDLZ research laboratorium, Marty Beurskens, 
Mark Boonstra, Wim van Duijn, Marij Mieremet-Ooms, Johan van der Reijden, Annie van 
der Zon en Eveline de Jonge-Muller, ben ik zeer erkentelijk voor hun inbreng bij het tot 
stand komen van de diverse publicaties. Mijn collega-stafleden in het LUMC, Andrea van de 
Meulen, Akin Inderson, Bart van Hoek, James Hardwick, Minneke Coenraad, Izäk Biemond 
en huidig afdelingshoofd Roeland Veenendaal hebben mij meerdere malen gedurende 
langere tijd moeten missen zodat ik aan dit proefschrift kon werken. Het was fijn dat jullie 
mij deze gelegenheid gegeven hebben. De samenwerking binnen de staf verloopt erg goed 
ik en hoop dat we nog lang op deze wijze verder kunnen werken.  
Mijn ouders verdienen een bijzondere plaats in dit dankwoord. Van jongs af aan hebben 
jullie mij gestimuleerd, waardoor ik gekomen ben waar ik nu ben. Naast jullie altijd 
belangstellende vragen en het bijhouden van mijn vorderingen via het internet, hebben jullie 
mij tevens door alle extra oppasdagen de gelegenheid gegeven tijd vrij te maken om dit 
proefschrift te kunnen afronden. Heel veel dank voor alles.  
Zonder de hulp van mijn broer Pieter was de lay-out van dit proefschrift zeker niet zo 
mooi geworden als hij nu is. Michel, jouw steun was van zeer grote waarde gedurende de 
afgelopen jaren. Eva en Amber, jullie hebben een heel bijzondere plek in mijn leven. Ik 
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geschonken vertrouwen en de inspirerende gesprekken. Professor Hans Vasen, 
medepromotor, we werken al jaren op een zeer prettige manier samen, je zit vol met goede 
ideeën en bent altijd enthousiast. Ik waardeer het zeer dat je de rol van mede-promotor op 
je wilde nemen. Hein Verspaget, co-promotor, jij maakte me enthousiast voor het 
onderwerp en dankzij jouw fantastische begeleiding heb ik dit proefschrift met een goed 
resultaat kunnen afronden. Je betrokkenheid, nauwgezetheid en gedrevenheid hebben mij 
en dit proefschrift heel veel goed gedaan. Je bleef vertrouwen houden in een goede afloop, 
ook als ik ergens in het traject weer helemaal werd ingenomen door de andere 
academische taken en het onderzoek even wat minder snel vorderde dan wij allebei 
hadden gehoopt. Kees Sier, co-promotor, het is ongelooflijk met welk enthousiasme je 
betrokken bent gebleven bij de in dit proefschrift verschenen manuscripten, ondanks het feit 
dat je inmiddels werkzaam was op een andere afdeling binnen het LUMC. Jouw 
begeleiding, je ideeën en je talent voor het maken van de meest prachtige illustraties 
hebben dit proefschrift zeker tot een hoger plan getild.  
De mede-auteurs, met name Frank Kubben, Luuk Hawinkels en Pim Koelink, de 
studenten en de medewerkers van het MDLZ research laboratorium, Marty Beurskens, 
Mark Boonstra, Wim van Duijn, Marij Mieremet-Ooms, Johan van der Reijden, Annie van 
der Zon en Eveline de Jonge-Muller, ben ik zeer erkentelijk voor hun inbreng bij het tot 
stand komen van de diverse publicaties. Mijn collega-stafleden in het LUMC, Andrea van de 
Meulen, Akin Inderson, Bart van Hoek, James Hardwick, Minneke Coenraad, Izäk Biemond 
en huidig afdelingshoofd Roeland Veenendaal hebben mij meerdere malen gedurende 
langere tijd moeten missen zodat ik aan dit proefschrift kon werken. Het was fijn dat jullie 
mij deze gelegenheid gegeven hebben. De samenwerking binnen de staf verloopt erg goed 
en ik hoop dat we nog lang op deze wijze verder kunnen werken.  
Mijn ouders verdienen een bijzondere plaats in dit dankwoord. Van jongs af aan hebben 
jullie mij gestimuleerd, waardoor ik gekomen ben waar ik nu ben. Naast jullie altijd 
belangstellende vragen en het bijhouden van mijn vorderingen via het internet, hebben jullie 
mij tevens door alle extra oppasdagen de gelegenheid gegeven tijd vrij te maken om dit 
proefschrift te kunnen afronden. Heel veel dank voor alles.  
Zonder de hulp van mijn broer Pieter was de lay-out van dit proefschrift zeker niet zo 
mooi geworden als hij nu is. Michel, jouw steun was van zeer grote waarde gedurende de 
afgelopen jaren. Eva en Amber, jullie hebben een heel bijzondere plek in mijn leven. Ik 
hoop nog heel veel mooie momenten samen met jullie te beleven. 
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